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poptosis is a form of cell death that occurs in individual cells in normal and diseased tissues. It occurs as a 
msequence of activation of a program of molecular events that results in the dismantlement and clearance of 
:lls, often without induction of an inflammatory response. Many of the molecular components that regulate and 
:ecute apoptosis have been identified. Some of these regulators are, or are related to, genes that are altered in 
oplasia, such as c- myc,p53 and Bcl -2. The effector molecules belong to a class of cysteine proteases, known 
the ICE -like proteases (e.g. Nedd2). Whilst the known components can have identifiable activity in apoptosis 
id (or) cell cycle control, it has been suggested that they interact to control apoptosis. Further, it is not known 
nv the regulatory molecules interact upon downstream effectors to control apoptosis induction. Until recently, 
has not been possible to examine the role of apoptosis genes in combination other than by combinatorial mouse 
lockouts - a very time- consuming and expensive exercise. It was therefore decided to direct the expression of 
, veral apoptosis -related genes (namely c -myc, p53, p21 WAF /CIP, and Nedd2) in tissue culture in order to 
.ovide useful tools to answer questions about the role of such genes in the control of apoptosis. 
wing to the limitations of existing conventional expression technology, where test genes are constitutively 
,erexpressed from a strong viral promoter often in transient expression assays, use was made of conditional 
inigenes: 1) A temperature- sensitive (ts) murine p53 (p53va1135) was employed to investigate the sensitivity of 
:tivated c- Ha -ras- transformed rat embryo fibroblasts (Clone 6) to DNA -damage induced by the genotoxic 
iemotherapeutic drugs etoposide and bleomycin; 2) An oestrogen -regulable c- myc -oestrogen receptor hormone 
nding domain fusion protein (myc -ER) was used in conjunction with p53va1135 in order to investigate whether 
,rced expression of phenotypically wild -type p53 was sufficient to trigger apoptosis by c -myc in Clone 6 and 
at -1 fibroblasts; and 3) Vectors were constructed that contain apoptosis genes under the control of semi - 
rnthetic promoters based upon the inducible E. coli lac operator- repressor system or a promoter containing 
east Gal-4 binding sites inducible by a tamoxifen -sensitive VP16GaElen chimaeric trans- activator protein. 
esults showed that: 1) Expression of ts p53 at the permissive temperature protected Clone 6 cells from 
rtotoxic drug- induced apoptosis, probably by enforcing a cell cycle arrest in G1. 2) Co- expression of myc -ER 
id ts p53 yielded no stable cell lines probably due to biologically significant basal activation of both p53val 135 
id myc -ER under the culture conditions used. This is consistent with a co- operative role for c -myc and p53 in 
)optosis triggering. 3) Control of expression in Rat -1 cells of the ICE -like protease Nedd2 (the mouse 
3mologue of human ICH- I) by the VP I6GalER`m system was tight enough to allow development of stably - 
ansfected cells, which upon induction with 4- hydroxytamoxifen, rapidly underwent apoptosis. In contrast, 
ansfections with a LacI- repressible Nedd2 expression vector could not produce repressed stable expression 
vets that were low enough to be compatible with colony survival following selection in tissue culture. 
this work, conditional expression technology was applied to the problem of control of apoptosis and shows 
tat gene expression experiments that increase the susceptibility of cells to apoptosis can be carried out in a 
:gulated fashion. Using this approach, a cytoprotective role of wild type p53 -mediated growth arrest was 
iscovered that was abrogated by c -myc. In addition, cell lines were developed that are suitable for the 
iochemical characterisation of the action of Nedd2 protease. iii 
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Chapter 1. 
1. General Introduction 
1.1 Introduction: Apoptosis 
1.1.1 Definition 
Apoptosis is a term applied to a dying cell which undergoes a defined series of 
morphological changes that results in the fragmentation of the cell and its components 
(Arends and Wyllie, 1991; Wyllie et al, 1980; Kerr et al, 1972) without the elicitation 
of an inflammatory response or interruption of organ function (Duvall and Wyllie, 
1986; Wyllie et al, 1980). If the cell formed part of a tissue, the fragments are 
phagocytosed by tissue macrophages or adjacent cells (Savill et al, 1993; Wyllie et al, 
1980). 
Since the definition of an apoptotic cell is a morphological one, a consideration of the 
structural changes that occur during apoptosis is necessary . 
1.1.2 Morphology (Fig. 1.1) 
Apoptosis usually occurs in scattered cells in contrast to cells dying by necrosis which 
usually affects sheets of contiguous cells. The course of apoptosis of cells in tissues is 
of short duration (a few minutes in length) and can be divided into three main 
morphological phases (Arends and Wyllie, 1991; Wyllie et al, 1980). In the initial 
stage the cell loses contact with surrounding cells, the cytoplasm condenses and 
membrane specialisations (such as microvilli and desmosomes) disappear. The cell 
1 
surface becomes pock- marked as vesicles of endoplasmic reticulum fuse with the 
plasma membrane. Cytoskeletal elements aggregate into parallel arrays and ribosomes 
form semi -crystalline clumps. Organelles become closely packed but retain their 
integrity, although the endoplasmic reticulum becomes dilated. These changes are in 
contrast with the "high amplitude swelling" of mitochondria observed in cells 
undergoing necrosis (Trump et al, 1981). In addition to the cytoplasmic changes at 
this stage, nuclear chromatin becomes condensed and forms cresentic caps adjacent to 
the nuclear membrane (margination). The nucleolus usually disintegrates with 
scattering of the transcriptional complexes leaving behind the argyrophillic centre 
(Arends et al, 1990). 
The second stage is characterised by extensive blebbing of the cytoplasm and nucleus 
and results in cellular fragmentation. Cellular fragments (apoptotic bodies) of variable 
size, characteristically consisting of densely -staining nuclear remnants set in markedly 
eosinophilic cytoplasm, are usually to be found in tissue sections as clusters of 
smooth, round, membrane -bound particles. These particles are usually phagocytosed 
by adjacent cells or shed into epithelial lumina. The majority of apoptotic bodies seen 
in tissue sections are contained within phagosomes as they remain visible for a few 
hours after engulfment (Bursch et al, 1990). 
Degradation of apoptotic bodies occurs in the final stage. For apoptotic bodies 
contained within phagosomes or released into lumina or tissue culture medium, 
apoptosis culminates in membrane rupture and increased permeability to vital dyes 
(such as trypan blue or nigrosine). The morphology of apoptotic cells in this stage is 
similar to cell undergoing necrosis and is sometimes referred to as "secondary 
necrosis ". There is, except in extreme instances, no inflammatory response or scar 
formation in tissues where apoptosis is occurring. 
2 
Fig. 1.1: Morphological Features of Apoptotic Events. A) A normal cell displaying a nucleus with 
nucleosome and chromatin: membrane specialisations. mitochondria. endoplasmic reticulum. ribosomes 
and Golgi apparatus. B) Early apoptotic cell which has shrunk in size. lost its membrane specialisations 
and contains dilated endoplasmic reticulum which is continuous with the cell surface. Also represented 
are intact mitochondria and nuclei with the beginnings of condensed chromatin that is seen to marginate 
at the nuclear membrane. C). Break -up of apoptotic cells into apoptotic bodies which may contain 
nuclear fragments with condensed chromatin. Mitochondria are still intact. D) Clearance of apoptotic 





1.1.3 The Significance of Apoptosis in Physiology and Pathology. 
It is widely recognised that in complex multicellular organisms, normal tissue turnover 
involves a balance between the production of new cells by mitosis and the depletion of 
senescent or superfluous cells by a process of physiological cell death or apoptosis 
(Arends and Wyllie, 1991; Wyllie et al, 1980; Kerr et al, 1972). The short period of 
time taken for an apoptotic body to form and be cleared from a tissue in vivo means 
that the identification of only a few apoptotic bodies on a tissue section can indicate a 
considerable cumulative cell loss. Small changes in the apoptotic index (percentage of 
cells that are apoptotic) can therefore have major biological importance. For example, 
intravenous injection of anti -CD4 antibody increases the apoptotic index in murine 
lymph nodes from 0.06% to 1.33 %, and this is sufficient to halve the total cell count 
of the nodes within 48 hours (Howie et al, 1994). 
Apoptosis can be observed in diverse developmental, physiological and pathological 
situations. Several important examples of the widespread involvement an importance 
of apoptosis in biological processes are given below. 
1.1.3.1 Development. 
Embryogenesis involves not just the generation of new cells but also the elimination of 
cells. Cells dying in developmental situations are sometimes referred to as undergoing 
"programmed cell death ", but the morphology and effector mechanisms of the cell 
death appear to be identical to cells undergoing apoptosis in other situations. 
Many more cells are produced in the neural ectoderm than are required to form the 
nervous system of the developing foetus. As these cells migrate and extend their 
axonal and dendritic processes towards target cells, there is great competition for a 
limited supply of neural survival factors. Cells that do not aquire access to sufficient 
factor, or to the incorrect mixture of survival stimuli, die by apoptosis. 
6 
1.1.3.2 Immunity. 
In the selection of T and B cell repertoires in the immune system, approximately 95- 
97% of cells are eliminated by apoptosis (Deenen et al, 1990). These are the cells that 
produce self -reactive receptor specificities or do not undergo valid antigen receptor 
gene rearrangement. Apoptosis is also the main form of cell death triggered by 
cytotoxic T lymphocytes (CTL), natural killer (NK) cells and antibody- dependent cell 
mediated cytotoxic mechanisms (Cohen, 1993). Disruption of the normal control of 
lymphocyte repertoire control leads to autoimmunity or immune deficiency. Mice 
harbouring genetic defects in the 1pr or gld loci (Fas or Fas ligand genes) develop an 
autoimmune syndrome resembling human systemic lupus erythematosus (SLE) 
(WatanabeFukunaga et al, 1992a) owing to a defect in deletion of autoreactive T 
cells. Conversely, HIV infection causes a progressive depletion of CD4+ T cells as a 
result of inappropriate apoptosis triggered by binding of viral envelope bound gp 120 - 
gp41 complex to the CD4 DI domain (Gougeon and Montagnier, 1993; Ameisen, 
1992). 
1.1.3.3 Inflammation 
At the onset of acute inflammation or infection, the inflammatory response is 
characterised by migration of large numbers of neutrophils and these are followed by 
eosinophils and monocytes. Neutrophils, eosinophils and monocytes die by apoptosis 
within a relatively short period. However death can be significantly delayed by 
proinflammatory cytokines such as C5a (neutrophils), IL -1ß, TNF -a, INF -y 
(monocytes) and IL -5 (eosinophils) (Stern et al, 1992; Mangan et al, 1991). The 
granules of these inflammatory cell types contain many components that can amplify 
the damage or the response to the damage at the site of inflammation. Therefore the 
control of the inflammatory reaction must take place in such a way as to limit the 
spillage of inflammatory cell contents. Apoptotic cells are normally rapidly engulfed 
by other cells, including macrophages and defects in the mechanism of such clearance 
may underlie some chronic inflammatory diseases. Mice without functional TGF(31, 
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which accelerates eosinophil apoptosis, suffer from multifocal inflammatory disease 
and tissue necrosis (Shull et al, 1992). 
1.1.3.4 Neoplasia. 
In addition to areas of ischaemic necrosis, apoptosis occurs in actively growing and 
regressing tumours (Moore and Evan, 1987; Kerr et al, 1972) and influences the rate 
of tumour expansion (Wyllie, 1985). The slow growth of basal cell carcinoma of the 
skin despite high rates of mitosis is attributable to apoptosis (Kerr and Searle, 1972). 
Equally, suppression of cell death, for example by constitutive expression of Bc12, is 
responsible for follicular lymphoma in humans (Tsujimoto et al, 1985) and the 
induction of hyperplastic and preneoplastic foci in experimental rodent 
hepatocarcinigenesis (Bursch et al, 1984). Suppression of cell death allows survival of 
damaged cells that would otherwise be deleted and therefore may contribute to 
tumour progression and metastasis (Harrison et al, 1995). 
Cytotoxic drugs (Sen and d'Incalci, 1992) and moderate -dose irradiation can induce 
apoptosis (Wyllie et al, 1980; Searle et al, 1975). Tissues and tumours that have high 
proliferative activity have high rates of apoptosis and can be most susceptible to 
induction of apoptosis by these agents (Wyllie et al, 1980). However many cancer cell 
types are resistant to the normal induction of apoptosis and failure to undergo 
apoptosis in response to cytotoxic injury induced by chemotherapeutic agents may 
explain the clinical observation of drug resistance even when the pharmacological 
mechanisms of tumour -drug interactions appear to be operating effectively (Hickman, 
1992). 
1.1.4 Cell Biology of Apoptotic Cells. 
1.1.4.1 Cytoplasmic Events. 
The rapid increase in cell density at the onset of apoptosis is due to the voiding of 
water and ions, probably by channelling though the endoplasmic reticulum to the cell 
8 
surface (Arends and Wyllie, 1991). The mechanism by which ions are transported are 
not well understood, but it may involve extrusion of K. ions (Barbiero el al, 1995). It 
is interesting that a protein known to be upregulated in thymocyte apoptosis, RP -2, 
has similarity to a ligand -gated ion channel (Brake et al, 1994). 
The cell size and shape changes during apoptosis require that dramatic changes to the 
cytoskeletal structure take place. Accordingly, although actin polymerisation is 
required for membrane blebbing and budding (Cotter et al, 1992), F -actin is 
depolymerised and specifically proteolysed in apoptosis (Mashima et al, 1995; 
Endresen et al, 1995). In some cell types, including hepatocytes, tissue 
transglutaminase non -specifically crosslinks protein into an insoluble shell that may 
stabilise the membrane blebs (Fesus et al, 1987). 
Although increased transcription of certain specific mRNAs is required for the 
apoptosis of certain cell types (see below), there is evidence that the degradation of 
ribosomal RNA (rRNA) and mRNA late in the course of events is due, at least in part, 
to a site -specific endogenous ribonuclease (Houge et al, 1995; Delic et al, 1993). 
Specific cleavage of macromolecules is a characteristic feature of apoptosis as site - 
specific endonucleases and proteases (discussed in more detail below) are also 
important effector molecules in apoptosis. 
1.1.4.2 Nuclear Events 
In contrast to mitosis, the nuclear membrane remains intact in apoptosis and serves to 
contain condensed chromatin inside nuclear fragments. However, the nuclear lamina, 
to which chromatin is anchored, is disassembled by nhosohorylation and subsequent 
depolymerisation of lamm filaments. Unlike mitosis where cdc2 kinase is responsible, 
the phosphorylation of lamins occurs in the absence of increased cdc2 kinase activity 
and is followed by degradation of the lamm monomers making the destruction of the 
nuclear lamina irreversible (Oberhammer et al, 1994; Lazebnik et al, 1993). 
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Change in chromatin structure is the most striking feature of apoptotic cells. While 
mitochondrial DNA remains intact in apoptosis (Topper and Studzinski, 1992; 
Murgia et al, 1992), chromatin is at first cleaved into large fragments of between 50 
and 300kbp (observable by pulsed -field gel electrophoretic techniques) and it is 
thought that these fragments represent chromatin domains, the large loops of DNA 
that are attached to the nuclear matrix (Huang et al, 1995; Cain et al, 1994). The 
condensed chromatin that marginates to edge of the nucleus probably represents these 
large DNA fragments released from the constraints of the nuclear matrix 
(Oberhammer et al, 1993a; Oberhammer et al, 1993b). Subsequently, in most cell 
types, chromatin is further cleaved into much smaller fragments that are multiples of 
180 -200óp. These fragments are caused by double strand cleavage of DNA at 
internucleosomal regions (nucleosomes contain 180bp of DNA in addition to histone 
proteins) and may leak out of apoptotic bodies. These oligonucleosomal fragments 
can be visualised as a characteristic DNA ladder on agarose gels (Wyllie, 1980). It is 
likely that degradation of proteins involved in maintaining chromatin structure (such 
as histone H2A by the ubiquitin degradation pathway (Marushige and Marushige, 
1996)) results in increased access of the internucleosomal DNA to nuclease 
attack(Delic et al, 1993). 
The identity of the endonuclease responsible for cleavage of chromatin into 
oligonucleosomes has proven to be elusive although several groups have suggested 
candidates that have included DNAseI (Peitsch et al, 1993), DNAseII (Barry and 
Eastman, 1993) and DNAses designated alpha, beta and gamma (Shiokawa et al, 
1994). It is a common finding that the endonuclease activity has a requirement for 
Ca2+ 
/Mg2+ 
and is inhibitable with Zn2+ ions (Zhang et al, 1995; Sokolova et al, 1995; 
Ribeiro and Carson, 1993; Arends et al, 1990) and although endonucleases with 
these properties have been purified from several cell types, no agreement has been 
reached relating to the optimal pH of an apoptosis specific endonuclease which acts 
specifically at internucleosomal DNA. A more detailed discussion of this subject 
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Fig. 1.2: C. elegans Programmed Cell Death Genes. (Adapted from Steller, 1995 ). 
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1.1.4.3 Surface Changes 
Cell surface changes during apoptosis that promote recognition and phagocytosis by 
adjacent cells or professional phagocytes are best characterised for apoptotic 
inflammatory cells. These changes include the exposure of phosphatidylserine and of 
glycoprotein side -chain sugars by loss of sialic acid. Another mechanism involves 
binding of thrombospondin (produced by macrophages) to an uncharacterised 
receptor on the surface of apoptotic cells and this acts as a molecular bridge between 
the apoptotic cell and CD36 or a30; integrin on the surface of macrophages. 
Recognition of apoptotic cells by macrophages despite stimulating phagocytosis does 
not cause macrophage activation and therefore does not induce inflammation (Savill el 
al, 1993). 
1.1.5 Molecular Regulation of Apoptosis 
1.1.5.1 Evolutionary conservation of apoptosis: C. elegans and Drosophila death 
genes. 
During the development of the microscopic nematode worm, Caenorhanditis elegans, 
a total of 1090 cells are formed of which 131 cells undergo programmed cell death. 
The remarkable thing about the development of wild -type C. elegans is that the 
parent- daughter cell relationship of each cell is identical from individual to individual. 
Using Nomarski optics it is possible to identify each cell of the transparent worm and 
the precise fate, in terms of differentiation state or cell death, can be predicted with 
absolute precision. By having access to this knowledge it was possible to identify 
several mutant worm strains which were cell death defective (ced) (Hedgecock et al, 
1983). Combinatorial analyses of these mutations revealed a cell death pathway where 
some genes control the commitment of individual cells to die (e.g. ces -1, ces -2, egr- 
1), some carry out the death program, whilst others are responsible for the engulfment 
and disposal of cell corpses (Fig. 1.2). Two genes (ced -3 and ced 4) are absolutely 
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required for the execution of all cell death as mutant animals contain excess cells (Ellis 
and Horvitz, 1986). The ced -9 loss of function mutants were embryonic lethal as 
many cells died, indicating that ced -9 prevents ectopic cell death. A rare ced-9 gain of 
function mutant (n1950) showed defects in the deletion of cells (Hengartner et al, 
1992). Other genes identified did not affect the decision of cells to die, rather there 
were defects in the processing of cell corpses in these animals. Most of these mutants 
showed defects in the engulfment of cell corpses (Ellis et al, 1991). One gene, ;nic -1, 
encoding an endonuclease, was not required for the execution of cell death or 
engulfment of corpses, but corpses were not degraded completely once engulfed by 
surrounding cells (Hevelone and Hartman, 1988; Sulston, 1976). It is not known 
whether this enzyme is similar to the Ca2-/Mg2 -- dependent endonuclease activated in 
mammalian apoptosis. 
Strikingly, following the cloning of cDNAs for several of the ced genes, sequence 
comparison studies found similarity between ced-3 and a mammalian protein, 
interleukin- 1ß- convertase (ICE), a protease which was known to be involved in the 
processing of pro-IL-1f3 to its mature secreted form. This protease had an unusual 
specificity for aspartate residues (single -amino acid code: D) and its overexpression in 
Ratl fibroblasts resulted in apoptosis (Yuan et al, 1993). Further, ced -9 was shown to 
be structurally homologous to the mammalian protein Bcl -2 (Hengartner and Horvitz, 
1994). Despite the fact that no mammalian homologue of ced -4 has yet been found, 
the obvious functional similarity between ced-9 and Bd-2 and the discovery of more 
cysteine proteases implicated in apoptosis (see below) indicated that the cell death 
machinery has been conserved in evolution from nematode to human. 
This evolutionary conservation has been underlined by the discovery in (Drosophila 
melanogaster of a small peptide, REAPER, that is expressed early (within 1 -2 hours 
of a death stimulus) in cells destined to die. Deletion mutations of the reaper gene 
abolish all programmed cell deaths during development. In addition, cell deaths 
caused by mutations in genes involved in morphogenesis as well as those following 
moderate -dose irradiation are blocked in the absence of REAPER (White et al, 1994). 
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REAPER expression causes apoptosis by activation of an ICE -like protease and is 
also responsible for ceramide generation (Pronk et al, 1996). A REAPER -like domain 
has been found in the cytoplasmic domains of the apoptosis- inducing cell surface 
receptors, APO1/Fas /CD95 and TNFR -1 (Golstein et al, 1995; Itoh and Nagata, 
1993). Mutations in this `death domain' are sufficient to prevent activation of cell 
death pathways caused by binding of ligand to these receptors ( Tartaglia et al, 1993; 
Itoh and Nagata, 1993). Despite the increased complexity and functional redundancy 
of mammalian cell death components, together with the slow pace of genetic 
manipulation in higher organisms, the genetic information derived from C. elegans 
and Drosophila will prove to be invaluable in the study of mammalian apoptosis. 
1.1.5.2 Organisation of the Apoptotic Program. 
The final events in the apoptotic process are believed to be determined by the activity 
of a set of gene products that regulate effector mechanisms. Genes encoding products 
involved in effector mechanisms constitute a stereotyped "program" of events which 
can be triggered in various ways depending on the cell type and state of differentiation 
(Fig. 1.3). The existence of such a final common pathway would be predicted to 
explain the similarity in morphology of many types of cells undergoing apoptosis. 
There is now strong evidence that some of the genes known to be able to cause 
apoptosis (the ced -3- related cysteine proteases, see below) are directly involved in 
cell dismantlement and are conserved between the nematode and humans. To what 
extent these molecular events are organised in linear cascades or parallel independent 
processes, that together result in the phenomenon we know as apoptosis, is not yet 
clear. However, there is known to be a degree of functional redundancy between the 
components. An obligate gene, one whose absence abolishes apoptosis in all 
situations, has not been found. 
Genes acting upstream of this effector pathway are critical in determining whether this 
program of events is switched on or off in a particular cell. These genes may also be 
suitable candidates for manipulation in future therapeutic strategies designed to 
enhance or diminish apoptotic cell death in clinical situations such as cancer or tissue 
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enhance or diminish apoptotic cell death in clinical situations such as cancer or tissue 
transplantation respectively. Some of these genes (e.g. c -myc, bc1-2, p53) are already 
known as oncogenes and oncosuppressor genes and appear to determine 
susceptibility of particular cells to cell death. 
Three main strategies by which the effector molecules of apoptosis can be activated 
in various cells can be identified on the basis of treatment of cells with mRNA or 
protein synthesis inhibitors such actinomycin D (actD) or cycloheximide 
(CHX)(Cohen et al, 1992; Cohen, 1991): 
Induction mechanisms are blocked by actD or CHX. Apoptosis in these systems (e.g. 
glucocorticoid- treated (Wyllie et al, 1984), irradiated or antigen stimulated 
thymocytes) is therefore dependent on the synthesis of new gene products, the likely 
functions of which may be to activate effector mechanisms. In 'y-irradiated 
thymocytes an apoptotic signal persists within the cells for a least 6 hours and may 
represent irreversible activation of effector pathways that are still dependent on new 
protein synthesis at points further down the pathway (Sellins and Cohen, 1987); 
Transduction of the apoptotic stimulus to the effector pathway, for example in 
cytotoxic T lymphocyte or NK cell- mediated cytotoxicity, is not inhibitable by actD 
or CHX (Duke et al, 1983). In nearly all cell types the essential molecular 
components of apoptotic cell death therefore appear to be constitutively present in 
most nucleated cell types, including some tumour cells. 
Release of cells into apoptosis can be initiated by treatment with actD or CHX 
(Rotello et al, 1991; Cohen, 1991) in some cell types (Cohen, 1991) and certain 
tumour cells (Cohen, 1991; Martin et al, 1990) implying that apoptosis may be 
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1.1.5.3 Decision making in Apoptosis - Regulation of the Effectors. 
1.1.5.3.1 Cell Autonomous Death. 
Some apoptosis is not externally -triggered but is cell autonomous. For example, cells 
of the interdigital web appear to undergo `programmed cell death', in that web space 
cells in the developing limb bud synchronously die in order to make way for 
independent digits (Kerr et al, 1972). It is not yet known what genetic factors are 
responsible for this pattern of cell death (Hurle et al, 1995) but limbs develop 
normally in Bcl -2- deficient mice (Veis et al, 1993). Other examples of cell 
autonomous cell death are found during C. elegans development (see above). 
1.1.5.3.2 External signals for Cell Death and Survival. 
It seems likely that the default response of a mammalian cell (with the possible 
exception of blastomeres) to isolation from signals from other cells is to undergo 
apoptosis. No normal cell type to date has survived attempts at single cell cloning in 
medium devoid of growth factors or other cytokines (Raff et al, 1993). Survival 
signals, in the form of soluble factors or contact with other cells or extracellular 
matrix must therefore act to prevent the death of normal cells, both in culture and in 
vivo. This process drives the competitive selection of neurones in the developing 
nervous system (Raff et al, 1993). In nephrogenesis, metanephric mesenchymal cells 
are induced to differentiate into the epithelium of the glomerulus and convoluted 
tubules by cells of the ureteric bud which form the collecting ducts. Cells that do not 
receive survival signals within certain time window undergo apoptosis (Koseki et al, 
1992). Competition for limiting survival factors is an important means of limiting the 
size of cell populations in constantly renewing tissue such as epithilia and bone 
marrow. Only a proportion of the daughters of stem cells survive to become 
terminally differentiated. Survival signals, including soluble cytokines and paracrine 
factors are required and determine cell number. Terminally differentiated cells also 
require survival support and these signals often differ from those required by 
immature cells. The epithelia of hormone -dependent tissues, such as prostate, breast, 
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endometrium and adrenal gland all undergo involution by apoptosis if the source of 
hormone is withdrawn (Arends and Wyllie, 1991; Kerr et al, 1972). Likewise, cells of 
the immune system are sensitive to the withdrawal of specific cytokines. In addition, 
differentiated epithelial and endothelial cells, in contrast to fibroblasts, require 
attachment to a basement membrane via integrin -matrix interactions for survival as 
disruption of integrin binding results in apoptosis. (Frisch and Francis, 1994; 
Meredith, J.E. el al, 1993). Escape from these site -specific attachments is therefore of 
prime importance in epithelial neoplastic progression and metastasis. 
For tissue homeostasis to occur, a balance between cell survival and cell death must 
be struck and this therefore implies that communication between cells must also be 
capable of actively causing apoptosis. Ligand binding to cell surface receptors can 
mediate cell survival or cell death. In some cases interaction between cells may 
involve simultaneous signals promoting death, survival or growth. In the dual signal 
model of antigen- mediated activation of lymphocytes, antigen recognition must also 
be accompanied by co- stimulatory signals. For example, antigen bound to surface 
immunoglobulin tends to cause apoptosis of B cells unless a second signal is provided, 
for example, through CD40. The ligand for CD40 is present on activated, but not 
resting helper T cells. Therefore B cell clones with immunoglobulin specificities for 
self antigen are not rescued and are deleted (Tsubata el al, 1993). Similarly, the 
activation of T cells requires co- stimulation from antigen presenting cells in addition 
to the activation of the T cell receptor (TCR) /CD3 complex (Smith et al, 1989). 
The TNF receptor family (Fig. 1.4) includes several members that are involved in 
activation or inhibition of cell death including Fas /APO- 1/CD95, TNFR -1, CD40 and 
low affinity -NGFR (Nagata and Golstein, 1995; Itoh et al, 1991). While the main 
activity of Fas is to cause death, TNFa can also cause fibroblast proliferation and 
prostaglandin synthesis amongst other functions (Tartaglia and Goeddel, 1992). All 
the TNFR family of molecules contain between three to six cysteine -rich, conserved 
extracellular domains. However, TNFR -1 and Fas possess similar stretches of about 
70 amino acids in their cytoplasmic portions and these `death domains' are necessary 
18 
and sufficient for transduction of the death signal upon binding of TNF -a or Fas- 
ligand (FasL) respectively (Tartaglia et al, 1993; Itoh and Nagata, 1993). The Fas 
antigen may also be stimulated by cross -linking with activating antibody or by soluble 
FasL released from activated cytotoxic cells (Tanaka et al, 1996; Ogasawara et al, 
1993; Yonehara et al, 1989). Fas is expressed weakly in most tissues but at much 
higher levels in liver, heart, lung, kidney, ovary (WatanabeFukunaga et al, 1992b) and 
most mouse, but not human, thymocytes other than immature CD47CD8" cells 
(Ogasawara el al, 1995; Andjelic et al, 1994). Additionally, Fas is upregulated on 
activated peripheral lymphocytes (Trauth et al, 1989). The spontaneous murine 
mutations of Fas (lpr (lymphoproliferation)), and FasL (gld (generalised 
lymphoproliferative disease) ) cause accumulation of activated lymphocytes. This 
results in lymphadenopathy and splenomegaly, and on the MRL strain background, 
autoimmune conditions such as glomerulonephritis and arthritis (Izui et al, 1984; 
Cohen and Eisenberg, 1991). Since positive and negative selection in the thymus is 
not disturbed in 1pr or gld mice, these immune system defects indicate that the Fas- 
FasL system is involved in peripheral clonal deletion and deletion of activated 
lymphocytes (Nagata and Golstein, 1995). Further, FasL is upregulated on the surface 
of activated cytotoxic T lymphocytes (CD8` or CD4- T 1 cells) (Nagata and Golstein, 
1995; Suda et al, 1993), which are the main effectors against virally infected cells. 
The importance of the Fas system as a mechanism of cytotoxicity was underlined in 
elegant experiments that showed that CD8- CTL killing by Fas and perforin was 
additive and sufficient to account for all cell -mediated cytotoxicity, at least in the 
short term in vitro (Lowin et al, 1996; Kagi et al, 1994). The importance of 
Granzyme B, an aspartate -specific serine protease found in cytotoxic cell granules and 
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Fig. 1.4: Comparison of the Structures of the TNF -R Superfamily. (From Nagata 
and Golstein, 1995). The extracellular domains are strongly similar between family 
members. The two death promoting members, Fas and TNFR -1, have similar, 
Reaper -like death intracellular domains that transmit death initiating signals (via 
TRADD or FADD and FLICE) to molecules in the cytoplasm.(bold). 
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I. 1.5.3.3 Signalling pathways. 
In order for a stimulus to have an effect on a cell, a signal must be transmitted within 
the cell to effector molecules. Signal transduction pathways originate at receptors and 
may involve protein -protein interactions, changes in ion fluxes, second messengers 
and protein kinase cascades. These pathways may be activated in parallel by the same 
stimulus. They are often pleiotropic, some being used by both growth promoting and 
apoptotic stimuli and depending on the circumstances, may act to promote or inhibit 
apoptosis. Signalling need not pass messages directly to the nucleus as enucleated 
cells are capable of undergoing apoptosis. 
A rise in intracellular Cat- usually precedes apoptosis and calcium ionophores and 
perforin are thought to be involved in apoptosis by increasing the intracellular Ca2- 
concentration. The precise mechanism of calcium entry of Cat- in apoptosis induced 
by other stimuli is not clear, nor are the targets known, although the endogenous 
nuclease responsible for internucleosomal DNA cleavage is known to be calcium 
dependent. It is possible that the response to calcium is mediated by calcium - 
calmodulin- dependent protein kinase or calpain although these enzymes have many 
substrates. The action of Cat. is not specific to apoptosis however as changes in 
cytosolic calcium are involved in other cell processes such as muscle contraction and 
T cell activation. Calcium is also required for the activation of protein kinase C (PKC) 
by another second messenger, diacyl glycerol, a product of phospholipase C- mediated 
hydrolysis of the membrane lipid phosphoinositol 4,5- bisphosphate (PIP2). 
Phospholipase C is regulated by G proteins whose activity is often controlled by cell - 
surface receptors such as the TCR/CD3 complex. Artificial stimulation of PKC by a 
combination of ionomycin (a calcium ionophore) and a phorbol ester such as phorbol 
myristate acetate (PMA) is known to cause apoptosis in some systems, but is 
protective in others. A signalling pathway involving arachidonic acid metabolism has 
been implicated in thymocyte apoptosis and the ras-rqf protein kinase cascade, a 
reasonably well characterised means of communication of signals from cell surface 
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receptors to transcription factors in the nucleus, has been found to inhibit apoptosis 
when activated in fibroblasts (Troppmair et al, 1992; Arends and Harrison, 1994; 
Arends et al, 1993). 
Signalling from the Fas and TNFR -I molecules has been of great interest to 
researchers looking into apoptosis mechanisms. Ligation of either TNFR -1 and Fas, 
and indeed irradiation of cells, can result in activation of sphyngomyelinases and 
production of ceramide (HaimovitzFriedman et al, 1994; Cifone et al, 1994; Obeid et 
al, 1993). This pathway is activated independently of damage in the nucleus as it can 
be activated in purified membrane preparations. Treatment of cells with C2- ceramide, 
a cell -permeable synthetic analogue, can induce apoptosis and this can bypass 
pharmacological blockade of acidic sphyngomyelinase (Higuchi et al, 1996). The 
means of action of ceramide in apoptosis is not well understood but it may involve a 
ceramide- activated serine /threonine protein kinase (Cifone et al, 1995; 
HaimovitzFriedman et al, 1994) or a ceramide- initiated ras signalling pathway 
(Gulbins et al, 1995). The ceramide pathway may interact with other signalling 
pathways as several groups have observed that ceramide production and apoptosis 
following Fas or TNFR -1 ligation can be inhibited by the PKC agonist PMA (Tepper 
et al, 1995; HaimovitzFriedman el al, 1994; Obeid et al, 1993). 
Despite the detail that has been collected concerning the workings of signal 
transduction pathways, many questions remain to answered with regard to their role 
in apoptosis. In particular, it remains to be seen how these pathways connect up with 
and activate effector molecules. However, in the case of Fas and TNFR -1, exciting 
recent research has demonstrated a direct physical link between the cytoplasmic death 
domains and a death -promoting signal complex consisting of an adapter molecules 
containing death domains, MORT1/FADD (Fas associated protein with death 
domain) for Fas (Chinnaiyan et al, 1995; Boldin et al, 1995) and TRADD for p55 
TNFR -1 (Hsu et al, 1995), and another protein, MACH/FLICE, which binds to these 
complexes and contains a domain with significant homology to the ced-3/ICE-like 
proteases (Fig. 1.5). It is likely that ligation of Fas or TNFR -1 induces the cysteine 
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cysteine protease activity of MACH/FLICE by causing autocatalysis and release of 
the active cysteine protease domain (Muzio et al, 1996; Boldin et al, 1996). Such 
proteases are thought to be the direct effectors of apoptosis. 
1.1.5.3.4 Signal Integration. 
As discussed above, both death and survival signals activate signal transduction 
pathways that regulate apoptosis. How these pathways are connected to the effector 
mechanisms in order to activate or prevent cell death is still unclear in most cases. 
However some of the molecules that are involved in making the decision of a 
whether a cell should survive or die have been identified. Given that cancer is 
essentially a problem of cell population control and that one means of controlling cell 
number is by deleting excess cells, it is hardly surprising that many of the genes that 
regulate the susceptibility of cells to undergo apoptosis were first identified as 
oncogenes (e.g. bc1-2, c -myc) or oncosuppressor genes (e.g. Rb, p53). 
Fig. 1.5 (overleaf): Signal Transduction by Fas via FLICE. A) Structure of FLICE (Muzio et al, 
1996). The QACQG sequence in the Ced -3 homology domain is similar to that in the active site 
(QACRG) of the other proteases. B) Activation of FLICE (Boldin et al, 1996). FasL binds to the 
extracellular portion of Fas and this causes the intracellular domain to bind to FLICE via 
FADD(MORTI). This interaction causes the activation of FLICE probably by autocatalytic cleavage 













1.1.5.4 A possible mechanism for signal integration: The bel -2 gene family. (Fig. 
1.6) 
The bel -2 oncogene (Tsujimoto and Croce, 1986) undergoes a translocation, t[14,18], 
to the immunoglobulin heavy chain enhancer (Eµ) in over 80% of human follicular 
lymphomas (Chen -Levy et al, 1989). The resulting B cell accumulation is thought to 
be a result of a block in apoptosis in these cells (Hockenberry et al, 1991; 
Hockenberry et al, 1990; Nuilez et al, 1990; Tsujimoto et al, 1987). Ep.-hcl -2 
transgenic mice with high levels of Bd-2 expression in cells of the B lineage also 
show a similar pattern of follicular lymphomas (McDonnell and Korsmeyer, 1991) as 
well as prolongation of cell survival (McDonnell et al, 1990; McDonnell et al, 1989) 
and most functions of B cells including memory (Nuñez et al, 1990). Production of 
autoantibodies in these mice has been described indicating increased tolerance of self - 
reactive B cells (Strasser et al, 1991 b). 
Apoptosis induced by a variety of agents (for example: glucocorticoids, radiation, 
cytokine deprivation or calcium ionophores) in thymocytes can be inhibited by Eµ- 
b0-2 or by Ick promoter -bcl -2 transgenes (Strasser et al, 1991a; Sentman el al, 
1991a; Strasser et al, 1990a). However, directed expression of bel -2 to immature 
thymocytes and in the WEHI -231 B cell lymphoma has been reported not to inhibit 
apoptosis induced by stimulation of the surface antigen receptors (Cuende et al, 1993; 
Fanidi et al, 1992; Sentman et al, 1991) or Fas- mediated cell killing (Strasser et al, 
1995). Bc1-2 has been shown to reduce growth factor requirements of fibroblasts and 
other cell types and can block Myc- mediated apoptosis in CHO cells 
(BISSONNETTE190?) and in Ratl fibroblasts (Wagner et al, 1993). Bc1-2 co- 
operates with Myc in B cell immortalisation (Vaux et al, 1988) and in tumour 
formation (Strasser et al, 1990). By uncoupling the proliferative from the apoptotic 
functions of oncogenes, BcI -2 allows cells to survive that otherwise would be 
eliminated and thereby facilitates oncogenesis. 
Sequence comparison has revealed that bel -2 contains sequence similarity to the C. 
elegans cell death inhibitory gene, ced -9. A bc1-2 transgene rescued cells from ectopic 
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cell death in ced -9 loss -of- function mutants and the conclusion was drawn that these 
two genes were structural and functional homologues (Hengartner and Horvitz, 
1994). Bc1-2 expression is not, however, critical for survival in all mammalian tissues. 
Mice with targeted knockout alleles (10-2 -I -) in the main develop normally, adult 
mice dying with polycystic kidneys and fulminant lymphoid apoptosis (Veis et al, 
1993). However knockout of a related gene, hcIX, results in the death of homozygous 
null embryos at stage E 13 accompanied by massive cell death of neurones and 
immature haematopoietic cells (Motoyama et al, 1995). The long splice variant, 
Bc1X1, which is protective against cell death, is expressed at high levels in brain (Boise 
et al, 1993 ). 
Two protein domains (BH I and BH2) in Bel -2 are conserved in both Ced -9 and 
BclX1, and are known to be involved in inhibition of apoptosis and heterodimerisation 
with the proapoptotic Bel -2 homologue, Bax (Yin et al, 1994a; Oltvai et al, 1993a). 
Using the BHl and BH2 sequences of the Bcl -2- related proteins it was possible to 
clone a further gene, Bak, that enhances the response to apoptotic stimuli (Kiefer et 
al, 1995, Chittenden et al, 1995). A dynamic equilibrium exists between Bc1 -2 /Bax 
(and Bc1X1 /Bax) heterodimers and homodimerisation of Bel -2 (or Bc1X1,) and Bax. 
Bax homodimers are proapoptotic (Yin et al, 1994a), whereas suppression of 
apoptosis by Bel -2 requires heterodimerisation with a killer protein such as Bax (Yin 
et al, I 994b). It is thought that the relative levels of killer and protective molecules 
determines the susceptibility of cells to an apoptotic stimulus (Fig. 1.7). This is 
supported by the discovery of proteins that have no obvious sequence homology to, 
and that interact with, Bel -2 family members in yeast two -hybrid protein interaction 
screens. Increases in the concentration of Bag/Bcl -2 heterodimers tends to increase 
the resistance of JURKAT cells to apoptotic stimuli, including anti -Fas (Takayama et 
al, 1995), whereas Bad binds to Bel -2 and Bc1X1, and displaces Bax thus enabling the 
formation of a greater number of proapoptotic Bax/Bax homodimers (Yang et al, 
1995). 
26 
The anti -apoptotic family members, Ced -9, Bc1-2, Bc1X,,, Mcl -1, A 1 and Nr -13, all 
contain an additional regional of homology (BH4) near the N- terminus that is 
essential for anti -apoptotic activity but is not required for binding to Bax (Hanada et 
al, 1995, Borner el al, 1994). However, Bax does not use its BH 1 or BH2 domains 
to form homo- or heterodimers but uses a separate BH3 domain for dimerisation with 
itself and Bc1-2 (Boyd et al, 1995; Zha el al, 1996). Although Bc1-2 contains a similar 
BI-13 domain, deletion of the Bc12 BH3 domain does not affect protein function but 
replacement of a small region containing the Bc1-2 BH3 domain with a 22 amino acid 
peptide containing the BH3 domain from Bax is sufficient to transfer death -promoting 
properties to Bcl -2 (Hunter and Parslow, 1996). Similarly, overexpression of a 
minimal deletion mutant Bak protein, containing little more than the BH3 domain, 
was sufficient to promote apoptosis (Chittenden et al, 1995a). Since NBK/Nip4Bik 
does not possess BH 1 or BH2, nor any significant homology to any other region of 
Bc1-2 family members except at the 9 amino acid BH3 motif (Boyd el al, 1995), the 
BH3 of proapoptotic family members Bik, Bak, Bax and Bc1Xs (an alternatively 
spliced form of Bc1X that does not contain BH1 or BH2) represents a critical `suicide 
domain'. 
It can be envisaged from the above observations that both apoptotic and survival 
signals perturb the balance between the proapoptotic and antiapoptotic dimers and 
that this integration of signals influences a cell's response to apoptotic stimuli (Vaux 
et al, 1994). However, it is still undecided which of the two groups of factors, the 
proapoptotic (BcIXs, Bak, Bax, Bik) and the antiapoptotic (Bc1-2, Bc1X,,), are 
responsible for passing on their decisions to effector molecules or how this is 
achieved. One model suggests that Bax and Bak are killers in their own right with 
Bc1-2 and Bc1X,, acting to inhibit their activity. Another model suggests that Bax and 
Bak have no function other than to bind Bel -2 or BcIX,, and therefore block their 
protective activity. An attractive alternative, given that the protectors and the killers 
have different functional domains, is that they have interrelated but distinct functions 
and that relative protein concentrations determine the outcome for the cell (Farrow 
and Brown, 1996). Confirmation of one of these models awaits elucidation of 
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immediate downstream effectors and the mechanisms by which they are activated and 
careful analysis of phenotypes of mice containing multiple knockouts of Bel -2 family 
genes. 
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Fig. 1.6: The Bcl -2 /Ced -9 Superfamily. Domain structure of the Bcl -2 family. BH: 
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Fig. 1.7: Model for Integration of Death and Survival Signals by the Bel -2 
Family. (Adapted from Fan-ow and Brown, 1996). The balance between dimers 
containing pro -apoptotic and inhibitory family members is seen in this model as 
being regulated by environmental cues representing death and survival factors. The 
tipping of the balance to the left causes an increase in resistance to death signals 
and vice versa. This therefore determines the susceptibility of cells to death signals. 
It is not known how the Bc1-2 family members interact with the effector molecules 
(ICE -like proteases) to regulate their activity, but both activation and inhibition 
may occur. 
30 
1.1.5.5 The Role o f c -myc in Apoptosis. 
A number of lines of evidence have pointed to the central role of the oncogene c -myc 
in many forms of apoptosis. Firstly, Wyllie et al (1987) noticed that experimental 
rodent fibrosarcomas overexpressing c -myc appeared to grow more slowly and were 
less aggressive than tumours with similar mitotic rates which overexpressed T24 Ha- 
ras. It was noted that there appeared to be a higher incidence of apoptosis in the c- 
myc tumours than in the ras tumours whereas the mitotic rates were similar. 
Secondly, c -myc has been identified as part of a cascade of genes induced by hormone 
withdrawal (Kyprianou et al, 1991; Buttyan et al, 1988; Quarmby et al, 1987) and is 
induced after activation of the T cell receptor of immature thymocytes (Riegel et al, 
1990). Constitutive expression of c -myc can accelerate apoptosis in an Il -3 dependent 
myeloid line upon 11 -3 withdrawal (Askew et al, 1991). Further, convincing evidence 
for a controlling role for c -myc in apoptosis, has come from studies of c -myc, c -myc 
deletion mutants and regulable c -myc genes overexpressed in fibroblasts in culture 
(Evan et al, 1992). 
In normal fibroblasts, c -myc is known to be involved in normal cell proliferation and is 
one of the immediate early growth response genes. While Myc protein levels peak at 
three hours after mitogen stimulation (3 -6 x 10' molecules per cell), unlike other 
genes of this group, levels persist in cells (1 -3 x 10' molecules per cell) so long as 
they remain in a proliferative state. The half -lives of c -myc mRNA and protein are 
very short and endogenous Myc levels fall rapidly when mitogenic stimuli are 
withdrawn, independent of cell cycle stage (Waters et al, 1991; Moore and Evan, 
1987; Dean et al, 1986). Quiescence (GO) is associated with undetectable levels of 
Myc. Enforced Myc expression can stimulate quiescent GO fibroblasts into the cell 
cycle (Eilers et al, 1989) although c -myc antisense oligonucleotides can inhibit 
progression into S phase and not entry into G1 from GO (Heikkila et al, 1987). Myc is 
a basic -helix -loop- helix -leucine zipper (b- I-ILH -LZ) protein and forms a heterodimeric 
complex with Max to form a transcription factor (Amati et al, 1993; Murre et al, 
1989; Landshultz et al, 1988; Blackwood and Eisenman, 1991) which binds to and 
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can activate transcription from a consensus DNA binding site called the E -box: 
CAC(G /A)TG (Prendergast and Ziff, 1991; Blackwood and Eisenman, 1991; 
Blackwell et al, 1990). Max can be displaced from Myc -Max complexes by binding to 
either of the related proteins Mad or MxiI and these interactions negatively affect 
transcription mediated by Myc (Zervos et al, 1993; Ayer et al, 1993). Only a few 
genes have been shown to be transcriptionally regulated by Myc in vivo (Reisman et 
al, 1993; Bello- Fernandez et al, 1993; Benvenisty et al, 1992; Eilers et al, 1991) and 
although there is little mechanistic evidence, Myc is thought to affect the activities of 
proteins that are involved in the proliferative response to mitogens, such as the cyclin 
D- and cyclin E- dependent protein kinases. Mutational analysis has identified a region 
of the c -myc coding region essential for the cotransformation, autoregulation and 
inhibition of differentiation functions of Myc (lying between amino acids 106 - 
I43)(Penn et al, 1990; Freytag, 1988; Stone et al, 1987), as well as regions involved 
with heterodimerisation, DNA binding and regions involved in transcriptional 
activation. These regions are also essential for apoptosis induced by c -myc (Evan et 
al, 1992). 
Evan et al (1992) found that Rat -1 fibroblasts or primary rat embryo fibroblasts that 
constitutively expressed Myc were unable to undergo growth arrest (as measured by 
DNA synthesis) in low serum. However, the cell populations did not increase in 
number due to substantial apoptosis. Proliferating cells overexpressing c -myc were 
induced to undergo apoptosis by conditions causing cell cycle arrest (in GO by serum 
deprivation, late GI by isoleucine starvation or S by thymidine block). Apoptosis was 
dependent upon active Myc and upon regions of Myc required for transformation, 
autosuppression and inhibition of differentiation Further, cells arrested at various 
points in the cell cycle were induced to die upon induction of an oestrogen -regulable 
Myc (MycER). Therefore, the expression of c -myc brings with it at least two 






c -mvc, B -mvb, 
E2F 
Survival Factors, via: 
Bc1 -2. Bc1XL, 
Ras 














Reaper -like Death Domains 
ICE -like proteases 
Apoptosis 
Fig. 1.8: Model for the Control of Apoptosis by Oncogenes such as c -myc. Activation of 
Mitogenic oncogenes such c -mvc causes cells to enter a proliferative compartment where sensitivity 
to cell death caused by various stimuli is increased. This susceptibility can be altered by factors that 
affect survival and by wild -type p53. 
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As result of the requirement of Myc for proliferation, a proliferating cell is therefore 
primed to undergo apoptosis and will do so if there are simultaneous, conflicting 
signals urging it to both proliferate and arrest. In the case of deregulated expression of 
c -myc, a common occurrence in tumours of various types (Bishop, 1991), a fail -safe 
mechanism is therefore in place that deletes cells unless apoptosis is specifically 
inhibited. Rat -1 fibroblasts with deregulated Myc deprived of serum can be rescued 
from apoptosis by the addition of survival factors IGF -1 or PDGF which are unlinked 
to mitogenesis. (Harrington et al, 1994). The selective advantages provided by Myc 
in tumour cells need therefore to be reinforced either by continuous provision of 
growth factors, the co- operation of another oncogene that suppresses apoptosis (e.g. 
Bc1-2 (Wagner el al, 1993; Bissonnette et al, 1992; Fanidi et al, 1992) or a lesion 
further downstream in the cell death pathway. 
Fig. 1.9 (overleaf): The Structure of p53 protein. (From Ko and Prives. 1996). A) Human cancer 
mutation frequency at various sites in the human p53 protein. Mutations cluster in the conserved 
regions (Ronan numerals). Six of the most common 'hot -spot' mutations are labelled. B) Functional 
organisation of the p53 protein. P: phosphorvlation sites. DNA -PK: DNA -dependent protein kinase. 
CK: Casein Kinase. CDK: Cvclin- dependent kinase. PKC: protein kinase C. NLS: Nuclear 
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1.1.5.6 Apoptosis as an Important Mechanism of Tumour Suppression by p53. 
Alteration of the p53 tumour -suppressor gene (Fig. 1.9) is the most commonly 
observed genetic abnormality found in cancers. Inactivation of the p53 protein by 
point mutation or gene deletion occurs in over 50% of sporadic human malignancies. 
Germline mutations in the human p53 gene cause the Li- Fraumeni syndrome of cancer 
susceptibility and homozygous deletion of the murine gene leads to greatly increased 
incidence of spontaneous tumourigenesis. p53 does not form part of a wider protein 
family and so represents a critical target for both mutational as well as viral 
oncogenesis. Strikingly, p53 knockout mice develop normally (except for a 
proportion of female embryonic deaths due to exencephaly) indicating that p53 plays 
no essential role in normal cellular proliferation. On the other hand, the principle 
function of p53 is to mediate the cellular response to DNA damage, thereby 
maintaining genomic stability and preventing the accumulation of oncogenic 
mutations. 
The response to genotoxic agents such as UV or y-irradiation, and chemotherapeutic 
drugs such as etoposide or bleomycin results in a large and rapid increase in p53 
protein concentration mainly owing to a decrease in the rate of degradation of the 
normally short half -life protein. This leads to suppression of cell population growth 
and of transformation initiated by combinations of oncogenes such as HPV16 E7 / 
ras. Cell cycle arrest and apoptosis have been identified as the two main mechanisms 
by which p53 exerts its oncosuppressive properties, although these may be 
supplemented by effects on differentiation, DNA repair, cellular senescence and 
angiogenesis. There has been much debate as to whether the cell cycle checkpoint 
activities of p53 are linked mechanistically to the apoptosis -promoting properties of 
p53. Therefore a discussion of research concerning both of the topics is relevant. 
1.1.5.6.1 Control of the Cell Cycle by p53 (Fig. 1.10). 
A number of inherited syndromes are associated with genetic instability and an 
increased susceptibility to cancer. One of these, ataxia telangiectasia (AT), an 
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autosomal recessive syndrome associated with progressive degeneration of cerebellar 
Purkinje cells leading to ataxia, is also complicated by radiosensitivity, radioresistant 
DNA synthesis and a measurably increased susceptibility to cancer. Cells from 
patients with this syndrome display a similar defect in their cell cycle checkpoint 
response to y- irradiation to that of cells that have defects in p53 function. Kastan et al, 
(1992) discovered that AT cells failed toinduce wt p53 protein in response to y- 
irradiation and that there was no delay of DNA synthesis in these cells. This indicates 
that the gene(s) mutated in AT is (are) normally upstream of p53 in a DNA- damage- 
cell -cycle -arrest signalling pathway. GADD45, a gene from a family of mammalian 
gene amplification and DNA damage genes inducible after ionising irradiation 
(Papthanasiou et al, 1991; Fornace et al, 1989), was found to contain a conserved 
p53- specific responsive element situated in its third intron. In contrast to normal cells, 
AT cells and cells without a functional wt p53 failed to induce GADD45 or p21 (see 
below) in response to y- irradiation and failed to elicit cell cycle arrest (Artuso et al, 
1995; Kastan et al, 1992). The designation of p53 as part of a pathway, lesions in any 
part of which leading to similar functional consequences, could explain how some 
cells sporting normal p53 genotypes may undergo PALA- selected gene amplification 
(Livingstone et al, 1992). 
Overexpression of p53 in many cell types results in arrest of the cell cycle in late G1 
although there is evidence to suggest that p53 may also play a role in arrests at G2 or 
mitosis (M). p53 can act as a sequence -specific transcriptional modulator, trans - 
activating some genes whilst repressing the expression of others. The ability of cells to 
undergo a growth arrest in response to DNA damage correlates well with ability of 
wild -type (wt) p53 and p53 point mutants to induce expression of a number of genes 
(Rowan et al, 1996; Crook et al, 1994; Pietenpol et al, 1994). The best characterised 
p53- responsive gene is p21"' (,I' whose enhanced expression (by overexpression of 
p53 or by DNA damage) is responsible for inactivation of the cyclin / cyclin 
dependent kinase (cyclin/CDK) complexes that orchestrate the timing and the order of 
events of the cell cycle (Dulic et al, 1994; Xiong et al, 1993; Harper et al, 1993). p21, 
by binding via a C- terminal peptide domain, can also inhibit PCNA (an essential 
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processivity factor for DNA polymerases, including polymerase 8) (Nakanishi et al, 
1995; Goubin and Ducommun, 1995; Luo et al, 1995; Chen et al, 1995; Pan et al, 
1995) and thereby inhibits replicative DNA synthesis (Waga et al, 1994). Short gap 
filling by polymerases 8 and c is less sensitive to increased binding of PCNA by p21 
and therefore nucleotide -excision repair of bulky DNA adducts is not as affected (Li 
et al, 1994). Deletion of the p21 gene results in complete abrogation of the p53- 
induced cell cycle arrest in HCT 116 human colorectal carcinoma cells (Waldman et 
al, 1995). Inhibition of the G1 cyclins D and E by p21 prevents phosphorylation of 
the retinoblastoma gene product, pRB, thus quenching the transcriptional activity of 
E2F -1. In turn, E2F -1- responsive genes such as B -myb, which can bypass the effects 
of p21 overexpression (Lin et al, 1994), are therefore inactive: the cell arrests in late 
G1 . A less complete effect of p21 deletion upon cell cycle arrest was seen in 
fibroblasts derived from p21 -/- mice (Bruarolas et al, 1995; Deng et al, 1995). This 
may reflect that other p53- induced proteins, such as GADD45 and cyclin G may also 
affect cell cycle progression and therefore represent redundant mechanisms of cell 
cycle control by p53. 
1.1.5.6.2 Induction r f p53- mediated Apoptosis and it's Relationship to Cell Cycle 
('ontrol. 
The first evidence that p53 was not only a cell cycle regulator but also had a role as an 
activator of cell death by apoptosis came in 1991 when Yonish -Rouach et al (1991) 
transfected a temperature- sensitive mutant of murine p53 (p53va1135) into the M1 
clone S6 mouse myeloid leukaemia cell line. This mutant was previously shown to 
induce a growth arrest in GI in rat embryo fibroblasts at 32.5 °C (Michalovitz et al, 
1990). However, in the transfected M1 cells, a growth arrest was not measurable and 
cells rapidly underwent apoptosis when cells were shifted from 37.5 °C to 32.5 °C 
when the mutant p53 protein adopts the wild -type conformation (Yonish -Rouach et 
al, 1991). Apoptosis was greatest when cells were in the GI phase of the cell cycle 
(Yonish -Rouach et al, 1993). In addition, colonic tumour -derived cells transfected 
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with a metallothionein -1 (MT -1) promoter- driven human wild -type p53 expression 
construct underwent increased apoptosis and regression of tumourigenesis in nude 
mice when induced with zinc chloride (Shaw et al, 1992). Similarly, apoptosis was 
induced at 32.5 °C in murine erythroleukaemia (MEL) cells transfected with the 
p53va1135 mutant (Ryan el al, 1993). The authors of this paper found that their cells 
arrested in GI prior to undergoing apoptosis. Cells synchronised by density arrest and 
released into S phase before activation of the switch to wild -type p53 completed the 
current cell cycle before arresting in the next GI before dying. Inhibition of cells at the 
G 1/S boundary or in GO by mimosine block or isoleucine starvation respectively did 
not result in cell death and it was concluded that p53- induced cell death and p53- 
mediated growth arrest are separate functions. Despite this, p21 expression was 
strongest in tissues and cells that have a high apoptotic rate (ElDeiry et al, 1994). 
Taken together, these studies suggested that p53- mediated apoptosis and GI arrest 
was intimately but not necessarily mechanistically linked, although apoptosis induced 
by wild -type p53 upregulation occurs preferentially in the GI phase of the cell cycle. 
Analysis of tissues from mice with targeted knock -outs of their p53 alleles has 
definitively shown that p53 is required for DNA damage- induced apoptosis of 
thymocytes (Lowe el al, 1993; Clarke et al, 1993), lymphocytes (Howie et al, 1994), 
myeloid progenitor cells (Lotem and Sachs, 1993), and intestinal epithelium (Merritt 
et al, 1994; Clarke et al, 1994). 
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Fig. 1.10: DNA -Damage -Induced Growth Arrest Mediated by p53. (Based upon Bates and 
Vousden, 1996). DNA damage (e.g. ultraviolet light, y- irradiation) is recognised and causes 
stabilisation of p53 which binds to recognition sites in various genes. Transcriptional activation 
causes increases in the concentration of several proteins, most importantly p21. p21 inhibits the 
activity of cyclin- dependent kinases resulting in hypophosphorylation of pRb. Hypophosphorylated 
pRb quenches the activity of the transcription factor E2F -1, which is essential for cell cycle 
progression into S phase. 
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the activities of other cysteine proteases of this novel family (the ICE -like proteases). 
To date the known family members include: ICH- 1/Nedd -2 (Kumar et a!, 1994; Wang 
et al, 1994), prICE (Lazebnik et a!, 1994), CPP32 /Yama/Apopain (Nicholson et al, 
1995; Tewari et al, 1995, FernandesAlnemri et al, 1994), TX/ICH- 2/ICErelll 
(Munday et al, 1995; Kamens et al, 1995; Faucheu et al, 1995), ICErellll /TY 
(Faucheu et al, 1996; Munday et al, 1995), Mch2 (FernandesAlnemri et al, 1995a), 
Mch3 /ICE -LAP3 (Duan el al, 1996; FernandesAlnemri et al, 1995), CMH -1 (Lippke 
et a!, 1996) and FLICE/MACH (Boldin et al, 1996; Muzio et al, 1996). 
1.1.6.1 Structural features of the ICE -like proteases. 
ICE was originally purified from the THP.1 monocytic cell line as a heterodimeric 
enzyme with a 10 kDa (p 10) and 20kDa (p20) subunits ( Thornberry et al, 1992). The 
mature enzyme is derived from a 45kDa precursor by removal of an N- terminal pro - 
domain and an internal region of 26 amino acids. The p45 proenzyme has been shown 
to oligomerise in transfected COS cells and this association may be essential for 
autoprocessing (Gu et al, 1995b). This processing occurs by autocatalysis at specific 
aspartate (Asp) residues (Wilson et al, 1994; Thornberry et al, 1992). The specific 
tetrapeptide acetyl- Tyr -Val -Ala- Asp -aldehyde (ac -YVAD -CHO) inhibits proteolysis 
by ICE by covalent interaction with the thiol group of Cys285 (Thornberry et al, 
I992)and catalytic activity can be abolished if Cys285 is altered by site- directed 
mutagenesis. Thus ICE was classified as a cysteine protease with substrate specificity 
for Asp at the P1 position (the first amino acid N- terminal to the cleavage site). 
Although the active cysteine is located in the p20 subunit, X -ray crystallography has 
shown that other critical amino acids concerned with the formation of the substrate 
binding pocket are to be found in both the p10 and p20 subunits. These structural 
studies also suggest that two p10/p20 heterodimers form a tetrameric active enzyme 
complex (Walker et aI, 1994; Wilson et al, 1994; Thornberry et al, 1992). 
Sequence comparison between ICE and other family members show approximately 
30% identity and suggest synthesis of inactive proenzymes is a common feature of all 
these proteases. The amino acids involved in recognition of the P1 Asp as well as the 
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QACRG sequence containing the active cysteine are conserved in all members. More 
diversity is found in the amino acid residues lining the groove for the P2 -P4 substrate 
positions and this may explain differences in the substrate preferences of the individual 
family members. While subunit molecular masses have only been accurately 
determined for ICE, CPP32 (Nicholson et al, 1995) and Ced -3 (Xue et al, 1996), it 
seems likely from sequence data and the available X -ray crystallography (Rotonda et 
al, 1996) that all the family members are proteolytically processed into a larger and a 
smaller subunit and that these form active heterotetrameric enzyme complexes. From 
the predicted size of the proenzyme and active subunits, the ICE -like protease family 
has been subdivided into the ICE -subfamily (ICE, ICErelIl, ICErelIII) and the Ced -3 
subfamily (Ced -3, CPP32, ICH- 1/Nedd2, Mch2, Mch3 and CMH -1). 
1.1.6.2 Evidence for the Role of ICE-like Proteases in Apoptosis. 
Overexpression of any of the proteases in Rat 1 cells results in apoptosis. However, 
this test alone is not sufficient to prove that a protease is directly involved with the 
apoptotic program. It has been claimed that loading of cells with proteases with 
entirely different substrate specificities, such as trypsin and proteinase K, is capable of 
inducing cell death that displays some of features of apoptosis including membrane 
blebbing, chromatin condensation and DNA degradation (Williams and Henkart, 
1994). Conclusive evidence for a role of the ICE -like proteases in apoptosis has 
come from experiments using natural or synthetic protease inhibitors, knockout mice 
and the characterisation of protease activity in apoptotic cell extracts. 
1.1.6.2.1 ¡Val Inhibitor Proteins. 
The existence of viral proteins that act as inhibitors of ICE -like proteases is indicative 
of the fact that apoptosis is a significant factor in the defence against viral infection. 
Expression of the cowpox virus gene crmA suppressed apoptosis induced by 
overexpression of ICE in Rat1 cells (Miura et al, 1993). CrmA is also capable of 
inhibiting apoptosis induced by growth factor withdrawal (Li et al, 1996; Gagliardini 
et al, 1994), anti -Fas (Tewari et al, 1995b; Tewari and Dixit, 1995b; Los et al, 
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I995b) and TNFa (Hsu e1 al, 1995). Some authors have noted that while CrmA can 
inhibit apoptosis induced by Fas or activation in lymphoid cells, it is less capable of 
inhibiting apoptosis induced by other stimuli such as dexamethasone (Memon et al, 
1995), y- irradiation or serum starvation (Strasser et al, 1995). The explanation for 
this may lie in the observation that CrmA fully inhibited ICE at 104 fold less 
concentration than that required to inhibit CPP32 (Nicholson et al, 1995). It is known 
that Fas- mediated, but not dexamethasone- or y- irradiation- induced apoptosis, is 
abolished in thymocytes from ICE knockout mice (Kuida et al, 1995). 
A baculovirus protein, p35 inhibits premature apoptosis of infected insect cells thus 
increasing the efficiency of virus production (Clem and Miller, 1994; Crook et al, 
1993). p35 is capable of inhibiting cell death of cells in embryonic (and reaper 
transgenic) Drosophila and C. elegans (Hay et al, 1994; Sugimoto et al, 1994; White 
et al, 1994) and blocks the activity of the mammalian proteins ICE, CPP32, ICH -1 
and ICH -2 (Bump et al, 1995). It seems probable that p35 has a broader range of 
target proteases than CrmA. Both p35 and CrmA have Asp residues in the context of 
ICE -like protease cleavage sites and act as suicide substrates for those enzymes: 
cleaved inhibitor protein is less easily dissociable from the enzyme than an ordinary 
substrate and therefore acts as an efficient inhibitor. Intriguingly, the broad spectrum 
of targets enjoyed by p35 can be transferred to CrmA by an exchange of protease 
cleavage sites (Xue and Horvitz, 1995) indicating that these two viral proteins act on 
specific ICE -like proteases by very similar molecular mechanisms. 
1.1.6.2.2 Ssynthetic Protease Inhibitors. 
Small peptides corresponding to the protease cleavage 
site can act as substrates and 
compete with endogenous substrates in cells or cell extracts. 
If the carboxy terminus 
of the peptide is derivatised at the P1 position with aldehyde 
or halomethylketone 
groups, these small peptides become extremely efficient 
inhibitors of protease activity 
and substrates with fluorogenic derivatives can be used 
to monitor enzyme activity 
(Pennington and Thornberry, 1994; Thornberry 
and Molineaux, 1995). In addition, 
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chloro- or fluoromethyketone derivatives also confer the advantage that the peptide is 
permeable to cell membranes allowing inhibition to occur in intact cells. The peptide 
ac -YVHD -CHO, corresponding to the ICE cleavage site in proIL -lß, is capable of 
inhibiting ICE. Substitution at the P2 position is tolerated and the peptide YVAD is 
the most potent ICE inhibitor peptide in practice and was used to purify ICE to 
homogeneity from cell extracts (Thornberry et al, 1992). Derivatives of YVAD that 
inhibit ICE activity have been shown to inhibit, for example, apoptosis mediated by 
Fas (Los et al, 1995; Enari et al, 1995), reaper overexpression in Drosophila (Pronk 
et al, 1996) or trophic factor -deprived chicken motor neurones (Milligan et al, 1995). 
In a similar way to that described for CrmA, apoptosis induced by other means cannot 
always be inhibited by YVAD peptides at concentrations at which cleavage of proIl- 
I ß is completely inhibited (Nett -Fiordalisi et al, 1995). Although YVAD is capable of 
inhibiting the activity of all of the ICE -like proteases, many of the enzymes require a 
much higher concentration of YVAD than does ICE to achieve complete inhibition. 
This may be explained by differences in substrate preference for different ICE -like 
proteases. Whereas ICE cannot cleave PARP (see below) except at high substrate 
concentrations, peptides that include the DEVD sequence inhibit PARP cleavage and 
apoptosis induced by enzymes such as CPP32 which have a strong preference for that 
sequence. Indeed CPP32 has been purified to homogeneity using DEVD peptides 
from the same cell line that ICE was similarly purified using YVAD peptides. 
(Nicholson et al, 1995). This difference in substrate preference between different 
members of the same enzyme class may suggest that each member may perform 
different functions in the apoptotic program or that they are differentially utilised 
depending upon the source of the apoptotic stimulus. However, although some of 
these patterns can be discerned, the fine detail is unlikely to be completely defined 
using peptide inhibitors alone because of the incomplete specificity of the enzymes for 
any one peptide substrate. The combinatorial analysis of ICE -like protease gene 
knockout mice may resolve this. 
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1.1.6.3 Target Substrates of the ICE -like Proteases. 
A large number of proteins are cleaved into specific fragments during apoptosis. One 
of the first identified substrates of an ICE -like protease was NAD-- dependent 
poly(ADP -ribose)polymerase (PARP). PARP is activated by double strand DNA 
breaks and adds chains of ADP -ribose to many proteins, including histones and DNA 
ligase II. Early on in apoptosis, PARP is inactivated by protease cleavage at an Asp 
residue which separates the DNA -binding domain from the catalytic domain. It is 
thought that this inactivation of PARP conserves energy, thus allowing apoptosis (a 
process that requires ATP) to proceed to completion (Earnshaw, 1995; Kaufmann et 
al, 1993; Althaus and Richter, 1987). 
A number of candidates for the PARP -cleavage enzyme have been proposed. A 
protease with similar preference for Asp residues at the PI position as ICE (prICE) 
was identified in chicken cell apoptotic extracts. As this protease activity could not 
process proIL -10 (Lazebnik et al, 1993) and as ICE needed to be present at 50 -100 
fold higher concentration to cleave PARP than to process proIL -113 in a transient 
overexpression assay (Gu el al, 1995a), it is thought that the PARP cleavage enzyme 
is not ICE. On the other hand, recombinant CPP32 can cleave purified PARP in vitro 
(Tewari et al, 1995b). When overexpressed, CPP32 cleaved PARP in stable PARP- 
transfected cell lines ( FernandesAlnemri et al, 1994) and CPP32 was activated at the 
same time that PARP cleavage occurred in anti -Fas- treated Jurkat cells (Schlegel et 
al, 1996). Cleavage of PARP can be inhibited by DEVD peptides (Schlegel et al, 
1996; Nicholson, 1996) and other members of the ICE -like protease family, including 
Ced -3, ICEreIII, Nedd2, Cmh -1, Mch2 and Mch3, are all capable of cleaving PARP 
(FernandesAlnemri et al, 1995a, Duan et al, 1996a; Xue and Horvitz, 1995a; Lippke 
et al, 1996a, Gu et al, 1995a). CPP32 and its close relations, Mch3 and Cmh -1 which 
also have similar enzyme kinetics to CPP32, are the most likely candidate PARP 
cleavage enzymes. 
Addition of purified CPP32 to isolated nuclei is not sufficient to cause changes in 
nuclear morphology (Nicholson et al, 1995) and PARP knockout mice do not show 
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the apoptotic proteases work in concert with each other to cause cell death and that 
substrates other than PARP are responsible for the changes in cellular morphology. 
Importantly, some components of the cytoskeleton and proteins that control cell 
shape such as fodrin, G -actin and Gas2 are known to be cleaved during apoptosis by 
as yet unidentified proteases (Kayalar et al, 1996; Brancolini et al, 1995; Martin et al, 
1995). The adenomatous polyposis coli protein (APC) which is associated with 
junctional complexes is also cleaved during apoptosis (Browne et al, 1994). 
In the nuclear envelope, intermediate filament proteins known as the nuclear lamins 
are probably responsible for maintenance of the integrity of the nuclear membrane 
and these proteins are cleaved in apoptosis (Lazebnik et al, 1993). In contrast to the 
early, parallel degradation of proteins such as PARP and Ul ribonuclear protein, 
lamin proteolysis occurs from 10 minutes following the completion of PARP 
cleavage. This late proteolytic step is 100 times more sensitive to YVAD than PARP 
and addition of the chemical inhibitor TLCK to apoptotic cell extracts inhibits the 
formation of nuclear fragments whilst allowing DNA fragmentation and chromatin 
condensation to occur (Lazebnik et al, 1995a; Lazebnik et al, 1995b). Therefore, 
events in the apoptotic program are temporally controlled with activation of a 
protease (probably CPP32) marked by PARP cleavage. This is followed by lamin 
proteolysis (most likely by Mch2 and not CPP32 (Takahashi and Earnshaw, 1996)) at 
a later stage which results in the break -up of the nucleus into membrane bound 
fragments. These data suggest that a central proteolytic cascade of ICE -like proteases 
controls events in the apoptotic program in an ordered fashion. 
There is further evidence for a cascade -type architecture in which the ICE -like 
proteases play a central role. Overexpression of the protease precursors in bacteria or 
eukaryotic cells can lead to autocatalytic activation. CPP32, however, can be 
activated by other ICE subfamily proteases (Enari et al, 1996; Shimizu et al, 1996; 
Tewari et al, 1995). Likewise ICErelll can cause processing of ICE precursor in COS 
cells and Mch3 contains a DSVD sequence that is similar to the CPP32 cleavage site. 
In addition, thymocyte apoptosis induced by several agents can be halted at various 
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stages with protease inhibitors of different specificities (Zhivotovsky et al, 1995; 
Fearnhead et al, 1995). Therefore, various cell death stimuli converge on the same 
molecular pathway that results in apoptosis. 
1.1.6.4 Regulation of the Protease Cascade (Fig.1.11). 
Once activated, the ICE -like proteases act as a co- ordinated engine that drives 
apoptosis in a stereotyped and temporally controlled manner. The internal 
organisation of this central pathway has been discussed above: the substrates for each 
protease include other members of the ICE -like protease family that act at a lower 
level in a protease cascade.This type of organisation could therefore ensure that the 
morphological and other biochemical events of apoptosis occur in the correct order 
and, depending on the enzyme kinetics for each substrate at each level, could also 
regulate the timing of events. Despite the recognition of some of the components of 
this death mechanism and their likely interactions, the molecular mechanism by 
which death and survival signals are integrated into the decision of a cell to die, or 
how these decisions activate the ICE -like protease cascade, is not known. A number 
of observations outlined below illustrate potential control points. 
At the transcriptional level, all of the ICE -like protease mRNAs can be detected in 
most tissues. One mechanism of activation of the proteases may be to cause an 
increase in the intracellular concentration of one or more of the enzymes. To support 
this, ICE is induced by loss of cellular adhesion and by the transcription factor IRF -1 
(Tamura et al, 1995; Boudreau et al, 1995). mRNA splice variants have been 
described for some of the family members including ICE, ICH- 1/Nedd -2, Mch2 and 
Mch3 (FernandesAlnemri et al, 1995b; Wang et al, 1994b; FernandesAlnemri et al, 
1995b; Alnemri et al, 1995b). The shorter of the two human ICH -1 splice variants 
encodes a truncated form of the protein (ICH -1s) that does not contain the active 
QACRG sequence. Expression of ICH -1s in Rat -1 cells inhibited apoptosis induced 
by ICH -1 L or serum deprivation presumably by hetero- oligomerisation between ICH- 
ls and ICH -1L (Wang et al, 1994). However, the mouse equivalent, Nedd2s, has no 
activity towards cell death in FDC -pl cells (Kumar and Harvey, 1995). Hetero- 
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oligomerisation between members of the same sub -family, for example between 
CPP32 and Mch3 or between ICE and ICEreiII, has been observed (Gu et al, 1995b; 
Faucheu et al, 1995b; FernandesAlnemri et al, 1995b) and this may act to regulate 
enzyme activity or to alter substrate preferences. 
Post -translational modification of the precursor protein seems the most likely control 
point for the ICE -like proteases. A role for glycosylation or phosphorylation has not 
been shown. Therefore, the critical step appears to be at the point of cleavage of the 
first protease precursor in the cascade into its active subunits. In the Fas death 
pathway, ligation of CD95 /Fas by its ligand results in the activation of the CPP32 - 
like activity of FLICE/MACH by direct protein -protein interactions at the 
cytoplasmic death domain of the receptor (Muzio et al, 1996; Boldin et al, 1996). 
FLICE and CPP32 can also be directly activated by proteolysis by the CTL granule 
serine protease Granzyme B (Muzio et al, 1996; Martin et al, 1996; Quan et al, 1996; 
Darmon et al, 1995). 
Not all death pathways are so simple, however, as some death signals may not always 
result in apoptosis. It is the integration of death and survival signals that determines 
the activation of the ICE -like proteases in these situations. The mechanisms to deal 
with these conflicting signals are therefore likely to be more complex than in Fas- 
mediated apoptosis. While activation of the proteases is not well understood, 
negative regulators of apoptosis have received much attention. Members of the Bc1-2 
family are related to the C. elegans ced -9 gene that negatively regulates the activity 
of ced -3 and ced -4 in embryonic cell death. Bcl -2, Bc1XL and viral homologues such 
as adenovirus E 1 B -19K have been shown to block cell death by many stimuli (see 
above). Activation of CPP32 is dependent upon the activation of ICE in PC12 cells 
and activation of ICE is blocked by Bcl -2 or Bc1XL (Shimizu et al, 1996). Similarly 
activation of CPP32 or Mch3 by E1A or following treatment with staurosporine was 
blocked by Bcl -2 or its apoptosis inhibitory homologues (Boulakia et al, 1996; 
Chinnaiyan et al, 1996). In contrast, Fas- or TNFR -1- mediated apoptosis, while 
sensitive to inhibition of protease activity by CrmA, is not sensitive to Bc1 -2 or 
49 
Bc1XL (except in the liver)(Duan et al, 1996; Memon et al, 1995; Chiu et al, 1995; 
Rodriguez et al, 1996), indicating that the point of control of most apoptotic 
pathways by ced -9 homologues lies upstream, or at the activation step of the ICE -like 
proteases. 
1.1.7 Apoptosis: Remaining Questions. 
As is apparent from the discussion above, there are many aspects of the control and 
execution of the apoptosis pathway that remain to be worked out despite intensive 
research activity that has led, in only a few years, to a recognition of the main 
molecules involved. In particular, the precise mechanisms by which molecules such 
as p53 and c -myc transmit death decisions to effector molecules (ICE -like proteases) 
remains to be determined. Co- operation between p53 and c -myc in the induction of 
apoptosis has been hypothesised. Experiments where apoptosis could be triggered by 
specific manipulation of the expression of individual (or combinations of) genes 
would be most informative, especially in stable cell lines or transgenic animals. Such 
systems could be eminently suitable for biochemical analysis and genetic dissection 







Mch4 ICE or 
Mch5 ICE -like 
CPP32 
PARP Cleavage Lamia Cleavage 
Fig. 1.11: Organisation of the ICE -like Protease Cascade. (Adapted from 
Fernandes- Alnemri et al, 1996). This scheme outlines the known proteolytic events 
that control the order and timing of the apoptosis effector program. A stimulus 
(FasL, Granzyme B or other stimulus X) results in activation of ICE -like proteases 
culminating in the activation of similar enzymes such as CPP32 that can mediate 
end -substrate cleavage or activation of downstream proteases that can cleave a 
different range of substrates. 
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1.2 Introduction: Conditional Mammalian Expression 
Systems. 
The ability of an organism (or a cell) to respond to a stimulus, biochemical or 
otherwise, in order to adapt its metabolism to its environment, is a central focus of 
biological research. The appearance in F. coli of specific enzymes only in the presence 
of certain substrates, such as lactose which leads to the induction of three enzyme 
activities including ß- galactosidase (LacZ), lead to the conclusion that such responses 
to external signals were mediated by genetic units. The co- ordinate induction of the 
enzyme activities following a single chemical stimulus and controlled by a genetically - 
linked but distinct regulator (repressor) protein acting at a site termed an operator, 
prompted Nobel laureates F. Jacob and J. Monod to describe such an organisation as 
an operon (Jacob el al, 1960). Subsequent extensive genetic and physical 
characterisation of the E. coli lac operon as well as operon architectures used in other 
prokaryotic and yeast gene systems, has provided much insight into the general 
mechanisms of the regulation of gene function (Miller and Reznikoff, 1980), the 
principles of which can be applied to the more complex mammalian systems. 
This project focused upon the application of experimental gene regulation systems for 
use in mammalian cells such that the activity of specific, introduced proteins could be 
specifically controlled in a temporal manner. In particular, genes known to have 
negative effects on cell viability or cell cycle were chosen for study for two reasons: 
Firstly, p53, c -myc and rredd2 as discussed above, have previously been directly linked 
to effects on apoptosis and (or) growth arrest and these properties may affect 
pathological processes such as oncogenesis. In addition, p21"AF' Cl' has been 
proposed as a candidate mediator of the oncosuppressive activity of p53. The ability 
to experimentally regulate the expression of these genes is clearly of interest to 
researchers working in the related fields of cancer biology and apoptosis. Secondly, 
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because of their potential to cause cell death or prolonged growth inhibition, p53, p2I 
and nedd2 are reasonable test genes to evaluate the stringency of regulation of gene 
expression in experimentally inducible gene expression systems. The originators of 
many of these systems have made suggestions, based upon relatively lower levels of 
expression of reporter genes in the uninduced state, that such systems should be 
suitable for the controlled expression of deleterious genes in tissue culture or 
transgenic animals. While such systems have been used to regulate expression of 
genes that positively control cell growth or are at least neutral as regards cell death 
and cell cycle effects, confirmation of such suppositions for genes that have intrinsic 
death -inducing activity has been lacking in the literature. 
1.2.1 Constitutive versus Conditional Gene Expression. 
A significant problem when investigating the functions of genes putatively involved in 
the control of apoptosis is the difficulty of producing stable cell lines that show 
elevated levels of expression of a cell death transgene. Conventional expression 
vectors containing apoptosis genes, such as Ichl Nedd (Wang et al, 1994), which 
cause constitutive overexpression, can only be used effectively in transient expression 
assays. This sort of assay usually requires the cotransfection of, or fusion with a 
reporter gene such as IacZ in order to mark transfected cells. If the test gene is lethal, 
then the majority of /acZ- positive cells will be apoptotic (Miura et al, 1993). The 
value of transient transfection assays in dissecting biochemical pathways is limited as 
the transfection efficiency is often low and there is considerable heterogeneity in both 
level and timing of expression. Furthermore, it has not been possible to generate 
transgenic animal strains in which the in vivo effects of cell death gene expression can 
be studied. An exception to this is the use of constitutive promoter /enhancer elements 
that are conditional in the sense that they are active only in specific tissues. 
An alternative approach for expression of cloned apoptosis genes is to use inducible 
genes. The activity of these genes should ideally 1) be specifically, rapidly and 
reversibly inducible by exogenous stimuli that otherwise have no detectable biological 
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activity in the test system; and 2) show minimal expression in the uninduced state, but 
good induction in the presence of an inducing stimulus. The remaining portion of this 
chapter introduces the gene systems that were considered for use in this project. 
Firstly, exogenous control at the protein level is considered for a temperature - 
sensitive allele of murine p53 and for fusion of steroid receptor hormone- binding 
domains to oncoproteins such as c -Myc. A survey of inducible promoter systems 
derived from mammalian viruses or endogenous mammalian genes follows. Finally, 
synthetic inducible vector systems derived from components drawn from E.coli, yeast 
and mammalian DNA and that have been claimed to conform closely to ideals 1) and 
2) above are discussed. 
1.2.2 Temperature -Sensitive Mutant p53 
Gannon et al, (1990) defined two alternative conformations of the p53 protein 
product: a pseudo- wild -type, growth- suppressor product immunoreactive with the 
monoclonal antibody PAb246 (Cook and Milner, 1990; Yewdell et al, 1986; Wade - 
Evans and Jenkins, 1985) and "an overtly mutant (PAb240 +) form" (Gannon et al, 
1990). It appears that a variety of activating mutations in p53 cause a common 
conformational shift (Gannon el al, 1990; Milner and Cook, 1986). Further, the 
conformation of temperature- sensitive mutants, for example murine p53Va1135, can 
be switched between a PAb246+ form (pseudo -wild -type) at 32°C to an activated 
mutant conformation (PAb240 reactive, PAb246-) within 5 minutes upon temperature 
shift to 37°C (Milner and Medcalf, 1990). 
Whilst wt -wt and mutant -mutant p53 complexes form readily when mixed post - 
translationally in vitro, complexes containing mutant and wt p53 can only be produced 
when translated together (Milner el al, 1991). Using the temperature- sensitive mutant 
p53va1135 and a cell -free translation system, Milner and Medcalf, (Milner and 
Medcalf, 1990) showed that the product of a wild -type allele is forced into the mutant 
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conformation when co- translated with temperature sensitive mutant p53 at 37 °C (Fig. 
1.12). Further, when translated at 32°C the complex formed consisted exclusively of 
p53 molecules in the wild -type (PAb246 +, PAb240-) conformation. Upon 
temperature shift to 370C there was a loss of reactivity of PAb246 and a co- ordinate 
gain in PAb240 reactivity indicating that the mutated p53 had driven the product of 
the wild -type allele into the mutant form. This shift can occur during or after 
translation (Fig. 1.12). 
In parallel to a temperature- dependent shift in antibody reactivity, p53val153 also 
undergoes a shift in function. When overexpressed in some cell lines, the temperature - 
sensitive mutant acts like wild -type p53 at 32 °C by causing apoptosis (Yonish -Rouach 
et al, 1991) and (or) growth arrest in late GI (Ryan et al, 1993; Yonish -Rouach et al, 
1993; Ginsberg et al, 1991; Michalovitz et al, 1990). At 37 °C, overexpressed 
p53val135 has the properties of a dominant negative mutant p53. Therefore this 
mutant can be used to study the overexpression of both mutant and wild -type p53 in a 
single stably -transfected cell line by maintenance of cells in culture at 37 °C until a 
temperature shift to 32 °C (wild -type) is required. 
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Wild type p53 Homodimers Mutant p53 Homodimers 
m 
p53va1135 p53va1135 
Homodimer at 32°C Homodimer at 37 C 
Wild type and p53va1135 Heterodimers 
Wild type and Mutant Heterodimers 
Fig. 1.12: Conformational Model of the Dominant -negative Effect of Mutant 
p53. p53 commonly oligomerises. Wild type (wt) only complexes adopt one 
conformation (circles) whereas mutant (m) homo -oligomers adopt a distinct 
conformation (rectangles). Temperature- sensitive p53 (p53va1135) (mTs) homo - 
oligomers can adopt either conformation depending on the temperature and readily 
change conformation upon temperature shift. Many p53 mutants including 
p53val135 at 37°C can force wt p53 to adopt the mutant conformation when co- 
translated. The conformational influence upon wt p53 by p53va1135 is reversed 
upon temperature shift to 32°C. Complexes containing non -temperature -sensitive 
mutant p53 molecules can adopt only one conformation (whereas wt only 
complexes may adopt a mutant -like conformation upon DNA binding (Halazonetis 
et al, 1993)). 
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1.2.3 Steroid Hormone -Regulable Chimaeric Proteins 
Picard et al, (1988) showed that fusion of the steroid hormone receptor binding 
domain (HBD) from the glucocorticoid receptor (GR)(Fig. 1.13) to a heterologous 
protein (the adenovirus E1A oncogene) rendered that protein inactive in the absence 
of the appropriate steroid hormone (dexamethasone (Dex)). Upon addition of Dex, 
however, activity and binding of E1A to its normal target sequence (E3) was restored 
to levels close to that of wild -type El A. Subsequently, successful regulation of many 
other proteins by HBD -fusion (reviewed by Walker and Enrietto, (1995)), including 
c -Myc (Eilers et al, 1989), Fos (SupertiFurga et al, 1991) and p53 (Roemer and 
Friedmann, 1993) has been reported. Most of the published fusion proteins involve 
fusion with the HBD of the human oestrogen receptor (hER) although other steroid 
receptor HBDs have been used (Table. 1.1). Non -ligand -bound HBDs are thought to 
interact with the large chaperone protein Hsp90 (Green and Chambon, 1991) thus 
rendering the fusion protein inactive and causing the release of fused transcription 
factors from their cognate DNA binding sites. 
The regulable nature of chimaeric proteins containing steroid HBDs has facilitated 
the study of cellular processes that are not ideally suited to dissection using 
traditional constitutive expression technology. For example, cell culture conditions 
that determine the differentiation of v -Rel transformed bone marrow cells to two 
independent cell lineages were arrived at using cell clones derived by transformation 
with a v- Rel -ER vector (Boehmelt et al, 1995). Discrimination between the short- 
and long -term effects of c -Fos expression on the differentiation of polarised epithelial 
cells was achieved with a Fos -ER construct. This technology also allows a distinction 
to be drawn between the proximal effects of proto -oncogene overexpression that may 
initiate cellular proliferation from irreversible changes that occur later in the course 
of oncogene- driven transformation. In addition, HBD fusion to proteins that 
themselves activate differentiation programs (e.g. C /EBP (Umek et al, 1991)) or 
induce cell death (e.g. p53 (Roemer and Friedmann, 1993)) allow the transfected 
cells to be propagated in the absence of inducer until stimulated with ligand. Fusion 
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specific recombination proteins, such as Cre and FLP, have enabled the design of 
increasingly more complex and biologically meaningful gene targeting experiments 
that overcome the problems of embryonic lethality of many mutations inserted by 
conventional targeting technology (Zhang et al, 1996; Metzger et al, 1995; Logie and 
Stewart, 1995 ). The c- Myc -ER fusion protein was instrumental in the demonstration 
that constitutive activation of c -myc in serum- deprived Rat -1 fibroblasts not only 
caused inappropriate cell proliferation but also induced apoptosis (Evan et al, 1992) 
that was rescued by specific survival factors such IGF -1 (Harrington et al, 1994). 
Owing to the low toxicity and specificity of the inducing agents, the steroid receptor 
chimaeras, in particular those involving the ER HBD, together with some other 
inducible gene systems, open up the possibility of identification of downstream target 
genes of transcription factors by subtractive or differential cDNA techniques from 
otherwise identical cell lines or tissues. Using these methods, MHC -I and HMG 14(b) 
were two genes whose expression were altered by ligand- activated v -relER (Boehmelt 
et al, 1992). 
The use of fusion proteins has several advantages over the isolation and use of 
temperature- sensitive mutants. Firstly, it is often more convenient to construct a 
fusion gene in vitro than it is to screen many potential mutant proteins for 
temperature- sensitive activity in vivo. Secondly, fusion protein activity is tightly 
controlled by the presence or absence of ligand and switching of activity is fast and 
readily reversible. Often, is proteins, for example p53val135, although readily 
reversible by temperature shift are not completely `on' or `off' at a particular 
temperature and may need to be shifted to temperatures that are non -physiological 
(and that may elicit the pleiotropic heat -shock response) in order to achieve maximal 
effect. However, use of fusion proteins have a few disadvantages: Responses to ligand 
cannot be studied in cells with endogenous hormone receptors or that produce 
endogenous ligand. In most cases, though, the HBD chosen is an attenuated human 
hER (HE 14: Kumar et al, (1986)) which has a mutation (G400V) that results in 
relative insensitivity to endogenous mildly oestrogenic compounds but not to the 
physiological inducer: 17J3- oestradiol. In addition, laborious procedures are required 
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to charcoal -strip steroids from serum used in tissue culture and cells must be cultured 
in medium devoid of Phenol Red, a mildly oestrogenic pH indicator dye. This 
procedure may not completely prevent low -level activation of the hER however 
(Berry el al, 1990; Danielian et al, 1993). It is possible that oestrogenic compounds 
may also leach from certain tissue culture plastics and thus confound experiments with 
ER- fusion proteins. Also, when considering experiments with transcription factor - 
HBD fusions, it is important to exclude the possibility that, other than the introduction 
of steroid sensitivity, fusion of the receptor to an heterologous protein does not itself 
produce a novel activity. Disruption of important protein functions caused by an 
adjacent HBD fusion can be controlled for by making two fusion proteins: fusions 
being made for both the amino or carboxyl termini. Further, HBDs of steroid 
receptors overlap with a region that contain endogenous transcriptional activation 
property (the TAF -2 activity). The TAF -2 activity may contribute to ligand- 
independent activity: for example in a FosB -ER fusion (Schuermann et al, 1993). The 
transcriptional activity of ER TAF -2 can be separated from the activity of the fused 
transcription factor by comparison of the effects of ligand, l 73- oestradiol, and its 
analogues ICI 164.384 and Z- 4- hydroxytamoxifen (4 -OHT). ICI164.384 [N-n- butyl- 
1 I (3,173- dihydroxyestra- 1, 3, 5( 10)- trien- 7a- yl)- N- methylundecamide] (Wakeling and 
Bowler, 1988) is a competitive antagonist of the oestrogen receptor and its TAF -2 
activity and therefore results in complete inactivation of fusion proteins. However, 4- 
OHT is a partial antagonist that, like 1713-oestradiol stimulates the TAF -1 activity in 
the amino terminus and release of Hsp90 by the ER. 4 -OHT does not, however, 
stimulate the TAF -2 activity. Therefore 4- hydroxytamoxifen activates ER- fusion 
proteins but does not elicit transactivation by TAF -2 in such a setting. 
Many of the drawbacks of the ER HBD domain in fusion proteins has been recently 
overcome by the isolation of a mutant murine ER (G525R: ER`m) that is insensitive to 
estradiol but remains sensitive to 4- hydroxytamoxifen (Littlewood et al, 1995; 
Danielian et al, 1993). The G525R mutant disrupts the TAF -2 activity and alleviates 
the need to use charcoal -stripped serum and Phenol Red -free medium. It also opens 
up the possibility of using ER`m- fusion proteins as transgenes in vivo. Tamoxifen has 
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been well characterised in both animal and human trials, being metabolised to 4- 
hydroxytamoxifen in the liver, although it has been shown to exert oestrogenic effects 
(probably mediated by TAF -1- dependent trans- activation) upon certain tissues such 
as endometrium and bone (Gottardis et al, 1988, Jordan et al, 1987; Jordan, 1984). 
Table. 1.1. Steroid receptors used in chimaeric proteins (Walker and Enrietto, 
1995) 
Steroid Receptor Ligand Action of Ligand 
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Fig. 1.13: Hormone -Binding Nuclear Receptors: GR and ER. (Data from Green and Chambon, 
1991 and Eilers et al, 1987). A) Structure of the human glucocorticoid receptor (hGR) showing the 
DNA -binding (DBD) and hormone - binding (HBD) domains. Also indicated are the two trans - 
activating domains zl and z2. The HBD used in fusions to heterologous genes is shown (lower 
portion). B) Structure of the hER. TAF -1 and TAF -2 are the two trans- activating regions. The lower 
portion represents the HBD (HE14) used in ER- fusion proteins. 
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1.2.4 Systems Based Upon Mammalian Inducible Genes. 
1.2.4.1 Heat -shock Promoters. 
Temperature elevation or exposure to toxins constitute physiological and 
environmental stresses and the cellular survival response to such stimuli is universal 
and mediated by the co- ordinated induction of a highly conserved set of heat shock 
proteins (HSPs) (see Kroeger and Morimoto, (1995) for review). As the severity of 
the inducing stimulus increases, a rapid (within minutes) general repression of 
transcription occurs concomitantly with a 50 to 100 -fold induction of HSPs. The 
function of the inducible heat shock proteins is to catalyse (chaperone) the correct 
refolding of denatured or nascent proteins during heat shock. The multiple related 
heat shock genes correspond to the classical operon architecture of Jacob and Monod 
(see above) as the induction of HSP genes is dependent upon activation of a heat - 
regulable (in this case trimeric) transcription factor, Heat Shock Factor (HSF), which 
binds to a heat shock element (HSE) found within the promoters of the inducible 
HSP genes (Fig. 1.14). The HSE is a symmetrical element consisting of a minimum 
of three inverted direct repeats of the structure: 5'- nGAAn -3' (Kroeger et al, 1993; 
Perisic et al, 1989; Xiao et al, 1991; Xiao and Lis, 1988; Amin et al, 1988). When 
linked to the promoter of an heterologous reporter gene, the HSE is capable of 
rendering that promoter heat -inducible (Bienz and Pelham, 1986; Pelham and Bienz, 
1982). The distance of the HSE from a basal promoter and co- operation between 
HSF and the basal promoter- binding factors determines the degree of activation of 
the promoter by heat (Williams and Morimoto, 1990; Greene and Kingston, 1990). 
Once sufficient HSPs have been produced, HSF is dissociated from the HSE owing 
to binding by HSP70 in an autoregulatory negative feedback loop (Abravaya et al, 
1991; Abravaya et al, 1992). 
Whilst promoters containing HSEs linked to heterologous genes have found a use in 
transgenic plants, nematodes and flies as inducible gene expression systems and as 
62 
biosensors for environmental agents, heat shock -inducible promoters have been used 
with heterologous reporter genes in mammalian cells, but these vectors are effectively 
limited to the study of inducible gene expression following cellular stress and in 
transgenic mice to monitor cell lineage dependent Hsp70 expression (Dix el al, 1996). 
These vectors have failed to find general applicability in experimental mammalian 
systems owing to the manifold stimuli that can elicit an heat shock response, 
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Fig. 1.14: A) Structure of the Proximal Promoter of the Human HSP70 Gene. 
(Kroeger and Morimoto, 1985). Indicated are the critical sequence elements of 
transcription factor binding sites. HSF: Heat Shock Factor; CBF: CCAAT -box- 
Binding Factor. CTF: CCAAT- box -Binding Transcription Factor. B) Human Heat 
Shock Factor -I (hHSF -1). Black box: DNA binding domain. Green and red boxes: 
Leucine zipper motifs that mediate HSF trimerisation. 
1.2.4.2 Metal Responsive Promoters. 
The metal ions that are essential for life as trace elements are: Zn2`, c02-,Ni2-,Cu' l- 
and Fe'.. These ions are integral constituents of many proteins and more than 300 
enzymes are known to require zinc, including the zinc finger transcription factors 
(Vallee and Auld, 1990) and carbonic anhydrase (Keilin and Mann, 1940). Specific 
import systems and non -specific cotransport systems have evolved to provide for 
cellular metal ion requirements, but mechanisms are required to ensure that 
intracellular metal concentrations do not become toxic or to ensure that toxic heavy 
metals, such as cadmium and mercury, are removed from the cell. In eukaryotes, the 
best understood mechanism for dealing with both essential and toxic metals is by 
intracellular sequestration by metalothioneins (reviewed by Heuchel et al, (1995). 
Metalothioneins are small cysteine -rich proteins (-61 amino acids, 20 of which are 
cysteines) that are strongly conserved from fungus (Neurospora crassa) to man and 
can bind up to the equivalent of seven bivalent transition metal ions, which in most 
cells are mainly Zn2 -, Cu2- and Cd2- (Fig. 1.15 A). Cadmium has 104 -fold higher 
affinity for metallothionein than zinc ( Durnam and Palmiter, 1987). 
The four mouse metalotheinein genes (MT -I to MT -IV) are clustered within a 50kb 
region on chromosome 8, whereas there is one MT -II gene, a cluster of tightly- linked 
MT -I genes on chromosome 16 and several pseudogenes in the human genome 
(Quaife et al, 1994; West et al, 1990; Searle et al, 1984). Regulation of 
metallothionein activity is at the transcriptional level, although only MT -I and -11 
proteins are inducible by heavy metals (Quaife et al, 1994; Palmiter et al, 1992; 
Durnam and Palmiter, 1981; Karin and Herschman, 1980). Multiple metal response 
elements (MREs: 6 in the mMT -1 promoter (Fig. 1.15, B and C)) have been found 
within 200bp upstream of the transcriptional start site of the MT -I and -II genes and 
in the mMT -I gene conform to a consensus sequence: 5'- CTNTGCRCNCGGCCG -3' 
(the minimal core for metal responsiveness is underlined) (Mueller et al, 1988; Stuart 
el al, 1984). Tandemly- repeated MREs confer metal responsiveness to an 
heterologous reporter gene when placed upstream of a minimal promoter (TATA 
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box)(Stuart el al, 1985) and 8 copies of the strongest MRE from the mMT -I 
promoter (MREd) can act as a metal- responsive enhancer when placed at a distance 
to an heterologous gene (Westin and Schaffner, 1988; Serf ling et al, 1985). 
The transcription factor that binds to MREs and is responsible for metal inducibility is 
MTF-1, a zinc -finger protein. In contrast to wild -type embryonic stem (ES) cells, 
MTF -1 -/- ES cells contain no detectable MT -I or MT -II mRNA either in the 
presence or absence of zinc, cadmium, nickel or lead. In addition, transfection of a 
4xMREd reporter gene into MTF -/- stem cells produced barely detectable levels of 
expression with or without 400µM zinc. Restoration of basal and inducible reporter 
gene activity was restored to levels observed in wild -type ES cells by cotransfection 
of an MTF -1 expression vector (Heuchel et al, 1994). The requirement for MTF -1 for 
basal promoter activity is intriguing as it may suggest that the concentration of zinc 
may determine the tightness of binding of MTF -1 zinc fingers to MBEs or that other 
factors are involved in the regulation of the transcriptional upregulation elicited by 
increased metal concentration (see Heuchel et al, (1995) for further discussion of 
these possibilities) 
metallothionein promoters from mouse, human and sheep have been used to 
experimentally regulate the expression of several heterologous genes, including 
several oncogenes (Khan et al, 1996; Touray et al, 1991; Bonham et al, 1991). In 
particular, metal responsive constructs have been successful in controlling certain 
circumstances where expression of an antisense RNA or a dominant -negative mutant 
protein has effects that inhibit cell growth and transformation (Touray et al, 1991; 
Kaplan, 1994; Schilbach et al, 1990). The sheep MT -Ia promoter has been 
particularly effective as an inducible promoter it exhibits low or negligible uninduced 
expression, lower than achieved by the murine MT -I promoter (Walter et al, 1991). 
Whilst it produced a graded induction of v -Myc in response to Zn2+ in Rat 1 cells 
(Bonham et al, 1991), the mMT -I promoter linked to an APRT gene produced a 
stepped threshold response in CHO cells (Walter et al, 1991). Human promoters have 
not been so effective. The hMT- 1 a promoter has been observed to exert "tight, but 
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not absolute control of transcription" by zinc (Khan el al, 1996), while leaky 
expression from an MT -SV40 large T antigen construct in the uninduced state was 
sufficient to allow inappropriate cellular proliferation of primary fetal intestinal cells 
that resulted in no observable difference in differentiation markers between the 
induced and uninduced states (Paul el al, 1993). Further, hMT -IIa- regulated 
expression of an MHC -I1 antisense RNA transgene in the spleen was only increased 5- 
fold by zinc administration (lmoto et al, 1993). In addition, several MT promoters, 
including hMT -IIa, are also responsive to activation of the glucocorticoid receptor as 
they also contain glucocorticoid response elements (GREs)(Touray el al, 1991). 
Concerns about the responsiveness and basal activity of MT promoters, together with 
the known toxicity of the inducing agent (commonly cadmium or high concentrations 
of zinc), compromises the choice of such vectors for experiments involving the 




a -54 CTTTGCGCCCGGACT -40 
b -56 GTTTGCACCCAGCAG -70 
f -94 CTATGCGTGGGCTGG -80 
mMT-1 
c -132 AAGTGCGCTCGGCTC -118 
d -150 CTCTGCACTCCGCCC -136 
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Fig. 1.15: A) Metallothionein Binding of Metal Ions (from Heuchel et a1,1995). B) Metal 
Response Elements from the mouse Metallothionein-I (mMT -I) gene promoter (Heuchel et al, 1995). 
C) Structure of the mMT -I Promoter. MRE: metal response element. 
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1.2.4.3 Glucocorticoid Inducible Vectors. 
Two mammalian expression vectors, pMAMneo (Clontech) and pMSG (Pharmacia), 
are commonly used for the glucocorticoid- inducible expression of exogenous genes. 
Both these vectors contain an expression cassette containing the long terminal repeat 
(LTR) enhancer /promoter of the mouse mammary tumour virus (MMTV) which 
contains several glucocorticoid response elements (GREs) (Schule et al, 1988; Strahle 
et al, 1988; Ponta et al, 1985; Buetti and Diggelmann, 1983; Scheidereit et al, 1983; 
Payvar et al, 1983), deletion of which results in a loss of inducibility (Kuhnel et al, 
1986; Hynes et al, 1983). The response to glucocorticoids (such as dexamethasone 
(DEX)) and progestins is mediated by binding of the appropriate ligand -bound 
hormone receptor to the GREs. Whilst the progesterone receptor (PR) has a more 
limited cell -type distribution, the glucocorticoid receptor (GR) is expressed in nearly 
all mammalian cells. The GR was the first identified and characterised member of the 
steroid receptor superfamily (Evans, 1988) and like the other members (see above) 
has three main domains: an N- terminal domain which contains the t 1 transcriptional 
activation activity; a DNA binding domain which specifically recognises the GRE 
sequence by two zinc finger motifs; and a C- terminal hormone binding domain which, 
in addition to mediating ligand binding, also contains the t2 trails- activation function 
as well as the determinants for specific nuclear localisation and dimerisation (reviewed 
in Eggert et al, (1995)). In the non -ligand bound state, the inactive GR is located in 
the cytoplasm and GR monomers are bound by two Hsp90 molecules and one Hsp59 
molecule. Upon activation by ligand this complex dissociates and the GR is 
transported to the nucleus where it binds to the GRE as a homodimer. Unlike the PR 
and the ER, which are known to interact directly with the transcription initiation 
complex (TIC) by contacts with TFIIB (Ing et al, 1992), such an interaction has not 
been proven for the GR. However, the GR is known to synergise with other 
transcription factors (e.g. AP -1) bound to adjacent sites on glucocorticoid- inducible 
promoters, possibly by co- operative binding or via other accessory factors (Eggert et 
a!, 1995). 
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In rat hepatoma cells, expression from integrated MMTV proviral DNA is suppressed 
by a putative repressor protein and the maximal inducibility of viral mRNA in these 
cells is determined by the relative level of GR (Tanaka et al, 1993). Accordingly, 
synthetic promoters containing multiple GREs are highly inducible in cells that 
overexpress the GR (Israel and Kaufman, 1989) or PR (Mader and White, 1993). 
Cells transfected with MMTV -based vectors containing both the GR and reporter 
genes result in positive feedback when treated with DEX and this results in high 
inducibility factors, in one case of the order of 104 -fold without a significant increase 
in background expression (Ko et a1, 1989). The glucocorticoid- inducible system has 
found use with a wide variety of genes, including the dexamethasone- regulated 
production of modest amounts of wild -type p53 in a glioblastoma cell line (Mercer et 
al, 1990). This cell line was exploited by El -Deiry et al, (1993) to clone the p53 
responsive -gene p21" ' by subtractive hybridisation. However, like the heat shock - 
and interferon- inducible systems, glucocorticoid- inducible vectors suffer from the 
pleiotropic nature of the cellular response to the inducing agent and therefore requires 
careful consideration of control experiments. More importantly, dexamethasone has 
been shown to induce apoptosis of thymocytes (Wyllie et al, 1980), thus limiting the 
general applicability of this system for the study of apoptosis genes in transgenic 
animals. 
1.2.4.4 Other Inducible Mammalian Promoters. 
Other promoters that have been used for the regulation of reporter genes either in 
transfected cell lines and in transgenic mice include several induced by interferon or 
double stranded RNA (p(I:C)) (including that from the human 6 -16 gene) 
(Chernajovsky and KirbySanders, 1990), retinoic acid (Colbert et al, 1993) and dioxin 
(De Benedetti and Rhoads, 1991). All of these systems suffer from similar 
fundamental drawbacks (leakiness and pleiotropism and (or) toxicity of inducer) to 
the other mammalian promoter systems described above when considered for use with 
apoptosis or cell cycle regulatory genes. 
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1.2.5 Inducible Promoters Containing Bacterial or Yeast Gene Control 
Elements. 
The probability of a specific 18bp nucleotide sequence occurring at random is (0.25)18 
which corresponds to an incidence of 0.04 times per haploid mammalian genome of 
3x l 0`'bp. Any similar sequence differing by no more than four substitutions is likely to 
occur at random with a probability of less than 4x10 -9 (13 times in the mouse 
genome). Since 1% of the genome contains genes it is likely that sequences similar to 
prokaryotic and yeast DNA binding protein recognition sites will occur in mammalian 
genes at a frequency of less than 0.13 per gene (Liu el al, 1992) and at lower 
frequencies at sites critical for gene regulation. Therefore, the interaction of 
prokaryotic or yeast DNA binding proteins to their cognate recognition sites is likely 
to be highly specific to exogenous constructs in mammalian cells. This is the basis of 
the use of such genetic elements in experimental inducible gene systems. 
1.2.5.1 Mammalian Inducible Expression Systems based upon the E. coli lac 
Operon. 
The E. coli lac operon was the first gene regulation system to be described and 
characterised and provided confirmation of the predictions of Jacob and Monod 
concerning the organisation of gene structure and function (Jacob and Monod, 1961). 
The response of E. coli to the presence of the sugar lactose in its environment it to 
induce the expression of three enzyme activities from a single genomic polycistronic 
transcriptional unit up to 1000 -fold: ß- galactosidase (ß -D- galactoside 
galactohydrolase E.C.3.2.1.23), the product of the lacZ gene that is responsible for 
hydrolysis of galactoside substrates to galactose; lactose permease (lacY); and 




The E. coli lac Operon 






LacZ LacY LacA 
Fig. 1.16: The E. coli lac Operon. OP: lac operator sequence. 
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Allolactose is both the natural inducer and substrate of the lac operon and is produced 
from lactose by f3- galactosidase itself by the transfer of the galactosyl group from the 
4 to the 6 position of glucose (Zabin and Fowler, 1980). Allolactose and the synthetic 
non -hydrolysable inducer IPTG (isopropyl -ß -D- thiogalactoside) bind to a 
homotetrameric repressor protein (the product of a separate, but closely- linked, 
constitutively expressed gene: lac!). The functional domains of the Lac! protein 
monomer have been determined by extensive mutational and physical analysis and are 
outlined in Fig. 1.17 B which shows that the first 60 amino acids are responsible for 
sequence- specific DNA binding whereas the central core of the molecule is involved 
in ligand- binding and dimerisation. The carboxyl -terminal peptide contains a leucine 
zipper motif and is involved in formation of stable homotetramers (Beyreuther, 1980). 
Binding of inducer by Lacl elicits a conformational change that causes a reduction in 
the affinity of the repressor for a specific DNA sequence found in the lac promoter 
known as the operator (lacOp). In the absence of inducer the affinity of Lacl for 
operator -containing DNA is very high: of the order of 10 '3M -`. This association 
equilibrium constant (Ko) is reduced by a factor of about 300 (EK0= 3x10 "'M -1) by 
saturating concentrations (10 -1M) of IPTG. Thus in the absence of inducer, 
transcription of the structural genes is repressed by binding of the operator by Lacl 
and this repression is relieved by addition of inducer which increases the rate of 
dissociation of LacUlacOp complexes (Barkley and Bourgeois, 1980). DNase 
protection and filter- binding studies have indicated that the binding of the repressor to 
the operator ( -3 to +21) and binding of RNA polymerase ( -24 to +19) to the lac 
promoter is mutually -exclusive (Reznikoff and Abelson, 1980; Gilbert, 1976; Gilbert 
and Maxam, 1973). The nucleotide sequence of the natural operator revealed a high 
degree of symmetry but also showed that the sequence was not perfectly palindromic 
(Fig. 1.17 A). DNase protection studies using a battery of chemically modified or 
substituted lacOp sequences showed that alterations to residues making critical 
contacts with LacI in the left half of the operator had a much greater affect on 
repressor binding than did corresponding alterations at symmetrical sites in the right 
half. For example, the thymidine methyl group at position 8 of the wild -type lacOp 
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mediates a 12 -fold increase in affinity for Lacl when compared to a mutant operator 
site containing a uracil substitution at that position. The corresponding substitution in 
the right half of the operator at position 14 does not significantly affect the affinity of 
repressor binding. Experiments with synthetic, perfectly symmetrical operator 
fragments based upon the sequence of the left half and lacking the central G -C pair 
showed that repressor bound with 8 to 11 -fold higher affinity in vitro whilst still 
retaining the ability to release the operator in the presence of IPTG. It has been 
suggested that the palindromic `ideal' operator site is bound symmetrically by a Lad 
tetramer by two (or two pairs of) subunits whereas the wild -type sequence is only 
bound strongly by one (or one pair) subunit asymmetrically. A symmetrical 
oligonucleotide composed of the right half sequence (Fig. 1.17 A) binds LacI only 5 
to 10% as strongly as does the wild -type sequence (Simons et al, 1984; Sadler et al, 
1983). 
The lac repressor protein has been shown to bind to operator sites in DNA that has 
been packaged into nucleosomes in vitro (Chao et al, 1980) and has been shown 
inhibit transcription from several eukaryotic and viral promoters (SV40 early 
promoter, RSV -LTR, mMT -I and a semi -synthetic MSV -SV40 early promoter) 
containing operator sites at various positions relative to the TATA box and 
endogenous transcription start points (TSPs)(Figge et al, 1988; Brown and Scott, 
1987; Hu and Davidson, I 987)(see below). Thus chromatin structure does not inhibit 
Lacl protein expressed in mammalian cells from specifically interacting with lacOp 
DNA. Indeed, the strong non -specific DNA binding activity of Lacl for naked 
prokaryotic DNA is diminished by the presence of histones (Chao el al, 1980). The 
inducer of the lac system, IPTG is taken up into mammalian cells rapidly, exceeding 
extracellular levels within 2 hours and the concentration in the nucleus slightly 
exceeds that of the cytoplasm. IPTG is cleared equally rapidly upon withdrawal from 
the medium. In mice, IPTG is cleared from the blood with a half -life of 15 -30 minutes. 
In addition, IPTG has apparently no toxic or other side effects at concentrations up to 
50mM (Wyborski and Short, 1991). Owing to these observations, the lac repressor 
has been developed as an inducible modulator of mammalian transcription. 
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Fig. 1.17: A) Natural and Synthetic Ideal lac Operators. (Adapted from Barkley and Bourgeois. 
1980 and Sadler et al. 1983) Symmetric portions of the sequence are boxed. The axis of symmetry is 
indicated with an arrow and the central nucleotide position is indicated in the natural operator by 
bold type. In the ideal operator. the minimal sequence used in experimental inducible systems is in 
bold type. B) Modifications of the lac Repressor for use in Mammalian Cells. (Data from Fieck et 
a/, 1992). GTG: prokaryotic translation initiation codon. TGA. stop codon. Kozak ATG: consensus 
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Several plasmid vectors have been constructed that direct the expression of Lacl in 
mammalian cells. These consist of standard constitutive mammalian expression 
cassettes containing an enhancer /promoter element; the lac! gene with modifications 
such as the conversion of the E. coli GTG prokaryotic translation initiation codon by 
a eukaryotic ATG sequence; and RNA processing signals: most commonly, the SV40 
small T intron and a polyadenylation signal. A LacI expression vector containing the 
RSV -LTR resulted in the expression approximately 2.5x104 repressor tetramers per 
cell, 10% of which were found in the nuclei of stably transfected mouse LTK- cells. 
This level of expression resulted in 87 to 92% repression of a reporter gene from a 
promoter containing one natural operator 42bp downstream of the TSP in, whereas 
Lac! binding to two operators in similar vector caused a 96 to 98% reduction (Brown 
and Scott, 1987). A stronger promoter such as the CMV early promoter (pCMV /acI) 
resulted in higher levels of expression of Lacl (4x104 molecules per cell)(Figge et al, 
1988) and greater inhibition (98.5 %) of transient expression of CAT (chloramphenicol 
acetyl transferase: an E. coli gene commonly used as a reporter) from an SV40 early 
promoter containing a single optimal /acOp sequence overlapping the TSP (on 
pSV /acOCAT) than a similar Lacl expression construct (pMT1acI) containing the 
weaker mMT -I promoter (Brown and Scott, 1987). The cytoplasmic virus, vaccinia 
(VV) has been modified by several groups to express Lacl. Repressor- mediated 
inhibition of expression of virus -encoded proteins whose promoter regions contain 
operator sites has been reported to have be greater than 99.9 %. This may be due to 
greater availability of Lacl in the cytoplasm compared with nucleus (Zhang et al, 
1992; Rodriguez and Smith, 1990; Fuerst et al, 1989). A further refinement has been 
to incorporate an SV40 T antigen nuclear localisation signal (NLS) following a 
flexible linker peptide at the extreme carboxy terminus of LadI (p3'SS: Fig. 1.17 B). 
Approximately, 98% of this modified LacI -NLS molecule is localised to the nucleus 
thereby increasing the effective nuclear repressor concentration. In vitro, this protein 
has increased affinity for operator (probably due extension of the leucine zipper which 
may stabilise tetramers) while also possessing a greater responsiveness to IPTG 
(Fieck el al, 1992). 
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In order to confer repression by Lacl to a test gene, it is necessary to insert one or 
more /acOp sites into the promoter region. Initial experiments by Hu and Davidson 
(1987), investigated the optimal number and position of 40bp wild -type operator sites 
in an SV40- derived promoter linked to a Moloney sarcoma virus (MSV) enhancer 
(Fig. 1.18 A). Insertion of these sequences decreased the expression of a reporter 
gene in the absence of Lacl in all positions tested and the effect increased with 
increasing copy number. The inhibition was least when operator(s) were inserted 
between the TATA box and the endogenous TSP where, with one operator 
(pSMB01 CAT), expression of the CAT reporter gene reached 80% of the level 
produced by the parental vector. Three tandem operators caused almost complete 
inhibition. Inhibition was greatest when operators were placed upstream of the TATA 
box (thereby weakening binding of transcription factors to the transcription initiation 
complex) or downstream of the TSP (probably by causing inhibition of translation by 
forming hairpin secondary structures in the 5' UTR of the CAT mRNA: this is 
avoided in the Lacswitch vectors pOPRSVICAT and pOPI3CAT by placement of 
operators downstream of the TSP in an intron (DuCoeur et al, 1992)). In the 
presence of LacI, expression was repressed (see above) and was induced to a modest 
degree in 20mM IPTG. However, induced expression was never fully returned to 
unrepressed levels. 
Brown et al, (1987) constructed a reporter vector (pSV / acOCAT) containing a single 
18bp optimal operator site inserted as a 22óp linker overlapping the TSP of the SV40 
early promoter (Fig. 1.18 B). This insertion had no effect upon the maximal levels of 
expression from this promoter in the absence of Lacl when compared with the 
parental vector. In transient co- transfections of pSV /acOCAT and pCMVIacI, IPTG 
relieved repression by -60 %. However, the relative difference between induced and 
uninduced CAT expression decreased as the concentration of pSV /acOCAT plasmid 
increased (i.e. titration of the available Lacl molecules with operator DNA) until the 
operator -containing construct became saturating. Therefore, definitive induction 
experiments were carried out in doubly stable transfectants (Figge et al, 1988). In 
these stable transfectants with single copy integration of the operator construct, an 
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induction ratio of 60 was measured following exposure to 50mM IPTG. A plateau in 
the induction response was not reached as IPTG concentrations in excess of 50mM 
were toxic. Sufficient Lacl was present to mediate >99.9% repression and uninduced 
expression was not significantly higher than background. These observations may 
indicate that other, similar constructs with stronger promoters, such as the CMV early 
promoter, combined with more responsive Lacl molecules (such as the LacI -NLS that 
is produced from p3'SS) may allow larger induction ratios. 
The optimised IPTG- inducible vector system (Lacswitch: Statagene) used in this 
project consisted of the LacI -NLS expression vector p3'SS (Fieck et al, (1992) and 
see Chapter 2: General Materials and Methods) and two alternative lac operator - 
containing reporter vectors: pOPRSVICAT and pOPI3CAT (Fig. 1.19). 
pOPRSVICAT contains two optimal operators: one between the TATA box and the 
endogenous TSP of the RSV -LTR; and one in an intron downstream of the TSP. 
pOPI3CAT contains 3 intronic optimal operator sites. Previously, the largest 
induction ratio with 5mM IPTG (10 -fold lower than toxic doses) obtained in an 
individual clone derived from a stable cotransfection with p3'SS and pOPRSVILuc (a 
related plasmid to pOPRSVICAT) was 48 -fold higher than the basal repressed 
expression level that was equivalent to 10 -20 luciferase molecules per cell. 95 -fold 
induction from a slightly lower basal level was observed in a clone derived with 
pOPI3Luc. Induction of luciferase was rapid: maximal between 4 -12 hours (DuCoeur 
et al. 1992). The properties of these vectors, combined with the favourable 
pharmacokinetics, low toxicity and specificity of IPTG made this system an attractive 
choice for the purposes of this project. 
Fig. 1.18 (overleaf): A) Effect of Copy Number and Position of Insertion of 40bp Natural 
Operator sites into a promoter.(data from: Hu and Davidson. 1987). The effect of operator 
insertion on promoter -driven CAT (chloramphenicol acetyl transferase) activity in the absence 
repressor protein. MSV: Moloney murine sarcoma virus. SV4Oe: SV40 early promoter. TSP: 
transcriptional starting point. Op: 4Obp natural operator sequence. B) Insertion of an ideal lac-Op 
site at the TSP (Data from Brown et al. 1987: Figge et al. 1988). The insertion of a single ideal lac 
operator site ( /acO) overlapping the TSP has no significant effect on promoter -driven CAT activity. 
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Fig. 1.19: Lacswitch (Stratagene) Operator Vectors. The Lacswitch vectors 
pOPRSVICAT (middle) and pOPI3CAT (lower) are variants of plasmid pRSVNot 
(Top). RSV -LTR: Rous sarcoma virus long terminal repeat promoter. Op: ideal lac 
operator site. TSP: endogenous transcriptional start point. TK pA: polyadenylation 
signal from HSVtk gene. NeoR: G418 resistance cassette. AmpR: prokaryotic 
ampicillin resistance (ß- lactamase) gene. Ori: prokaryotic (ColE1) or filamentous phage (fl 
( +)) origin of replication. CAT: chloramphenicol acetyl transferase gene. 
1.2.5.2 Tetracycline -Inducible Mammalian Expression Systems. 
A similar genetic architecture to the lac operon is employed in E.coli strains resistant 
to the antibiotic tetracycline (tet): A repressor protein (tetR) binds with high 
specificity to an operator site (tetO) downstream of the TATA box in the tet promoter 
to prevent activation of the tetracycline resistance genes in the absence of tetracycline 
(Kleinschmidt et al, 1988). In contrast to the conversion of lactose (an anti -inducer of 
3- galactosidase as well as a substrate) to allolactose which is the preferred ligand for 
Lact, tetracycline directly binds with high affinity to tetR to alleviate transcriptional 
repression (mediated by steric hinderance of RNA polymerase) of the tetracycline 
resistance genes (Degenkolb et al, 1991). This alleviation is caused by a 
conformational change in the ligand -bound tetR protein that releases tetR from the 
tetO (Fig. 1.20 A)(Hinrichs et al, 1994). 
An expression system based upon the tetRItelO interaction has been used in transgenic 
plants (Gatz, 1996) but has not been used in mammalian systems, probably because 
repression by tetR is mediated by mechanical and not biochemical interactions and 
would therefore require high occupancy of the tetO. It is difficult to produce 
detectable quantities of tea in stable mammalian cell lines as it appears to be toxic. 
(Gossen and Bujard, 1993). However, a tet- regulable trans- activation system has 
been developed by Gossen and Bujard, (1992) in which the telR is fused to the trans- 
activation domain of VP16 (see 1.2.5.3 below) to produce a tetracycline responsive 
trans- activator (tTA) protein. When constitutively expressed from the CMV 
immediate early promoter, the tTA binds to and strongly activates transcription from a 
minimal promoter on a separate plasmid that contains the CMV TATA box devoid of 
enhancers via seven tandem copies of the tetO placed immediately upstream. In the 
presence of tet, the tTA is released from the promoter and the transcription rate drops 
to a low level (Fig. 1.20 B). 
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Fig. 1.20: A) Repression by tetR. (From Shockett. 1996) In the absence of tetracycline (tet). the tetR 
binds to the tetO and thereby represses transcription from an upstream promoter. When tetracycline 
is present and binds to the repressor transcription occurs as a result of release of the teal from the 
tet0. RNA pol: RNA polymerase B) Conversion of the tetR to a transcriptional activator by fusion 
NNith the transcriptional activation domain of VPI6 (tTA). C) Reverse tetracycline trans -activator 
(rtTA). 
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This basic system has been extensively used in tissue culture for the expression of 
wide variety of genes including luciferase (over a105 -fold range of expression levels) 
(Gossen and Bujard, 1992), cyclins (Resnitzky et al, 1994), Bc1 -2 (Yin and Schimke, 
1996), HIV -1 Rev protein (Yu et al, 1996) and p53 (over a 60 -fold range)(Lassus et 
al, 1996; Agarwal et al, 1995). Lower levels of inducibility of the luciferase reporter 
gene has been observed when this system has been introduced into transgenic mice 
and inducibility is heterogeneous between different tissues (maximum 5x103 -fold in 
seminal vesicle versus 2 to 12 -fold in testis and liver)(Furth et al, 1994). To what 
extent this is due to position effects on expression in different tissues as a result of 
the transgenesis procedure as opposed to intrinsic tissue -dependent effects on the 
minimal promoter involved is difficult to assess and there may be scope for more 
refinement. Recently, the components of the tTA/tetO system have been combined 
in self -contained retroviral (pBABE) expression cassettes. One vector mediated up to 
336 -fold induction of luciferase in NIH3T3 cells whereas induction ranged from only 
24- to 127 -fold in other cell lines. This variation may be due species preferences by 
the ecotropic virus stocks used (Paulus et al, 1996). In contrast, a self -regulatory 
tTA- responsive LacZ expression cassette was inserted into a self -inactivating (SIN) 
pBABE vector. Thus transduction and integration of the virus resulted in the deletion 
of the vector U3 enhancer /promoter sequences from the proviral DNA, thereby 
preventing unwanted enhancement of the tetO -CMV promoter by the retroviral 
LTRs. This system produced up to 600 -fold induction of ß- galactosidase in murine 
myoblasts (Hofmann et al, 1996). Vectors such as this may be useful in the 
controlled and safe introduction of exogenous gene expression in gene therapy 
situations. 
Tetracycline has low toxicity for mammalian cells and although it blocks prokaryotic 
peptide elongation and inhibits mammalian mitochondrial protein synthesis, the 
affinity of tetR for tet is 103 -fold greater that for the 30S ribosome (109M "1 versus 
106M -') allowing use as a ligand for tTA at 21,1M in mammalian cells without 
significant effects on mitochondrial function (Gossen and Bujard, 1992; Takahashi et 
al, 1986). There is a suggestion, however, that the long term culture of Rat -1 cells in 
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toxicity (Dr. C. Boyle, personal communication). It is not known whether tet 
analogues such as anhydrotetracycline may circumvent this as they bind to tetR with 
much greater affinity (1011M-1: (Hecht et al, 1993)) enabling the use of lower 
concentrations of ligand. The response of the tTA system to withdrawal of 
tetracycline from cell cultures is slow. It takes up to 48 hours for a maximal response 
to occur as tetracycline is eliminated from cells only by passive diffusion. This means 
that this system is unsuitable for the study of short term effects of gene expression. As 
apoptosis is often completed within 24 hours following a stimulus, the tTA system is 
not ideal for the expression of apoptosis inducing genes, despite the attraction of the 
low basal and high induced expression levels achievable. 
In an important recent development, a mutant tetR has been isolated that has an 
inverted response to ligand enabling the construction of a reverse tTA (rtTA) that 
binds to tetO only in the presence of tet analogues doxycycline or anhydrotetracycline 
(Fig. 1.20 C)(Gossen et al, 1995). Using this modified system luciferase activity was 
induced 103 -fold in 20 hours in a dose -dependent manner. It has been proposed that 
this latest refinement of the tet system could be useful in situations where long term 
exposure to tetracycline is undesirable or inconvenient (e.g. in vivo gene therapy or 
transgenìc animals) or where the slow (up to 48hours) passive elimination of tet from 
cells in culture or animals may confound studies where rapid induction is required 
(Shockett and Schatz, 1996; Gossen and Bujard, 1992). 
1.2. 5.3 A Synthetic Tamoxifen -Inducible Mammalian Ga14- Responsive Promoter 
St'stem. 
The occurrence of separable functional domains in a wide variety of protein families 
has been suggested to reflect that in evolution (and recapitulated in lymphocyte 
ontogeny), elements from a small pool of genes were combined to generate a larger 
pool of genes containing a diverse selection of activities. Transcription factors contain 
at least two functional domains: a domain that mediates sequence -specific DNA 
binding and one that has effects on transcriptional activation. As discussed in the 
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section on fusion proteins above, the nuclear hormone receptor family also contain 
ligand- binding regulatory domains that may overlap with trans- activation activities. In 
a similar manner to evolutionary processes, the molecular biologist can dissect genes 
and recombine the fragments in vitro to generate proteins with novel functions. Such 
technology has been exploited in the generation of novel transcription factor activity 
whose function is ligand- dependent: VP16GaIER (Braselmann et al, 1993). 
The first 74 amino acids of the Saccharomyces Gal -4 transcription factor contain a 
zinc -finger DNA binding domain (Sollerbrant et al, 1995) that binds specifically to the 
17bp sequence: 5'- CGGAGGACAGTCCTCCG -3'. The transcriptional activation 
domain of intact Gal -4 thus more readily able to exert its effects at a promoter 
containing a Gal -4- binding site than in free solution. This enhancement of 
transcription by Gal -4 does not require both activities on the same polypeptide but so 
long as there is a physical association between two proteins each contain one of the 
separated domains of Gal -4, then specific transctivation of a reporter gene can occur. 
This is the basis of the 2- hybrid interaction screen which is a genetic assay for 
interacting proteins in vivo. Fusion of the Gal -4 DBD to an heterologous 
transcriptional activity can also result in novel transcriptional activity. One such fusion 
protein (Ga14 -VP 16) involves the C- terminal trans -activation domain (amino acids 
416 -487) from the Herpes simplex virus (HSV) VP16 (Vwm65) protein (Triezenberg 
et al, 1988a). VP16 is a component of the HSV virion and mediates the immediate 
early transcriptional response by binding via N- terminal sequences to host proteins 
bound to promoters thus bringing the highly acidic trans -activation domain into 
contact with the transcriptional machinery (McKnight et al, 1987; Preston et al, 1988; 
O'Hare and Goding, 1988; Triezenberg et al, 1988; Triezenberg et al, 1988). Ga14- 
VP 16 is unusually efficient at stimulating transcription when bound to Gal -4 
recognition sites placed close to, or at a distance (at least 1.8kb) from a mammalian 
promoter (Sadowski et al, 1988). 
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Test gene intron SV40pA 
Fig. 1.21: A) VP16GalER" Fusion Protein. (constructed by Dr. S. Pellengaris). 
VP16: Trans- activation domain from Herpes simplex virus VP16 protein. Gal -4 
DBD: Gal -4 DNA binding domain. mER(G525R) HBD: mutant mouse 
(tamoxifen- sensitive) oestrogen receptor hormone binding domain. B) Structure 
of a synthetic Gal -4- responsive mammalian promoter (Braselmann et al, 1993). 
pA: polyadenylation signal. TSP: transcription start point. 
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A tripartite fusion protein, Gal -ER -VP 16 and a synthetic Gal -4 responsive mammalian 
promoter (see Chapter 2: Materials and Methods and Fig. 1.21 B) was constructed by 
Braselmann et al, (1993). The chimaeric protein takes advantage of the strong 
transcriptional activity of the VP 16 trans -activation domain, the exogenous sequence 
specificity of Gal -4 combined with regulation by the oestrogen receptor HBD (Fig. 
1.21 A). In transient transfection, at least 100 -fold induction of a Gal -4 responsive c- 
Fos gene was measured by S1 analysis within 1 -2 hours of the addition of ß- oestradiol 
and uninduced expression was very low. A VP16Ga1ER`'" fusion protein has also 
been constructed (Dr. S. Pelengaris, ICRF London: personal communication)(see 
Chapter 2: Materials and Methods for details) that contains the mouse ER(G525R) 
mutant that is responsive only to tamoxifen. This construct was assessed in this 
project. 
1.2.6 Conclusion: Conditional Apoptosis Experiments. 
Conditional expression technology provides a powerful tool for the investigation of 
potentially lethal or growth inhibitory genes. In this project, several conditional 
expression systems were evaluated and used to study the susceptibility of fibroblasts 
to undergo apoptosis under conditions where the expression of individual test genes 
could be exogenously- regulated. Using the temperature- sensitive p53, the 
susceptibility of fibroblasts to chemotherapeutic drug treatment was examined in the 
case of overexpression of phenotypically wild -type or mutant p53. Experiments were 
designed to show that the outcome of activation of wild -type p53 (by using either the 
temperature- sensitive mutant or by controlling levels of p53 expression by using the 
Lacswitch or VP 16GalER"° systems) could be altered by changes in the cellular 
environment such as co- expression of c -myc (using the myc -ER fusion protein and 
(or) the Lacswitch or VP16GalER`m systems). Inducible p21" ciP1 expression 
vectors were constructed with the intention of producing cell lines which undergo an 
IPTG- or tamoxifen- dependent cell cycle arrest but grew normally in the absence of 
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inducer. Such constructs could be used, together with appropriate c -myc expression 
constructs, to test whether p21 could substitute for p53 in triggering myc- driven 
apoptosis. It is known that several treatments, such as thymidine block or isoleucine 
starvation which elicit cell cycle arrest even when cells are cultured with serum is 
sufficient to cause Ratl /myc cells to undergo apoptosis (Evan el al, 1992). It is 
important to identify the function of p53 that is responsible for the induction of 
apoptosis as this could have an impact upon the direction of anticancer research, 
especially for the targets of gene -based therapeutic strategies. 
A rapidly expanding area of apoptosis research is the characterisation of the ICE -like 
proteases. Much effort has been focused upon the structure and mechanism of action 
of these enzymes. Identification of physiological substrates has been hampered by 
observations that individual proteases can activate other family members. Assays of 
the biological activity of a newly identified protease in live cells often include a 
transient overexpression experiment. These assays are, for several reasons, not 
conclusive proof that a particular protease forms part of the apoptosis effector 
pathway. The most common criticism of this approach is that loading of cells with any 
protease may be sufficient to cause the death of cells by a process that resembles 
apoptosis (Williams and Henkart, 1994). The advent of highly -regulable and titratable 
inducible- expression systems may circumvent this problem. 
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Chapter 2. 
2. General Materials and 1 lethods 
2.1 Eukaryotic Expression Vectors 
2.1.1 pBKCMV and pPUR 
pBKCMV (Stratagene) (Fig. 2.1) is an expression/cloning vector that contains a 
multiple cloning site (MCS) towards the 5' end of the E. coli lacZ (a- peptide) gene 
that enables a- complementation in E. coli with the /acZAMI5 mutation_ The MCS is 
flanked by T3 (5') and T7 (3') RNA polymerase promoters. Expression of inserts 
cloned into the polylinker in eukaryotes is driven by the cytomegalovirus (CMV) 
intermediate -early promoter. The lacZ sequence 3' of the polylinker is contained 
within an SV40 intron which lies 5' to an Herpes simplex virus thymidine kinase 
(HSVtk) gene polyadenylation signal. The plasmid is based upon a pBluescript SK( -) 
ColE 1 origin of replication and selection in both prokaryotes and eukaryotes is on the 
basis of neomycin (kanamycin or G418) resistance_ The neo gene is expressed under 
the control of a ß- lactamase promoter in bacteria and a simian virus 40 (SV40) 
promoter in eukaryotes_ 
pPUR (Clontech) (Fig. 2.2) is an expression vector that contains a 1392bp 
PvulIBamHI fragment which encompasses the Streptomyces alboniger puromycin N- 
acetyl transferase (PAC) gene in an SV40 virus early region mammalian expression 
cassette. This vector provides resistance against puromycin in eukaryotic cells. The 
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Sma I (1027) 
Bst XI (1029) 
Not I (1050) 
;' Sc c II (1050) 
;i;Xho I (1069) 
'1;i' Hind III (1075) 
EcoR I (1084) 
BamH I (1093) 
";Spe 1(1099) 
'Sal I (1105) 
Pst I(1115) 
Sac I (1127) 
T3 
CMV IE Promoter 
Nsi I (1901) 
TK pA 
COLEI ORI 
Apa LI (2264) 
Fig. 2.1. pBK -CMV (Stratagene) is a cloning vector that contains a multiple 
cloning site towards the 5' end of the E. coli lacZ (a- peptide) gene that enables a- 
complementation in E.coli with the lacZAM15 mutation. The MCS is flanked by 
T3 (5') and T7 (3') RNA polymerase promoters. Expression of inserts cloned into 
the polylinker in eukaryotes is driven by the cytomegalovirus intermediate -early 
(CMV IE) promoter. The lacZ sequence 3' of the polylinker is contained within an 
SV40 intron. Selection in both prokaryotes and eukaryotes is on the basis of 
neomycin (kanamycin or G418) resistance (NEO( R). 
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Apa LI (4213) 
LYEFF 
pBR322 origin 
Apa LI (3715) 
Pst I (2899) 
API. 
SV40 Early Promoter 
Nco I (232) 
Hind III (341) 
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Ava I (1133) 
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Pst I (1941) 
SV40 pA 
BamH I (1392) 
Fig. 2.2. pPUR (also referred to as pBSpac &delta;P) confers puromycin resitance 
to mammalian cells and can be used to select for stably transformed cell lines. The 
Streptoyces alboniger puromycin -N- acetyl transferase (PAC) gene has been cloned 
between the SV40 early promoter and the polyadenylation signals to create a 
cassette that will express in mammalian cells. Apr: prokaryotic ampicillin resitance 
gene. A: polyadenylation signal. SD SEQ: Shine- Delgarno sequence. P(BLA): 
prokaryotic ß- lactamase promoter 
93 
2.1.2 IPTG- Inducible Expression System Based Upon the E. coli lac Operon. 
This system consists of two components: one plasmid containing a lac repressor 
(lacl) expression cassette (p3'SS) and reporter plasmids containing lac operator sites 
in and/or downstream of a eukaryotic retroviral promoter (pOPRSVICAT and 
pOPI3CAT). These plasmids were obtained from Stratagene Cloning Systems. 
Plasmid p3'SS (Fieck et al, 1992)(Fig. 2.3) is an expression vector based upon a 
pBluescript derivative (pint.lacI) and contains a modified lad gene under the control 
of the mutant F9 -1 polyoma promoter subcloned as a 820bp BglII fragment from 
PyF9 -1CAT (Bohnlein et al, 1985). The E. coli lac!' GTG start codon (bases 29 -31) 
has been replaced with a modified Kozak consensus ATG sequence (CCACCATG: 
(Kozak, 1986)). In addition an SV40 nuclear localisation signal (NLS: 
CCTAAGAAGAAGAGGAAGGTT) has been placed immediately in front of the 
lacPstop codon (TGA: bases 1109 -1111) but is separated from base 1108 of lac!' by 
a 9bp linker (AGCAGCCTG) and an StuI restriction enzyme site (AGGCCT). The 
9bp linker translates to Ser- Ser -Leu and this extends the heptad repeat of the C- 
terminal leucine zipper motif and thereby enhances the stability of repressor 
tetramerisation (Fieck et al, 1992). An SV40 polyadenylation and small intron from 
pKO -Neo (Vandoren et al, 1984) have been placed downstream of this modified 
gene. Selection in eukaryotic cells is provided by hygromycin -B resistance gene from 
COS -203 (Kioussis et al, 1987). 
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P(BLA) 
Apa LI (6418) F1 ORI (-) 
AmpR Bgl II (469) 
BamHI(475) 
Kpn I (540) 
F9-1 polyoma promoter 
Stu I (1072) 
Apa LI (5172) 
p3'SS 
Bgl II (1294) 
COLE1 ORI 
6672 bp 
Kpn I (1353) 
NsiI(4809)_. `Apa LI (1693) 
Sac II (4247) modified Lac! 
Apa LI (4049)2 9bp linker 
Pst I (3804)_(3804). _Stu I (2454) 
SV40 NLS 
Apa LI (3747) Pst I (2555) 
EcoR I (3710) % 
,1 
SV40 small T intron 
Sma I (3451) ¡' SV40 pA 
Pst 1(3411) Hind III (3000) 
EcoR I (3314) 
Fig. 2.3. LacI -NLS expression plasmid p3'SS. AmpR: prokaryotic ampicillin 
resitance gene. PolyA, pA: polyadenylation signal. ORI: prokaryotic or filamentous 
phage origin of replication. HygR: mammalian hygromycin resitance cassette. F9 -1 
promoter: from F9 -1 polyoma strain. NLS: nuclear localisation signal. 
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Apa LI (5924) TK pA 
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F1 ORI ( -) 
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Sac II (2061) 
Bst XI (2062) 
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Sal I (2615) 
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Hind III (2674) 
BamH I (2754) 
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Apa LI (4678)' 
Nco í(4148) 
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Not I (3839 
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Fig. 2.4. Lac -operator- containing mammalian expression vector, pOPRSVICAT. 
AmpR: prokaryotic ampicillin resistance gene. P(BLA): prokaryotic ß- lactamase 
promoter. HSV TK: Herpes simplex virus thymidine kinase. RSV LTR: Rous 
sarcoma virus long terminal repeat. TK pA: polyadenylation signal. ORI: prokaryotic 
or filamentous phage origin of replication. LacOP: ideal lac operator site. NEO (R): 
mammalian G418 resistance cassette. CAT: chloramphenicol acetyl transferase gene. 
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Apa LI (4788)- 
pO P 13CAT 
EcoR I (1208) 
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62 8 9 bp 
F1 ORI (-) 
TK pA 
NotI(3949) ' rf . " Sac II (2125) Sac 1(2118) 
Nco I (3714) ' Bst XI (2126) 
CAT . . RSV LTR 
Eco R I (3413) " EcoR I (2605) 
Not I (3172)Í Apa L1(2685) 
Hind III (3165) Bgl II (2692) 
Hind III (2698) 
Lac OP 
Sal I (2790) 
Lac OP 
Sal I (2833) 
Lac OP 
Sal I (2876) 
BamH I (2907) 
BamH I (3130) 
Fig. 2.5. Lac -operator- containing mammalian expression vector, pOPI3CAT. 
(Labels as for pOPRSVICAT). 
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The /ac- operator -containing vectors pOPRSVICAT and pOPI3CAT (Figs. 2.4 and 
2.5) were constructed from the parental plasmid vector pRSVNot (DuCoeur et al, 
1992). pRSVNot contains a Rous sarcoma virus long terminal repeat (RSV -LTR) 
promoter upstream of an SV40 intron a NotI cloning site and an Herpes simplex virus 
thymidine kinase (HSVtk) polyadenylation signal. Selection in bacteria and 
mammalian cells is by ampicillin and neomycin (G418) resistance respectively. 
pOPRSVICAT contains two modified ideal lac operator sequences 
(ATTGTGAGCGCTCACAAT: (Simons et al, 1984), one in the SV40 intron and one 
placed between the TATA box and the transcriptional starting point of the RSV -LTR. 
pOPI3CAT contains three copies of the operator sequence in the SV40 intron. Both 
plasmids also contain a chloramaphenicol acetyl transferase reporter gene cloned as a 
777bp Noti fragment into the Noti site between the intron and the polyadenylation 
signal. 
Fig. 2.7 (Page 100). pBabeNeoVP16GaIERtm is an MoMSV -based retroviral expression vector 
containing the VP16galER1N' fusion genc.in a 1471bp BamHI/EcoRI fragment. The fusion gene 
consists of a 237 bp HindIII/Sall fragment from the Herpes simplex virus VP16 trans -activation 
domain (amino acids 416 -487). a 223bp SaII /Xhol fragment encoding the DNA binding domain 
from the yeast Gal4 protein (amino acids 2 -74). a 15bp XhoI/SacI /ClaI spacer and a 1162bp 
Clal/EcoRI fragment encoding a 4- hydroxvtamoxifen- sensitive mutant (G525R: Littlewood et al. 
1995) of the murine oestrogen receptor steroid binding domain (amino acids 282 -595). Resistance in 
eukaryotes is provided by a G418 resistance cassette. amp`: prokaryotic ampicillin resistance gene. 
neo`: eukaryotic G418 selection marker. ER"': murine oestrogen receptor steroid binding domain - 
tamoxifen mutant. Gal: gal4 DNA binding domain. LTR: Long terminal repeat. MoMSV: Moloney 
murine sarcoma virus. pA: polyadenylation signal. pUC ori: prokaryotic origin of replication. SV40: 
SV40 early promoter. VP16: Herpes simplex virus VP16 transactivation domain. A: AatII. B: 
BamHI. Bg: Bg1II. C: Clal. E: EcoRl. H: HindIII. N: Notl. Nh: NheI. Pv: Pvui. S: SaIII. ScI: SacI. 
Sca: Seal. Sp: Spel. X: Xhol. 
Not drawn to scale. 
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Fig. 2.6. pSP65GC (Top) and Gal -4 -responsive promoter (Bottom)(Braselmann 
al, 1993). AmpR: prokaryotic ampicillin resitance gene. PolyA, pA: 
polyadenylation signal. Ori: prokaryotic origin of replication. ATTGG: inverted 
CCAAT box. Inr: initiation region. MCS: multiple cloning site. B: BamHI. C: C1aI. 
E: EcoRI. H: HindI11. X: Xholl. Xm: XmaIII. Plain boxes: CCAAT and TATA 
boxes. Bold text in light grey boxes: synthetic polyadenylation signal. Shaded 


































2.1.3 Tamoxifen -Sensitive, Ga14- Responsive Promoter System 
This inducible vector system is based upon an expression cassette containing synthetic 
Gal4- responsive promoter (pSP65GC)(Fig. 2.6) and a vector that expresses the yeast 
Gal -4 DNA binding domain fused to the steroid -binding domain of a 4- 
hydroxytamoxifen (4 -OHT)- sensitive mutant murine oestrogen receptor (Littlewood 
et al, 1995) and a strong Herpes simplex virus VP16 transactivation domain 
(pBabeNeoVP16GalER': provided by Dr. S. Pelengaris, ICRF)(Fig.2.7). Only when 
4 -OHT is present will the fusion protein bind to the Gal -4 binding sites in the reporter 
vector and thereby activate transcription from the synthetic promoter. 
The Gal -4- inducible expression cassette (Braselmann et al, 1993) has been 
constructed as a 859bp BamHI/PvuII fragment between the EcoRI (destroyed) and 
Pvull sites of pSP65 (Promega). The construct contains four copies of the Gal -4 
binding sequence (CGGAGGACAGTCCTCCG) upstream of an inverted CCAAT 
box from the murine class Il MHC Ea gene and the initiation region and TATA box 
from the adenovirus major late transcription unit (from -39 to +15). An multiple 
cloning site (MCS: SalI/EcoRV /XbaI/PstI), an intron and an SV40 polyadenylation 
signal have been placed downstream of this synthetic promoter. A synthetic 
polyadenylation signal was inserted upstream of the Gal -4 binding sites in order to 
suppress read -through transcription from upstream promoters at the integration site 
upon transfection with this vector. The VP- Gal -ERT fusion gene consists of a 1444bp 
BamH1/EcoRI fragment which contains codons 416 -487 of VP I6 fused in frame to 
codons 2 -74 of Gal -4 and a 15bp linker followed by codons 282 -599 of the murine 
oestrogen receptor (mutant G525R). This fragment has been cloned into the 
BamHI / EcoRI sites in the MCS downstream of the 5' LTR in the Moloney murine 
leukaemia virus (MoMuLV) retroviral vector pBabeNeo (Morgenstern and Land, 
1990). This vector also contains an internal SV40 early promoter driving a neomycin 
(G418) resistance gene for selection in mammalian cells. 
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2.1.4 Plasmids Containing p53 Sequences 
Plasmid pMSVcL (Finlay el al, 1988) was constructed by digesting 
pLTRp53cGval135 with XhoI and BamHI to completion and replacing the p53va1135 
and S V40 sequences with the XhoI/BamHI fragment from p 1 1 -4 (Tan el al, 1986). 
The p53 cDNA thus created is identical in sequence to the wild -type p53 clone pp53- 
17c originally derived and sequenced from an F9 embryonal carcinoma cell line 
(Pennica el al, 1984). 
pSV53C contains a full length murine p53 clone constructed from two fragments of 
cloned cDNA (p 1 -B and p27.1 a) generated from mouse SV3A 1 E7 polyadenylated 
mRNA (Jenkins el al, 1984). The cDNA is contained within a 1375bp EcoRI/Bglli 
fragment and has four mutations in the non -conserved 5' end of the coding sequence: 
Arg48 (CGA), G1n79 (CAG), Trp80 (TGG), de181. 
2.1.5 Plasmids pMV7 and pMV7 -MER 
The retroviral expression vector pMV7 (Kirschmeier el al, 1988) is based on a 
derivative of pBR322 which contains a polyomavirus origin of replication as well as 
retaining the pBR322 origin and ampicillin resistance genes (Dailey and Basilico, 
1985, Luskey and Botcham, 1981) It also contains a 4.1kb XhoI fragment encoding a 
modified Moloney murine sarcoma virus (MoMSV). This MoMSV derivative was 
produced by removing 3.95kb of MoMSV genomic sequences (coding for the viral 
gag genes and large parts of v -mos and the pol gene) by digestion with PstI (Perkins 
el al, 1983). It retains both 5' and 3' LTRs and regulatory elements for virion RNA 
encapsidation and reverse transcription. An HSVtk /neomycin phosphotransferase 
cassette which acts as a dominant selectable marker in eukaryotic cells has been 
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inserted 0.3kb 5' of the 3' LTR. Two unique cloning sites (EcoR I and Hind III) are 
found 0.5 -0.6kb downstream of the 5' LTR start of transcription. 
pMV7 -MER (Eilers et al, 1989) contains a 2.4kb EcoR I fragment inserted into the 
unique EcoR 1 site of pMV7. This fragment consists of a chimaera of cDNA 
sequences coding for exons II and III of the human c -myc protooncogene (Stone et 
al, 1987) fused to cDNA sequences representing the hormone binding domain of the 
human oestrogen receptor (Kumar et al,, 1986). 
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2.2 Fibroblast Cell Lines 
2.2.1 Rat -IA Cells 
Rat I A (also known as F2408) is an immortalised, but untransformed, fibroblastoid, 
3T3 -like cell line spontaneously derived from F344/f (Fischer) rat 19 -21 day embryos 
(Freeman et al, 1970 and 1973). It is phenotypically "normal" by various criteria and 
it is diploid with a modal chromosomal number of 42 (Topp, 1981; Prasad et al, 
1976). The cells are capable of exponential growth in 1% FCS with a mean doubling 
time at 37 °C of 18 hours, reaching a saturation density of about 2 x 105 cells per cm2. 
Cloning efficiency of Rat 1 cells is approximately 80% in 10% FCS (Topp, 1981). In 
transfection experiments, 1 -2% of Rat 1 cells stained positively for T antigen 
expression following calcium phosphate precipitation (Wigler et al, 1979) with 1µg 
SV40 viral DNA per 60cm plate (Topp, 1981). 
2.2.2 Clone 6 Cells 
This cell line (kindly provided by M. Oren) constitutively expresses the temperature - 
sensitive p53 mutant, p53va1135 which adopts wild type conformation and functional 
properties at permissive temperatures (32°C) and mutant conformation and properties 
at 37°C (Michalovitz et al, 1990). Clone 6 is a cell line derived from low passage 
rodent embryo fibroblasts transformed by murine p53val135 and a human 
mutationally- activated c- Harvey -rasl gene (Michalovitz et al, 1990) using the 
calcium phosphate coprecipitation technique (Graham and Van der Eb, 1973). Clones 
were propagated from foci that developed as a result of co- operation between Ha -ras 
and p53va1135 in transformation of the transfected rat embryo fibroblasts at 37 °C 
(Eliyahu et al, 1984; Michalovitz et al, 1990). Activated Ha -ras in these cells is 
encoded by plasmid pEJ6.6 (Shih and Weinberg, 1982). In Clone 6, p53va1135 is 
under the transcriptional control of a Harvey murine sarcoma virus long terminal 
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repeat (LTR) and is encoded by plasmid pLTRp53cGva1135 (Kaczmarek et al, 1986; 
Eliyahu et al, 1985). 
2.3 RNA Extraction 
2.3.1 Treatment of Water and Equipment for use with RNA 
Batches of deionised distilled water (DDW) were prepared for use in RNA work by 
treating with diethyl pyrocarbonate (DEPC) at a concentration of 0.1% overnight in a 
fume cupboard and were then autoclaved. 
Similarly, items of equipment for use with RNA such as electrophoresis tanks, 
forceps, glass dishes and slot -blot apparatus were treated with DDW containing 0.1% 
DEPC overnight. Equipment was then autoclaved or rinsed thoroughly with diethyl 
pyrocarbonate- treated deionised distilled water (DEPC/DDW). 
2.3.2 Isolation of Total RNA 
Total RNA was isolated from mouse tissues or from cell cultures using a monophasic 
solution of guanidine isothiocyanate and phenol (TRIzol, Life Technologies) in a 
modified Chomczynski and Sacchi (1987) protocol. Autoclaved plasticware and filter 
tips were used to prevent RNA degradation by contaminating RNAses. Stock 
solutions and pipettes for RNA work were kept separate from those used for other 
purposes. 
Tissues were removed from freshly killed mice and promptly snap frozen in liquid 
nitrogen and stored at -70 °C until required for RNA extraction. Approximately 
100mg of tissue was homogenised in 1 ml TRlzol solution and incubated at room 
temperature for 5 minutes before vigorously mixed with 20011 chloroform (Sigma). 
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The mixture was incubated at room temperature for 3 minutes and then centrifuged at 
6500 rpm at 4 °C in an MSE MicroCentaur centrifuge. The aqueous phase was then 
carefully removed and total RNA was precipitated with 0.5 ml isopropanol (propan -2- 
ol, Sigma) at room temperature for 10 minutes. The precipitated total RNA was 
collected by centrifugation at 13000 rpm for 10 minutes at 4 °C and washed once with 
70% ethanol in DEPC/DDW. The pellet was dried in vacuo for 3 -4 minutes and then 
resuspended in 100µ1 DEPC/DDW. The concentration of total RNA was estimated by 
ultraviolet spectrophotometry at 260nm using a Genequant II RNA/DNA Calculator 
(Pharmacia). RNA samples were stored at -70 °C until required. 
RNA from cell cultures was prepared directly from cells grown as monolayers on 
10cm tissue culture plates (Nunc). The cells were washed twice with 5 ml phosphate 
buffered saline (PBS) and lysed in situ with 1 ml TRlzol solution. Isolation of total 
RNA from the TRIzol lysates was carried out as above except that RNA pellets were 
resuspended in S0µ1 DEPC/DDW. 
2.4 Reverse Transcriptase Polymerase Chain Reaction 
f RT -PCR) 
2.4.1 Reverse Transcription 
First strand complementary DNA (cDNA) was synthesised from total RNA using an 
RNAse H- Moloney Murine Leukaemia Virus (MoMuLV) Reverse Transcriptase 
(Superscript II, Life Technologies) and an oligo(dT) primer. 1 -2 µg of total RNA was 
heated with 100ng primer p(dT),,, (Boehringer Mannheim) to 70 °C for 5 minutes and 
plunged on ice for a further 5 minutes. A reaction mixture containing 4111 5X First 
Strand Buffer, I1_11 0.1M dithiothreitol (DTT), 200 Units RNAse H- Superscript and 
I pl 10X mixed dNTP stock solution (Appendix A) was prepared. This reaction was 
then incubated on ice for 10 minutes before being placed on a thermal heating block 
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(Omni -gene, Hybaid) on the following programme: 37 °C for 10 minutes, 1 hour at 
42 °C, 10 minutes at 50 °C and 10 minutes at 94 °C to inactivate the reverse 
transcriptase. Control reactions were carried out to which no RNA was added. 
cDNAs were diluted to 100µ1 with DDW and stored at -20 °C. 
2.4.2 RT -PCR for Human c -Myc 
Total RNA from the A549 human lung epithelial cell line was isolated and reverse 
transcribed as described above and subjected to PCR with oligodeoxyribonucleotide 
primers: 5'- CCGAATTCGACGATGCCCCT -3' (5987: myc5') and 5'- 
GGCCGCTTACGCACAAGAGTT-3' (3212: myc3'). Both primers were custom - 
manufactured and cartridge -purified by Cruachem Ltd. 
The PCR reaction mixture contained 5µ1 of diluted A549 cDNA, l0µ1 10X 
Thermophilic Buffer, 6µI 25mM magnesium chloride, 3 Units Tag (Thermu.s 
aquaticus) DNA polymerase (Promega), 2111 mixed dNTP stock solution (Appendix 
A) and 100ng of each primer made up to a final volume of 100µ1 with autoclaved 
DDW. The mixture was overlaid with 75111 paraffin oil (Boots) and amplification was 
carried out on a thermal cycler (OmniGene, Hybaid) on the following programme: 
Step 1: 94 °C, 3 minutes, 
55 °C, 1 minute, 
72 °C, 2 minutes; once. 
Step 2: 55 °C, 30 seconds, 
72 °C, 2 minutes, 
94 °C, 30 seconds; repeated 34 times. 
Step 3: 60 °C, 1 minute, 
72 °C, 5 minutes, 
30 °C, 30 seconds; once. 
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IOW of RT PCR products were analysed on a 1% agarose gel in 1X TBE as described 
below. Products were stored at -20 °C. 
2.4.3 RT -PCR for the Mouse Nedd2 Open Reading Frame 
Total RNA from 129/Sv mouse liver was isolated and reverse transcribed as described 
above and subjected to PCR with oligodeoxyribonucleotide primers: 5'- 
AAATGGCGGCGCCGAGCGGGAGGTCGCAGT-3' (3444: Nedd2 5') and 5'- 
GGCGGCATCACGTGGGT-3' (3445: Nedd2 3'). Both primers were custom - 
manufactured and purified by High Performance Liquid Chromatography (HPLC) by 
Cruachem Ltd. 
The PCR reaction mixture contained 20µ1 of diluted mouse liver cDNA, l01.1.1 l0X 
Thermophilic Buffer, 61..1 25mM magnesium chloride, 3 Units 7aq (7hermres 
aquaticus) DNA polymerase (Promega), 2µl mixed dNTP stock solution (Appendix 
A) and 100ng of each primer made up to a final volume of 10(411 with autoclaved 
DDW. The mixture was overlaid with 75p1 paraffin oil (Boots) and amplification was 
carried out on a thermal cycler (OmniGene, Hybaid) on the following programme: 
Step 1: 94 °C, 3 minutes, 
55 °C, 1 minute, 
72 °C, 2 minutes; once. 
Step 2: 55 °C, 30 seconds, 
72 °C, 2 minutes, 
94 °C, 30 seconds; repeated 34 times. 
Step 3: 60 °C, 1 minute, 
72 °C, 5 minutes; 
30 °C, 30 seconds, once. 
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l0µ1 of RT PCR products were analysed on a 1% agarose gel in IX TBE. Products 
were stored at -20 °C. 
2.4.4 RT -PCR assay for nedd2 mRNA Expression in Transfected Cells. 
Total RNA from transfected Rat -1 fibroblasts was isolated, treated with 
Amplification -Grade DNase -I (Life Technologies) according to the manufacturer's 
instructions and reverse transcribed as described above and subjected to PCR with 
oligodeoxyribonucleotide primers: 5'- AGCATGTCGTGGAGATGAGA -3' (N5) and 
5'- GGCGGCATCACGTGGGT -3' (3445: Nedd2 3'). Both primers were custom - 
manufactured and purified by High Performance Liquid Chromatography (HPLC) by 
Cruachem Ltd. 
The PCR reaction mixture contained 20µl of diluted (I in 10) DNase- treated cDNA, 
4% DMSO, 5µl l0X Thermophilic Buffer, 3µI 25mM magnesium chloride, 1.25 Units 
Tag (7hernnrs aquaticus) DNA polymerase (Promega), 21_11 mixed dNTP stock 
solution (Appendix A) and 100ng of each primer made up to a final volume of 50µI 
with autoclaved DDW. The mixture was overlaid with 75µ1 paraffin oil (Boots) and 
amplification was carried out on a thermal cycler (OmniGene, Hybaid) on the 
following programme: 
Step 1: 94 °C, 3 minutes, 
55 °C, 1 minute, 
72 °C, 2 minutes; once. 
Step 2: 55 °C, 30 seconds, 
72 °C, 30 seconds, 
94 °C, 30 seconds; repeated 34 times. 
Step 3: 60 °C, 1 minute, 
72 °C, 5 minutes; 
30 °C, 30 seconds; once. 
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l01.t1 of RT PCR products were analysed on a I% agarose gel in IX TBE. Products 
were stored at -20 °C. 
2.4.5 RT-PCR for Murine p21" F'iC IP' (Second Exon) 
Total RNA from 129 /Sv mouse liver was isolated and reverse transcribed as described 
above and subjected to PCR with oligodeoxyribonucleotide primers 5'- 
CAGGATCCATGCCAATCCTGGT-3' (G5650: WAF5') and 5'- 
TCGGTACCTGTCAGGCTGGT-3' (G5649: WAF3'). Both primers were custom - 
manufactured and purified by HPLC by Oswel DNA Service. 
The PCR reaction mixture contained 5µ1 of diluted mouse liver cDNA, l0µ1 l0X 
Thermophilic Buffer, 6µ1 25mM magnesium chloride, 5µ1 dimethyl sulphoxide 
(DMSO), 3 Units Tag (Thernms aquaticus) DNA polymerase (Promega), 2µ1 mixed 
dNTP stock solution (Appendix A) and 100ng of each primer made up to a final 
volume of 100p1 with autoclaved DDW. The mixture was overlaid with 75µ1 paraffin 
oil (Boots) and amplification was carried out on a thermal cycler (OmniGene, Hybaid) 
on the following programme: 
Step l : 94 °C, 3 minutes, 
55 °C, 1 minute, 
72 °C, 2 minutes; once. 
Step 2: 55 °C, 30 seconds, 
72 °C, 1 minute, 
94 °C, 30 seconds; repeated 34 times. 
Step 3: 60 °C, 1 minute, 
72 °C, 5 minutes, 
30 °C, 30 seconds; once. 
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10p1 of RT PCR products were analysed on a 2% agarose gel in 1X TBE as described 
below. Products were stored at -20 °C. 
2.4.6 High Fidelity RT -PCR for Murine p21WAF1iCIP1 
High Fidelity amplification was carried out for two oligodeoxyribonucleotide primer 
sets: one set, WAF5' and WAF3', produce a 446bp product corresponding to codons 
1 -143 of p21 cDNA and the other set, WAF5' and WAF23 (15027, 5'- 
GGCACTTCAGGGTTTTCTCTTGC-3': Cruachem Ltd) amplifies the full ORF 
encoding p21 and includes the stop codon (codon 160; underlined). 
Total RNA from 129 /Sv mouse liver was isolated and reverse transcribed as 
described above and subjected to high fidelity PCR with either of the primer sets. 
High Fidelty PCR was achieved using a mixture of conventional Taq (Therm us 
aquaticus) DNA polymerase and Pwo (Pyrococcus woesei) DNA polymerase 
(Expand High Fidelity, Boehringer Mannheim). In addition to the 5' -3' polymerase 
activities of both thermostable polymerases, this mixture takes advantage of the 
proofreading 3' -5' exonuclease activity of Pwo to provide a 4 fold lower error rate 
(8.5 x 10 "1) as compared to Taq (2.6 x 104). Expand High Fidelity PCR products 
consist of mixtures of molecules with 3' adenosine overhangs and blunt -ended 
fragments and are thus suitable for use in T/A cloning procedures. 
For Expand High Fidelity PCR, two mastermixes were made so that template and 
nucleoside triphosphates were kept separate until the latest possible moment prior to 
denaturation in order to prevent degradation of the template and nucleosides by the 
exonuclease activity of Pwo. Mastermixes were made large enough to allow for 6 
reactions, one additional reaction with control reverse transcription product (no 
RNA) and an extra reaction to allow for errors in pipetting. For each reaction, 
Mastermix A contained 2111 dNTP stock solution, 200ng of each primer from one of 
the above primer sets, 5111 diluted cDNA and 41111 DDW. Mastermix A was then 
dispensed in S0µ1 aliquots into 0.5 ml microcentrifuge tubes and 1,2,3,4,5 or 6111 
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dispensed in 500 aliquots into 0.5 ml microcentrifuge tubes and 1,2,3,4,5 or 61Al 
25mM magnesium chloride added and made up to 56µl total volume with DDW. For 
each reaction Mastermix B contained 10X magnesium free PCR buffer, 0.75µl 
Expand enzyme mix and DDW to a final volume of 44µ1. Prior to amplification, 44µ1 
of Mastermix B was mixed with the 56µl aliquots of Mastermix A containing cDNA 
and magnesium chloride and overlaid with 75µl paraffin oil (Boots). Amplification 
was carried out on a thermal cycler (OmniGene, Hybaid) on the following 
programme 
Step 1: 94 °C, 2 minutes, once. 
Step 2: 94 °C, 45 seconds, 
55 °C, 1 minute, 
72 °C, 1 minute, repeated 10 times. 
Step 3: 94 °C, 45 seconds, 
55 °C, 45 seconds, 
72 °C, 1 minute + 20 seconds increment per 
cycle; repeated 20 times. 
Step 4: 72 °C, 10 minutes; once. 
10µl of RT PCR products were analysed on a 1% agarose gel in IX TBE as described 
below. Products were stored promptly at -20 °C. 
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2.5 General Plasmid DNA Analytic and Preparative 
Techniques. 
2.5.1 Restriction Endonuclease Digestion of Plasmid DNA 
Plasmid DNA was digested in sterile microfuge (Eppendorf) tubes containing a 
mixture of DDW, the appropriate restriction endonuclease and the recommended, 
correct ionic strength buffer. All restriction enzymes were supplied by Boehringer 
Mannheim, Promega or Stratagene. 
10 X stock buffer solutions were used diluted 1:10 in the final reaction mix. 
Restriction enzymes were stored at -200C in buffers containing 50% glycerol and 
kept on ice while in use. Sufficient enzyme was used to ensure complete digestion: 1 
unit of enzyme being the amount required to digest I µg of pBR322 plasmid DNA to 
completion in 1 hour. The amount of enzyme was kept below 10% of the final 
reaction volume as glycerol can interfere with enzymatic activity. Digestion was 
carried out at 37°C for most enzymes for a minimum of 1 hour. 
2.5.2 Agarose Gel Electrophoresis of DNA 
Agarose gel electrophoresis was carried out in order to confirm digestion, 
characterise plasmids or purify restriction fragments. DNA molecules are separated by 
electrophoresis according to size, conformation (supercoiled, nicked circular or 
linear), agarose concentration and applied current. Tris- borate EDTA (TBE: appendix 
A) was routinely used as an electrophoresis buffer. Preparation of gels and 
electrophoresis in BioRad MiniSub Cells or Anachem Origo H3 gel tanks was carried 
out as described by Sambrook et al, (1989). Samples were loaded by adding 0.1 
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volume gel loading buffer (Appendix A) and applied to the wells of a gel submerged 
in electrophoresis buffer. Fragment sizes were estimated with reference to a kilobase 
marker (Life Technologies) or Marker V (Boehringer Mannheim). 
2.5.3 Isolation of DNA Fragments from Agarose Gels 
Digested DNA fragments visualised by UV transillumination were excised from 0.8 %- 
1 % agarose / TAE buffered (appendix A) gels and purified using the GlassMAX DNA 
Isolation Spin Cartridge System (Life Technologies) according to the manufacturer's 
instructions. 
2.5.4 Phenol:Chloroform Extraction and Ethanol Precipitation of DNA 
These procedures were carried out as described in Sambrook et al, (1989) in order to 
remove proteins and to concentrate DNA. The resulting DNA pellets were then 
briefly air -dried and redissolved in an appropriate volume of TE (pH 8.0: appendix 
A). 
2.5.5 Estimation of DNA Concentration and Purity 
Two methods for the estimation of the concentration of DNA solutions were used: a 
spectrophotometric method and an ethidium bromide fluorescent quantitation method 
(Sambrook el al, 1989). DNA samples from large and small scale DNA preparations 
were quantitated by ultraviolet spectrophotometry. 
The optical densities (OD) of 1:100- diluted DNA solutions were measured in a 
Genequant II RNA/DNA Calculator (Pharmacia) at k= 260nm. An of OD260 of 1 was 
taken to be equivalent to a concentration of 50p.g/ml of double- stranded DNA in the 
diluted sample. The ratio of the ODs at A. =260nm and at X =280nm is a measure of the 
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purity of a DNA sample. Accordingly, OD260 280 ratios measured in the Genequant 
were recorded for DNA samples. 
The concentrations of certain DNA solutions (such as the eluates from GlassMAX 
columns) were estimated by an ethidium bromide fluorescence method. Small samples 
of DNA (eg. 0.5µI) and a range of serially- diluted kilobase ladder were spotted onto a 
plastic Petri dish containing 1% agarose gel and 5µg/ml ethidium bromide. After 10- 
15 minutes to allow absorption of DNA onto the gel, the plate was exposed on a 
ultraviolet transilluminator and the DNA concentration was estimated by comparison 
of the fluorescent intensity of the sample against that of the standards. 
2.5.6 Modification of the Ends of linear DNA molecules: Blunt -Ending 
Restriction fragments of plasmids were blunt -ended by addition of 0.1 volume 10mM 
dNTP stock solution and 1µl T4 DNA polymerase directly to a completed restriction 
reaction mix and incubated at 37 °C for 30 minutes. T4 DNA polymerase blunt -ends 
both 5' and 3' overhangs effectively as it has an efficient 3' -5' exonuclease activity as 
well as its 5' -3' polymerase activity. The enzyme was inactivated by incubation at 
65 °C for 15 minutes. 
2.5.7 Modification of the Ends of Linear DNA Molecules: Linker Addition 
2µg Blunt -ended linear DNA molecules were ligated with 1µg of phosphorylated 
synthetic linkers containing an appropriate restriction enzyme recognition sequence. 
1 µ1 of linker (1µg), 6 units T4 DNA ligase and 0.1 volume 10X Ligase Buffer were 
added to a heat -inactivated restriction enzyme (and blunt -ending) reaction mix and 
ligated overnight at 4 °C. In the case of restriction reactions that could not be 
inactivated by heat, linkers were ligated to blunt -ended fragments that had been 
phenol /chloroform extracted and ethanol precipitated. 
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Following ligation, the ligase was inactivated by heating to 65 °C for 15 minutes and 
the linkers were digested by the addition of 30 units of the appropriate restriction 
enzyme and incubated at 37 °C for at least 4 hours. If necessary, the buffer conditions 
were altered to those optimal for the restriction enzyme. The digested reaction mix 
was then run on a TAE gel and the appropriate band recovered and purified. The 
purified bands contained compatible cohesive termini of the appropriate restriction 
enzyme. 
2.5.8 Modification of the Ends of Linear DNA Molecules: Dephosphorylation 
In a ligation reaction in which the vector has compatible or blunt ends, 5' 
dephosphorylation of the vector fragment considerably reduces the number of 
background non -recombinants that can be transformed into E. col i. This means that 
there is a strong chance that in a small number of colonies (6 -12) screened by small 
scale DNA preparations, the desired recombinant molecule can found. Accordingly, 
wherever possible, gel- purified vector fragments were treated with either calf - 
intestinal alkaline phosphatase (CIAP: Promega) or arctic shrimp alkaline phosphatase 
(SAP: United States Biochemicals) prior to use in ligation reactions. SAP has the 
advantage that it is easily inactivated by heating to 65 °C for 15 minutes, wereas CIAP 
is more resistant to heat and needs to be eliminated by phenol/chloroform extraction 
and ethanol precipitation. 
I unit SAP or CIAP was added to 40111 gel -purified vector fragment together with the 
appropriate dephosphorylation buffer and DDW up to a final volume of 501.1l. This 
reaction was incubated at 37 °C for 1 hour and then the phosphatase was inactivated 
using the appropriate method. Vector fragments were quantitated by the ethidium 
bromide plate method and used in ligation reactions. 
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2.5.9 T/A Cloning of RT -PCR Products into Plasmid Vectors 
RT -PCR products were cloned by ligation into the pGEM- 5Zf( +) plasmid vector 
linearised at an EcoRV site. This site is modified so that it possesses 3' -A overhangs 
in order to complement 5' -T overhangs on PCR products (pGEM -T Vector System, 
Promega). 11_1.l of PCR product was ligated to 50ng pGEM -T vector in a 10µl ligation 
reaction containing 3 units T4 DNA ligase and IX Ligase Buffer (Promega; Appendix 
A) at 15 °C overnight. 1111 of the reaction was transformed into XL 1- BIueMRF' 
competent cells (Stratagene; see below) and plated onto L -Amp plates that had been 
treated with 100111 20mM IPTG ( isopropyl -3 -D- thio -galactopyranoside; Stratagene) 
and 100µI 0.5% X -Gal (5- bromo -4- chloro- 3- indoyl -13 -D- galactopyranoside: 
Boehringer Mannheim) for 30 minutes at 37 °C (L- Amp/X -Gal /IPTG plates). Plates 
were incubated overnight at 37 °C. White (or light blue) colonies indicated 
recombinant plasmids containing cloned PCR product or having a IacZ_ a- peptide 
reading frame that was disrupted by some other mechanism. 
2.5.10 Sub -Cloning of Gel- Purified DNA Fragments Between Plasmid Vectors 
Plasmid DNA was digested with the appropriate restriction enzyme(s) in order to 
release a desired fragment to be subcloned or to linearise a vector prior to ligation. 
211g of plasmid was cut for production of vector or 5µg of plasmid was cut in order to 
release a fragment for subcloning. If modification of fragment ends by blunt -ending 
or linker addition was required, this was carried out at this point. The digested (and 
modified) fragments were then gel- purified as described above. Vector fragments 
were then dephosphorylated in order to limit recircularisation and therefore non - 
recombinant frequencies. Usually three ligation reactions were carried out per 
experiment. One control reaction contained only vector fragment, while the other 
experimental reactions contained a 1:1 or a 2:1 molar ratio of insert to vector 
respectively. The mass of vector was kept constant (50ng) and the amount of insert 
required for a 1:1 ratio was determined using the following formula: 
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50ng (mass of vector) x size of insert (kb) = mass of insert (ng). 
size of vector (kb) 
The vector and insert were ligated in a l0µ1 ligation reaction containing 3 units T4 
DNA ligase and 1X Ligase Buffer (Promega; Appendix A) at 15 °C overnight. 1µi of 
the reaction was transformed into the appropriate strain of competent cells. 
2.5.11 Transformation of Competent Eschen chia coli with Plasmid DNA 
Circularised plasmid DNA was introduced into commercially produced competent E. 
coil of the appropriate strain (eg. XL1BlueMRF' competent cells: Stratagene. For 
more information on strains see Appendix B) according to the following protocol: 
Competent cells were defrosted on ice and aliquoted into pre- chilled 1.5 ml microfuge 
tubes. 1 µl of undiluted ligation reaction was gently mixed with 2041 of competent 
cells and incubated on ice for 20 minutes. Cells were then heat - shocked at 42 °C for 40 
seconds and plunged on ice for 2 minutes. Following the addition of 80µ1 of room 
temperature SOC medium (Appendix A) the cells were incubated at 37 °C in an orbital 
incubator at 220 rpm for 1 hour to allow expression of antibiotic resistance. 
Transformed cells were innoculated onto L -amp plates (LB agar with 1001_tg/ml 
ampicillin: Appendix A) or onto plates containing 501_1g/m1 Kanamycin Sulphate 
(Sigma) in the case of bacteria containing pBKCMV- derived vectors. Plates were 
incubated at 37 °C for 16 -24 hours. Controls were provided by parallel 
transformations with pUC 19 DNA (positive control) or no DNA (negative control) 
plated onto L -amp plates or bacteria treated as above but with no DNA plated onto 
LB plates (positive control: no antibiotic) 
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2.5.12 Identification of Recombinant Plasmids by Colony Hybridisation 
Recombinant clones were identified by colony hybridisation if there was a large 
number of non -recombinant clones on the bacterial plate corresponding to the control 
(0: I ) ligation. Colonies were replica -plated onto duplicate L -Amp plates, one having a 
gridded nylon filter (Hybond N +: Amersham) in contact with the agar. After 
overnight incubation at 37 °C, the master plates were stored at 4 °C and the gridded 
filters were processed according to a protocol modified from Sambrook et al, 1989. 
Briefly, filters were placed colony side up on 0.75 ml 0.5N NaOH on a piece of 
Clingfilm for 3 minutes. The underside of the filters were blotted on a paper towel and 
were treated again with NaOH and blotted. The filters were neutralised on two 5 
minute changes of 1 M Tris (pH7.4) followed by one change of 1.5M NaOH, 0.5M 
Tris (pH7.4). The filters were allowed to dry on a piece of 3MM paper for 20 -30 
minutes and the bacterial DNA was UV- crosslinked to the filters (Spectrolinker 
XL 1500: Spectronics Corporation). Filters were stored dry between pieces of 3MM 
paper until required for hybridisation. Hybridisation was carried out as detailed below 
and recombinant colonies were identified on the master plates by alignment with the 
autoradiographs. 
2.5.13 DNA /DNA Hybridisation 
DNA probe fragments were gel purified and 20ng labelled with 501.1Ci, 3000Cí /mmol 
[a -52P] -dCTP (ICN) using the Prime -It RmT random primer labelling kit 
(Stratagene). Unincorporated nucleotides were removed by passing labelled probes 
down a Sephadex G50 column (NICK Column: Pharmacia). 
Filters were prehybridised in a hybridisation oven (Hybaid) for at least 4 hours at 65 °C 
in Hybridisation Buffer (Appendix A). Labelled DNA probe was denatured by boiling 
and then immediately diluted in hybridisation solution at 65 °C and the prehybridised 
filters were hybridised at 65 °C with the probe overnight. 
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The hybridisation solution was discarded and the filters washed once in 100m1 2X 
SSC (Appendix A), 65 °C for 30 minutes; once in 100m1 2x SSC, 1% SDS, 65 °C for 
30 minutes; once in 100m1 0.5X SSC, 1% SDS, 65 °C for 30 minutes and once in 
100m1 0.1 X SSC at room temperature for 30 minutes. The filters were sealed moist in 
heat -sealable plastic bags and exposed to Fuji R -X film at -70 °C in an 
autoradiography cassette with intensifying screens. 
2.5.14 Small -scale Preparation of Plasmid DNA (Mini -preps) 
Isolation of plasmid DNA from bacterial cultures for the verification of plasmid 
identity by restriction digestion was carried using the Wizard Minipreps DNA 
Purification System (Promega). Small -scale preparations suitable for manual 
sequencing were performed using the QlAprep Spin Plasmid Kit (Qiagen). Both 
systems were used to purify plasmid DNA from cleared bacterial alkaline SDS lysates 
using high concentrations of chaotropic salts (guanidine hydrochloride or guanidinium 
isothiocyanate) and a silica gel -based DNA -binding resin (Wizard kit) or membrane 
(QlAprep kit). The DNA on the mini -columns was washed with ethanol containing 
high -salt solutions and eluted in low salt (TE) buffer. 
Preparation of cleared bacterial lysates for use with the Wizard columns is described 
as an example below; the procedure for the QlAprep system is similar and will not be 
detailed here. The plasmid DNA was purified from cleared lysates with the kits in 
accordance with the manufacturers' instructions. 
Single colonies were picked from L -amp plates and innoculated into 5mis LB medium 
containing the appropriate antibiotics (10014m1 ampicillin or 50pg/ml kanamycin) in 
Falcon 2059 tubes (Becton Dickinson). After an incubation period of 14 -16 hours at 
37 °C in an orbital incubator at 220 rpm, a 1.5ml sample (3m1 for QlAprep) from each 
of the resulting late logarithmic phase cultures was transferred to a microfuge tube 
and the bacteria pelleted by microcentrifugation at 6500 rpm for 5 minutes. The 
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supernatants were discarded and the bacterial pellets resuspended in 200µl Cell 
Resuspension Buffer (Appendix A), lysed by the addition of 2001..t1 of an alkaline 
sodium dodecyl sulphate solution (SDS)(Cell Lysis Buffer: appendix A. The SDS 
denatures bacterial proteins and the strong alkaline conditions used in this procedure 
cause denaturation of both plasmid and chromosomal DNA) and gently mixed by 
inversion. The mixture was then neutralised with 200µl Neutralisation solution 
(Appendix A). This neutralisation caused rapid renaturation of circular plasmid DNA 
wereas most chromosomal DNA, bacterial protein and SDS (as potassium dodecyl 
sulphate) formed a white gelatinous precipitate which was separated from the 
aqueous, plasmid- containing supernatant upon microcentrifugation at 13000 rpm for 5 
minutes. This supernatant (cleared lysate) was promptly separated from the debris by 
pipetting into clean microfuge tubes. 
I -2111 samples of DNA purified from cleared lysates were digested with appropriate 
restriction enzymes and analysed by agarose gel electrophoresis (2.3.1). 
2.5.15 Large -scale Preparation of Plasmid DNA (Maxi- and Mega- preps) 
This method is a larger scale version of the alkaline lysis procedure described above 
and rapidly prepares large amounts DNA of a quality that is suitable for ligation, 
sequencing and transfection. The DNA from the bacterial lysates is highly purified by 
anion -exchange column chromatography (Qiagen Tip -100 or Tip -2500, Qiagen). 
Cleared bacterial lysates were prepared according to the column manufacturer's 
instructions from a 100m1 (maxi -prep: Tip -100) or a 500m1 (mega -prep: Tip -2500) 
overnight culture (no longer than 16 hours incubation) and then decanted through 
stainless -steel strainers into 50m1 polypropylene universal containers and applied to 
equilibrated (with QBT buffer: Appendix A) Qiagen columns. The plasmid DNA was 
washed with the supplied wash buffer (QC: Appendix A), eluted in a buffer containing 
I.25M NaCI at pH 8.5 (QF: Appendix A) into clean Oakridge centrifuge tubes and 
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precipitated with 0.7 volume room temperature isopropanol. The DNA was collected 
by centrifugation at 11500rpm in a Sorval SS -34 rotor and washed with a small 
volume of ice -cold 70% ethanol. After removal of excess ethanol, the pellets were 
dried in vacrio for no more than 5 minutes before being resuspended in an appropriate 
volume of sterile TE (Appendix A). The concentration and purity of the DNA was 
estimated as above. 
2.5.16 Dideoxynucleotide Chain -Termination (Sanger) Sequencing of Plasmid 
DNA 
Double -stranded plasmid DNA template was prepared by the QlAprep Spin mini -prep 
or Qiagen maxi -prep methods and then alkaline -denatured. For each sample, 5µg 
DNA was diluted in 45111 DDW and denatured with 5µl 2M NaOH, 2mM EDTA and 
incubated at ambient temperature for 5 minutes. The solution was neutralised with 2M 
ammonium acetate (pH4.6) and the DNA precipitated at -70 °C for 30 minutes with 
18511I absolute ethanol. The DNA was recovered by microcentrifugation at 13000 
rpm at 4 °C for 10 minutes and the pellet was washed once with ice -cold 70% ethanol 
and dried in vacuo for 5 minutes. The DNA was either resuspended in 60 DDW 
immediately for further processing or was stored dry at -20 °C for up to one week. 
The resuspended DNA was annealed to 2pmol primer in 1X Sequenase Reaction 
Buffer (United States Biochemicals) in a final volume of 10111 by heating to 65 °C for 2 
minutes and then allowed to cool to 25 °C, slowly (over 15 -30 minutes) in a waterbath 
placed on the bench. The annealed template /primer mix was then labelled at ambient 
temperature for 4 minutes with 5p.Ci, (1000Cí /mmol)[a -35S] -dATP (ICN) and 
terminated at 37 °C for at least 5 minutes with each of the four dideoxyribonucleotides 
using dGTP reagents and protocols provided with the Sequenase Version 2.0 DNA 
Sequencing Kit (United States Biochemicals). Each termination reaction was stopped 
using the provided `Stop' solution which also acts as a dye -containing loading buffer. 
Samples were stored at -20 °C until required. 
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Processed samples (termination reactions) were denatured by heating to 75 °C 
immediately before loading 3111 into wells created by a shark's tooth comb at the top 
of a pre -run (45 °C) 6% denaturing polyacrylamide sequencing gel (Appendix A). The 
gel was poured between two glass plates separated with 0.4mm plastic spacers. One 
plate was coated with silicone (Gel- Slick) to prevent adhesion of the gel to both 
plates. The gel was run using S2 sequencing apparatus (Life Technologies) and a 
model 3000 microcomputer electrophoresis power supply (Life Technologies) at 70W 
in 1X TBE. 
Following running of a sequencing gel, the siliconed plate was removed and the gel 
was fixed with two 4 minute changes of 10% methanol, 10% acetic acid and 
transferred to a piece of 3MM paper. The gel was covered in plastic film (Clingfilm) 
and dried in vacuo for 2 hours at 80 °C using a model 583 gel dryer (BioRad) and 
vacuum pump. The Clingfilm was removed and the gel was exposed to Biomax MR 
film (Kodak) in an autoradiography cassette for 18 -48 hours. The film was then 
processed in a processor (Hyperprocessor: Amersham) and viewed on a white light 
box. 
2.5.17 Preparation of Uni- directional Nested Deletions in pBK53wt DNA. 
Uni- directional nested deletions were made in plasmid pBK53wt so that sequencing of 
the entire insert could be performed using only one sequencing primer. The method 
exploits the highly predictable rate of digestion by exonuclease III of double- stranded 
DNA to single- stranded DNA in the 3' -5' direction to produce a uniform series of 
progressively shorter DNA fragments. Exonuclease III does not digest the 3' ends of 
single- strand extensions or a 5' restriction overhang that has been filled in with a -thio 
dNTPs and therefore can made to digest only one arm of a doubly -digested plasmid. 
Mung bean nuclease digestion removes the remaining overhangs and the resulting 
blunt -ended DNA is then recircularised with DNA ligase and transformed into E. coli. 
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The T3 sequencing primer in pBK53wt was protected from deletion by exonuclease 
III by cutting 60µg plasmid with Sall in a 500µ1 reaction and filling in the 5' 
overhangs with 5 units Klenow fragment of F.co /i DNA polymerase I in the presence 
of 4µM ct -thio dNTPs ( Stratagene) at ambient temperature for 15 minutes. After 
phenol /chloroform extraction and ethanol precipitation the DNA was cut with EcoRl 
in a 500µ1 reaction and then ethanol precipitated. (The EcoRI site in pBK53wt is 
further away from the T3 priming site than SalI.) 
Exonuclease III reactions contained 30µg doubly- digested plasmid, 1 X Exo III buffer 
(Stratagene), 10mM freshly diluted 13- mercaptoethanol and 250 units exonuclease III 
in a final volume of 300µ1. The exonuclease III was added last and the reaction was 
incubated at ambient temperature (22 °C). At I minute intervals following the addition 
of the exonuclease, 12.5111 aliquots were taken and mixed with diluted 10X Mung 
Bean Nuclease Buffer (Stratagene) so that the DNA was diluted in a final volume of 
100111 1X Mung Bean Nuclease Buffer. These aliquots were snap- frozen in a dry- 
ice /methanol bath until all aliquots had been taken. The exonuclease was inactivated 
by heating the tubes to 68 °C for 15 minutes and then placed on ice. The DNA in each 
aliquot was blunt -ended with 15 units mung bean nuclease (Stratagene; diluted in 1X 
Mung Bean Dilution Buffer) at 30 °C for 30 minutes. 500ng of each aliquot was 
digested with BglIl and run on a I% agarose gel to check the extent of the deletions. 
6.5111 of each of the nuclease- treated DNA was recircularised in separate 20111 ligation 
reactions containing 3 units T4 DNA ligase and I X Ligase Buffer (Promega) at 4 °C 
overnight and then transformed into XL1BlueMRF' cells. Individual colonies from 
each of the samples were mini -prepped and analysed on a 1% agarose following 
double -digestion with Sacl and Bg1II. 12 clones were identified as containing nested 
deletions of the p53wt insert and were sequenced using the T3 primer. 
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2.5.18 Site -directed Mutagenesis 
Double -stranded, site- elimination site directed mutagenesis (Fig. 2.8) was used to 
introduce corrective mutations or other sequence modifications into plasmids. In this 
procedure double -stranded DNA is denatured and one or more 5'- phosphorylated 
mutagenic primers are annealed to one strand of the plasmid. Both primers are 
extended with a mixture of T7 DNA polymerase and T4 DNA ligase to complete the 
mutagenic strand. At least one of the primers mutagenises a non -essential, unique 
restriction site in the plasmid so that it eliminates restriction by that enzyme in 
plasmids derived from the mutagenic strand (Selection Primer). The other primer 
introduces a specific mutation in the region of interest in the plasmid (Mutagenic 
Primer). One primer suffices in the case that elimination of a restriction site and 
introduction of a specific mutation can be accommodated in one oligonucleotide. All 
the plasmid DNA in the mutagenesis reaction is incubated with enzyme that 
corresponds to the non -essential, unique restriction enzyme present in the unmutated 
strand in order to eliminate plasmids that have not incorporated the Selection Primer. 
Plasmids containing mutagenic strands remain undigested and are transformed more 
efficiently into XLmntS competent cells. In XLmutS cells selection of the strand which 
is chosen to repair the mismatches between the mutagenic and parental strands is 
random. This means that 50% of transformants will contain mutant plasmids. The 
transformants are grown in liquid culture overnight and mini -prepped. The mini -prep 
DNA is subjected to a further restriction digestion with the selection enzyme and 
transformed into E. coli wild -type for the mud gene (i.e. any of the usual laboratory 
strains). Since supercoiled DNA transforms E. coli much more efficiently than 
linearised DNA, individual transformants from the secondary transformation will most 
likely contain mutant plasmids and -70 -95 % will contain the desired mutation. 
250pmol of each of the oligodeoxyribonucleotide primers N29 (10734: 5'- 
GCTGTGACTATGACACAAGTCTCCCTTTC-3'), N30 (10735: 5'- 
GCCTATCCACAGATGCTACGGAACACTCCT-3'), NEO (12210: 5'- 
GCCAACGCTATGTCCTGATAGGGGTCCCCCACACCCAGCCGGCC-3') and 
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W26 (12482: 5'- ACCAGCCTGACATGATCCGAAATCAC -3') were 5'- 
phosphorylated with T4 polynucleotide kinase (PNK) (Promega) in a l00µ1 reaction 
containing 2mM ATP and 1 X PNK Buffer at 37 °C for 1 hour. 
Mutagenesis was carried out using reagents provided in the Chameleon Double - 
Stranded, Site -Directed Mutagenesis Kit (Stratagene). 25pmol of each of the primers 
N29, N30 (Mutagenic) and NEO (Selection) were mixed with 0.25pmol supercoiled 
pOPRNedd2 plasmid DNA in a 200 reaction containing 1 X Mutagenesis Buffer 
(Appendix A). Similarly, 25pmol of primer W26 (Mutagenic and Selection) was 
added to 0.25pmol of pGEM -WAF 1. The DNA was denatured by boiling for 5 
minutes, placed on ice for 5 minutes and the primers were annealed to the DNA by 
placing the tubes at ambient temperature for 30 minutes. The primers were extended 
and mutagenic strands ligated using a mixture of T7 DNA polymerase and T4 DNA 
ligase in the presence of 1mM dNTPs and I X Mutagenesis Buffer for 1 hour. The 
polymerase and ligase were inactivated by heating the tubes to 75 °C for 15 minutes. 
7p1 Buffer #7 and 20 units CspI were added to the pOPRNedd2 mutagenesis reaction 
and the volume adjusted to 70µI with DDW. 20 units KpnI and 290 DDW were 
added to the pGEM -WAF1 mutagenesis reaction so that the final buffer conditions 
were 0.5X Mutagenesis Buffer. The restriction enzyme reactions were incubated at 
37 °C for I hour and 1/10 volume of the restriction digests were transformed into 90µI 
XLmri1S competent E. coli that had been pre- treated with 25mM ß- mercaptoethanol 
on ice for 10 minutes. The cells were incubated with the DNA in Falcon 2059 tubes 
on ice for 30 minutes, heat -shocked at 42 °C for 45 seconds and placed on ice for 2 
minutes before the addition of 0.9 ml SOC medium. The bacteria were then incubated 
at 37 °C for 1 hour in an orbital incubator at 220 rpm. 3 ml of 2X YT broth (Appendix 
A) containing 100µg/ml amplicillin was added and the cultures were grown overnight 
at 37 °C in the orbital incubator. The overnight XLmrutS cultures were mini -prepped 
and mutant plasmids were enriched for by restriction with the appropriate enzyme 
(Cspl or KpnI) in a 200 reaction. 10 of each digest was then transformed into 200 
XL I Blue competent cells and individual colonies were mini -prepped and screened for 




























into E. coli 
Fig. 2.8. Site elimination, site- directed mutagenesis. m: mutant primer; s: selection 
primer; r: restriction enzyme site. 
127 
2.6 General Cell Culture Techniques 
All cell cultures were performed with sterile reagents and equipment. Sterile technique 
was employed during all manipulations of cultures and reagents. These were carried 
out in sterile laminar flow hoods except in the case of a few experimental procedures 
that required to be performed at 37°C. 
2.6.1 Maintenance of Fibroblast Stocks 
Cells were resuscitated from frozen stocks maintained in the vapour phase above 
liquid nitrogen at -196 °C, thoroughly washed and seeded into a 25cm2 culture flask 
(Costar) and grown until approximately 90% confluent before being transferred to 
larger flasks. 
Fibroblast cell line stocks were maintained as subconfluent monolayer cultures by 
regular passage attached to the bottom of 162cm2 tissue culture compatible plastic 
flasks (Costar) covered with 40 -50m1 Dulbecco's modified Eagle's medium (DMEM: 
Sigma) containing 4500mg/I glucose, supplemented with L- glutamine (0.1mM), 
sodium bicarbonate (0.01 M), 100U /ml Penicillin, 100U / ml streptomycin and 10% 
heat -inactivated foetal calf serum (FCS: Sigma). The flasks were gassed with a 5% 
CO2 / air mixture and the culture flasks were then placed in a humidified 5% CO2, 
37 °C incubator with the caps loosened slightly. 
Cells were passaged 1:10 when they approached approximately 90% confluence: cells 
were washed in 0.02% EDTA in phosphate buffered saline (PBS: appendix A) for 20- 
30 seconds or until the monolayer appeared opaque. The EDTA was replaced by 4m1 
of a solution of 0.1% trypsin in PBS and the monolayer was detached and 
disaggregated by gentle agitation. The resulting cellular suspension was transferred to 
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a conical- bottomed universal container and the trypsin was inactivated by adding an 
equal volume of DMEM/10% FCS. Clumps of cells were disaggregated by drawing 
the suspension up and down in a Pasteur pipette a number of times. Approximately 
0.1 volume of this (0.8m1) was reseeded per flask. 
2.6.2 Harvesting of Fibroblasts and Estimation of Cell Concentration 
Cells were harvested by trypsinisation as above and the cells were collected by 
centrifugation in universal tubes at 1000rpm in an MSE Mistral 3000 centrifuge for 
10 minutes and resuspended in an appropriate volume of PBS. Cells were either 
repelleted by centrifugation for storage at -20 °C or seeded into fresh flasks or plates 
after estimation of cell concentration using a Neubauer improved haemocytometer. 
2.7 Transfection of Plasmid DNA into Fibroblast Cell 
Lines 
2.7.1 Plating of Cells Prior to Transfection 
Cells were harvested by trypsinisation and placed into a universal tube. The cells 
were then passed once through a 19G needle to disperse clumps and diluted in 
complete medium (DMEM /10 %FCS). The concentration of cells was then estimated 
using an improved Neubauer haemocytometer and 5 -8 x 10' cells were diluted in 10 
ml DMEM /10 %FCS. This suspension was added to a 10 cm tissue culture plate, 
swirled to evenly distribute the cells over the surface and placed in a humidified, 50/0 
CO2, 37 °C incubator for 24 hours before transfection. 
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2.7.2 Calcium Phosphate Precipitation (Chen and Okayama, 1987) 
In this protocol (Chen and Okayama, 1987) which is a modification of the original 
HEPES method (Wigler el a!, 1977; Graham and Van der Eb, 1973), DNA is mixed 
with a calcium chloride and a slightly acidic (pH6.95 -6.98) buffered solution of 
sodium phosphate and this is added onto cells and incubated overnight at 35 °C with 
3% CO2. As the pH of medium slowly rises during the incubation, a calcium 
phosphate / DNA precipitate forms and settles onto the cells. Some of this precipitate 
is then taken up by the cells. 
20 -3511g supercoiled Qiagen- column -purified plasmid DNA was mixed with 500111 
0.25M CaC12 (Sigma). 50011l 2X BBS pH6.95 (Appendix A) was mixed with the 
DNA solution and incubated at ambient temperature for 10 -20 minutes. The DNA / 
CaC12 / BBS mixture was then added dropwise to a plate of cells whilst swirling the 
medium. The plate was then incubated for 16 -24 hours in a humidified 3% CO2, 35 °C 
incubator. Then plates were then washed twice with 5 ml PBS and 10 ml of DMEM / 
10 %FCS was added and the plates returned to a 37 °C, 5% CO2 incubator. Transient 
transfections were incubated for 48 -72 hours following addition of the DNA. 
2.7.3 Selection and Cloning of Stable Transfectants 
For stable transfections, washed transfected cells were incubated overnight before 
being split 1:10 by trypsinisation into fresh plates and incubated overnight. The 
medium was then aspirated and replaced with medium containing the appropriate 
antibiotic (200µg/ml hygromycin B (Boehringer Mannheim), 30011/ml active G418 
(Geneticin: Life Technologies) or 1 µg/m1 puromycin (Clontech)). Selective medium 
was replaced every 2 days for 10 -14 days. Plates were then washed with PBS and 
clones were picked using a 20011.1 pipette tip into wells of 96 -well plates (Costar) 
containing 10011l 0.1% trypsin in PBS. Cells were then fed with l50111 of selective 
medium and replaced in an incubator. When clones reached near -confluence they were 
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transferred to wells of a 24 well plate (Nunc) and subsequently into 6 well plates and 
then 75 cm` flasks (Costar). 
2.7.4 Colony formation assay. 
Cells were transfected and divided into replicate plates in selection medium for 11 -14 
days. Cells were then rinsed twice in PBS, fixed in 70% ethanol for 5 minutes and 
stained with 20% Giemsa in PBS for 10 minutes. Plates were rinsed with tap water 
and air dried. The number of colonies per plate was counted. 
2.7.5 Histochemical stain for 13- galactosidase (Lim and Chae, 1989). 
Cells transiently transfected with plasmid pCMV -ß were washed twice in PBS and 
fixed in 0.0% glutaraldehyde for 10 minutes. Plates were washed four times with PBS 
and stained at 37 °C with X -gal solution: 0.2% X -gal (from a 2% stock in 
dimethylformamide) in 1mM MgC12, 150mM NaCI, 3.3mM K4Fe(CN)6.3H20, 3.3mM 
K3Fe(CN)6, 60mM Na2HPO4, 40mM NaH2PO4. Several fields of cells were counted 
and transfection efficiency was expressed as the percentage of cells that stained blue 
for ß- galactosidase. 
2.8 Northern Blot Analysis 
2.8.1 Formaldehyde Gel Electrophoresis and Northern Transfer 
Total RNA samples (10µg) were mixed with 3 volumes of RNA Sample Buffer 
(Appendix A) and heated to 55 °C for 15 minutes. 0.2 volume of RNA Loading Buffer 
(Appendix A) was added and the samples were loaded into the wells of a 100m1, 1% 
denaturing agarose gel (I% agarose, 1 X MOPS Running Buffer (Appendix A), 18% 
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formaldehyde in DEPC /DDW) poured in a DEPC- treated Anachem Origo H3 gel 
tray. The gel was submerged in 1 X MOPS Running Buffer and electrophoresed at 
75mA until the bromophenol blue reached 70 -75% of the length of the gel. 
The RNA in the gel was then transferred to a positively- charged nylon membrane 
(Zetaprobe GT: BioRad) using a VacuGene XL vacuum blotter (Pharmacia). A piece 
of nylon membrane cut to the size of the gel was placed upon the porous support in 
the blotter and then surrounded with a plastic mask cut so that it overlapped the 
membrane by approximately 5mm on all sides. The gel was then placed on top of the 
membrane so that it overlapped the inside edges of the mask. The gel was covered in 
DEPC/DDW and a vacuum of 50- 55mBar was applied to the blotter for no more than 
5 minutes. The excess water was removed and promptly replaced with DEPC- treated 
and autoclaved 20X SSC so that the level of SSC was 2 -3 times the thickness of the 
gel. The gel was blotted (still under vacuum) for 30 minutes after which the blotter 
was disassembled and the filter washed in 20X SSC for no more than 5 minutes 
before being dried for 30 minutes between two pieces of 3MM paper. The RNA was 
fixed to the membrane by baking in vacuo at 80 °C for 30 minutes in a gel drier. Fixed 
filters were stored dry between two pieces of 3MM paper in plastic bags at 4 °C if 
required. 
2.8.2 DNA /RNA Hybridisation 
Filters were prehybridised overnight at 42 °C in hybridisation bottles containing 15ml 
of a prehybridisation solution containing 5X SSPE (Appendix A), 5X Denhardt's 
solution (Appendix A), 100µg/ml denatured, sonicated calf thymus DNA (Gibco) and 
50% deionised formamide (Appendix A). The following day a double- stranded DNA 
probe was labelled and purified as detailed in the section on DNA/DNA hybridisation 
and boiled before being added to 15ml of hybridisation solution (prehybridisation 
solution plus 5% dextran sulphate) at 42 °C. The prehybridisation solution was 
discarded and replaced with the hybridisation/probe mixture. Hybridisation was 
continued for 24 hours at 42 °C. 
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Probed blots were washed twice for 15 minutes at 20 °C in 1X SSC, 0.1% SDS and 
twice for 15 minutes at 20 °C in 0.25X SSC, 0.1% SDS. The filters were then sealed 
moist in plastic bags and exposed to Fuji R -X film at -70 °C in an autoradiography 
cassette with intensifying screens for at least 2 days. 
2.9 Indirect Immunofluorescence for LadI 
5 x 104 cells from hygromycin B- resistant clones obtained from transfections with 
p3'SS were plated into wells of 8 well Lab -Tek chamber slides (Nunc). One well per 
slide was seeded with untransfected Rat I cells as a negative control. The plated cells 
were incubated in 300µ1 DMEM /10 %FCS at 37 °C, 5 %CO2 overnight. The medium, 
chambers and rubber gaskets were removed and the slides were washed in PBS three 
times before fixing the cells in situ in 4% formaldehyde in PBS for 10 minutes. The 
cells were then permeablised in 0.1% Tween -20 in PBS for 5 minutes and washed in 5 
changes of PBS. The washed cells were incubated with rabbit polyclonal anti - /ac! 
serum (Stratagene) at a dilution of 1:100 in PBS, 5% normal porcine serum (Dako) 
for 1 hour. The slides were then washed 5 times in 0.1% Tween-20, 0.5% bovine 
serum albumen fraction V (BSA: Sigma) in PBS. The slides were then incubated with 
fluoresceine isothiocyanate (FITC)- conjugated porcine anti -rabbit Ig serum at 
25p.g/ml in 0.1% Tween -20, 0.5% BSA in PBS for 1 hour. After washing 5 times in 
0.1% Tween-20 in PBS the slides were mounted in an aqueous mountant and 
coverslipped. The fluorescence was viewed using a fluorescence microscope fitted 
with an FITC filter set. 
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Chapter 3. 
3. Apoptosis Induced by p53 is Dependent upon the 
Cellular Context: Use of a Temperature- Sensitive 
p53. 
3.1 Introduction. 
Many tumours are resistant to chemotherapy, either intrinsically or following an 
initial partial response. A number of pharmacokinetic explanations may account for 
this, including over -expression of the multidrug resistance gene mdrl, over -expression 
of drug detoxication enzymes, or alteration of the drug target, for example 
topoisomerase II isoform. However despite intensive study of drug- target 
interactions, and drug metabolism, it is clear that in many instances drug resistance is 
associated with a failure of induction of apoptosis, even after an appropriate 
triggering event. Since many anti- cancer drugs and ionising radiation damage DNA, 
the response of the cell in recognising injury and proceeding to repair or apoptosis is 
of paramount importance (Hickman, 1992). 
Entry to apoptosis is regulated by a number of genes (see Chapter 1, General 
Introduction: Apoptosis), each of which may show abnormal expression or function in 
cancer. In Rat -1 fibroblasts cell cycle arrest or serum deprivation in the presence of 
constitutive expression of the c -myc oncogene can cause apoptosis (Evan el al, 1992). 
By contrast, over -expression of hc12 directly inhibits apoptosis in both normal and 
neoplastic cells (Veis el al, 1993; Sentman et al, 1991; Miyashita and Reed, 1993; 
Miyashita and Reed, 1992; Hockenberry el al, 1990) and prevents c -myc driven 
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apoptosis (Wagner et al, 1993). More recently evidence has accumulated implicating 
the tumour suppressor gene p53 in an injury- response pathway leading to apoptosis. 
Thymocytes and myeloid progenitor cells from p53 knockout mice, fail to undergo 
induced apoptosis in the absence of a wild -type p53 allele following etoposide or 
ionising radiation treatment but not apoptosis associated with ageing in vitro or 
nonclastogenic insults such as dexamethasone treatment. (Lotem and Sachs, 1993; 
Lowe et al, 1993; Clarke et al, 1993). Furthermore over -expression of wild -type p53 
in a variety of cancer -derived cell lines such as MI myeloid leukaemia (Yonish- 
Rouach et al, 1991), murine erythroleukaemia (Ryan et al, 1993) and HT29 colon 
carcinoma (Shaw et al, 1992) resulted in an increase in spontaneous apoptosis. 
By contrast, studies of p53 null fibroblasts grown in primary culture have failed to 
detect alteration in cell survival characteristics after DNA damage as compared to 
normal primary fibroblasts (Slichenmeyer et al, 1993). In the latter experiments, cells 
were isogenic apart from p53 status. This suggests that other factors, including cell 
lineage and expression of oncogenes may modulate the effects of p53 on cellular 
physiology. In both experimental and human tumorigenesis p53 inactivation is 
believed to be a late event and is therefore superimposed on a series of progressive 
genetic abnormalities, such as activation of ras oncogenes (Fearon and Vogelstein, 
1990). 
The aim of this part of the project was to study the role of p53 in apoptosis of rodent 
fibroblasts in culture. In particular, two aspects were investigated: 1) to investigate 
the effects of DNA damage upon cells in which p53 phenotype can be independently 
modulated and 2) the interaction between p53 and apoptosis in the context of c -myc 
overexpression. 
Firstly, cells expressing p53va1135 were utilised in order to investigate the effect of 
wild -type and mutant p53 phenotype both upon cell cycle activity and upon the 
apoptotic response to DNA damage induced by two chemotherapeutic drugs known 
to cause DNA strand breaks and apoptosis, namely etoposide (VP16) and bleomycin. 
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Secondly, transfection experiments were designed such that expression of p53 and c- 
myc activity could be exogenously regulated. The temperature- sensitive mutant p53, 
p53va1135, was used which is capable of both wt and mutant properties. Also, activity 
of a c- myc- oestrogen receptor chimaera (myc -ER; (Eilers el al, 1989)) can be 
regulable by the addition of [3- oestradiol to the medium. In the first instance, an 
attempt was made to isolate sublines of cells containing constitutive c -myc and 
p53va1135. Further, transfection of cells expressing p53va1135 (Clone 6) with a 
mycER construct was attempted, with the intention of producing cells in which the 
activity of both genes could be regulated independently. 
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3.2 Materials and Methods. 
Details of general materials and methods used, including basic cell culture technique 
and plasmid DNA preparation and manipulation are to be found in Chapter 2. The 
specific details of materials and experimental procedures used for the work forming 
the basis of this chapter are given below. 
3.2.1 Eukaryotic Expression Vectors 
Five eukaryotic expression vectors, containing either a mutant p53 gene 
(pLTRp53cGva1135, pLTRp53cGphe132 and pLTRp53cGXK), the hygromycin B 
resistance gene (pHMR272) or a chimaera of the human c -myc oncogene and a 
portion of the human oestrogen receptor gene (myc- ER)(pMV7 -MER) were 
obtained as plasmid DNA samples and were transformed into competent Escherichia 
colt. Samples of ampicillin (or where appropriate, hygromycin B) resistant cultures 
were stored at -70°C (for details see below). A sixth plasmid (pMV7) was 
reconstructed from pMV7 -MER by removal of the myc -ER coding fragment from the 
vector as described below. Plasmid details are summarised in Table 3.1. Plasmid maps 
are included in Appendix C. 
3.2.1.1 Plasmids Gattaining Mutant p53 Sequences 
Plasmid pLTRp53cGval135 (Eliyahu et aI, 1985) is based on pBR322 (Bolivar et al, 
1977) and contains the 3.7kb Xhol -Sacll fragment from the murine p53val135 
genomic clone Ch53 -7 (Bienz et al, 1984) replacing the corresponding 0.95kb Xhol- 
Sacll region of a murine p53 cDNA clone (Pinhashi and Oren, 1984; Zakut -Houri cet 
al, 1983). The resulting hybrid contains eight of the ten introns found in genomic p53 
and encodes a temperature- sensitive missense mutant p53 with a substitution from 
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alanine to valine at position 135. The hybrid is placed downstream from the 5' proviral 
Harvey murine sarcoma virus long terminal repeat and is flanked at the 3' end by 
sequences containing the early SV40 polyadenylation site. 
Plasmid pLTRp53cGphe132 is similar to pLTRp53cGva1135 and was derived by 
gapped- duplex site -directed mutagenesis (Kramer et al, 1984) from 
pLTRp53cGva1135. The p53phe132 mutant has a corrected codon 135 (alanine) and 
is non -temperature- sensitive (Michalovitz et al, 1990). 
Plasmid pLTRp53cGXK is identical to the above plasmids except that a 2.75kb Xhol- 
Kpnl fragment has been deleted from the p53 coding sequences (Kaczmarek et al, 
1986). This plasmid potentially encodes only the first 14 residues of p53 (M. Oren, 
personal communication). 
3.2.1.2 Plasmid pHMR272 
pHMR272 (Bernard et al, 1985) is a plasmid/cosmid vector based on the Col E 1 
origin of replication and contains an aminoglycoside antibiotic resistance gene 
(aph)(Hmr) cloned from Streptomyces hygroscopicus which codes for the enzyme 
hygromycin B phosphotransferase (Kanter et al, 1983). This gene is used as a 
selectable marker in E. coli when under the control of the prokaryotic promoter pl 
and can be expressed under the influence of the herpes simplex virus thymidine kinase 
(HSVtk) promoter in eukaryotic cells (Bernard et aI, 1985). Selection of cells 
expressing Hmr in either prokaryotes or eukaryotes is performed by adding 
appropriate concentrations of hygromycin B (200- 500mg/ml) to the medium. 
Selection is independent of aminoglycoside resistance coded for by neomycin /G418 
resistance genes and therefore hygromycin B resistance can be used for selection in 
serial or cotransfection experiments. 
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3.2.1.3 Plasmids pMV7 and pMV7 -MER 
The retroviral expression vector pMV7 (Kirschmeier el al, 1988) is based on a 
derivative of pBR322 which contains a polyomavirus origin of replication as well as 
retaining the pBR322 origin and ampicillin resistance genes (Dailey and Basilico, 
1985; Luskey and Botcham, 1981) It also contains a 4. I kb Xhol fragment encoding a 
modified Moloney murine sarcoma virus ( MoMSV). This MoMSV derivative was 
produced by removing 3.95kb of MoMSV genomic sequences (coding for the viral 
gag genes and large parts of v -mos and the pol gene) by digestion with Pstl (Perkins 
el al 1983). It retains both 5' and 3' LTRs and regulatory elements for virion RNA 
encapsidation and reverse transcription. An HSVtk /neomycin phosphotransferase 
cassette which acts as a dominant selectable marker in eukaryotic cells has been 
inserted 0.3kb 5' of the 3' LTR. Two unique cloning sites (EcoR I and Hind III) are 
found 0.5 -0.6kb downstream of the 5' LTR start of transcription. 
pMV7 -MER (Eilers et al, 1989) contains a 2.4kb EcoR I fragment inserted into the 
unique EcoR I site of pMV7. This fragment consists of a chimaera of cDNA 
sequences coding for exons II and III of the human c -myc proto- oncogene (Stone el 
al, 1987) fused to cDNA sequences representing the hormone binding domain of the 
human oestrogen receptor (Kumar et al, 1986). 
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Fig. 3.1 : Restriction endonuclease analysis of plasmid pLTRp53cGval135. 
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Fig. 3.2 : Determination of linearising restriction sites for plasmid pLTRp53cGval135. 
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Fig. 3.3 : Restriction endonuclease analysis of plasmid pMV7 -MER. 
M: kilobase marker; Lane 1: uncut; Lane 2: EcoR I; Lane 3: BamH I; Lane 4: EcoR 1 and Barnes I; Lane 5 Xho 1: 
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Fig. 3.4 : Restriction endonuclease analysis of plasmid pMV7. 
M: kilobase marker. Lane 1: EcoR I; Lane 2: BamH I; Lane 3: EcoR I and BamH I; Lane 5 Xho I (note 
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Fig. 3.5 : Determination of linearisation sites for plasmid pMV7 -MER. No unique sites were found. However, 
Xho I cuts twice, bracketting the sequences essential for function of this expression vector. 
M: kilobase marker. Lane 1: uncut; Lane 2: Smal; Lane 3: Xbal ; Lane 4: Sall; Lane 5: AI; Lane 6: Pvut; 





M 1 2 3 
Fig. 3.6 : Restriction endonuclease analysis of plasmid pHMR272. 






3.2.2 Fibroblast Cell Lines 
A number of rodent fibroblast cell lines were procured and maintained in culture in 
which expression of the cellular oncogene c -myc or the temperature sensitive p53 
mutant p53va1135 had been augmented by genetic manipulation. The cell lines were 
originally produced by insertion of the corresponding gene into high expression 
vectors and subsequent introduction into the eukaryotic cells by either infection with 
recombinant retroviruses (Brown and Scott, 1987) or transfection of cells by the 
calcium phosphate co- precipitation technique (Graham and Van der Eb, 1973). 
Details of cell lines are summarised in Table 3.2. 
3.2.2.1 Clone 6 Cells and RcGphe132.4 cells. 
This cell line (kindly provided by M. Oren) constitutively expresses the temperature 
sensitive p53 mutant, p53va1135 which adopts wild type conformation and functional 
properties at permissive temperatures (32°C) and mutant conformation and properties 
at 37°C (Michalovitz et al, 1990). Clone 6 is a cell line derived from low passage 
rodent embryo fibroblasts transformed by murine p53va1135 and a human 
mutationally- activated c-Harvey-rasl gene (Michalovitz et al, 1990) using the 
calcium phosphate co- precipitation technique (Graham and Van der Eb, 1973). 
Clones were propagated from foci that developed as a result of co- operation between 
Ha -ras and p5 3val 135 in transformation of the transfected rat embryo fibroblasts at 
37°C (Eliyahu et al, 1984; Michalovitz et al, 1990). In Clone 6, p53va1135 is under 
the transcriptional control of a Harvey murine sarcoma virus long terminal repeat 
(LTR) and is encoded by plasmid pLTRp53cGval135 (Kaczmarek et al, 1986; 
Eliyahu et al, 1985). Activated Ha -ras in these cells is encoded by plasmid pEJ6.6 
(Shih and Weinberg, 1982). RcGphel32.4 cells contain a temperature- stable 
p53phe132 transgene in addition to activated c- Ha -ras1. The level of p53 expression 
in Clone 6 and RcGphel32.4 is similar (M. Oren, personal communication). All 
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manipulation of cell lines and counting was performed at the selected temperature to 
minimise the risk of inadvertent p53 conformational shifts. 
3.2.2.2 Rat- IA/mycdl45 -262 and Rat- JA/mycAI06 -143 Cells 
These rodent fibroblast cell lines were obtained from Dr. G. I. Evan (ICRF, London) 
and constitutively express either an active or an inactive deletion mutant of the human 
c -myc oncogene. Both of these lines were derived from the methylcholanthrene- 
treated Fischer rat embryo fibroblast cell line Rat I A (see Chapter 2: General Materials 
and Methods). In -frame deletion mutants of cDNA clones of exons II and III of the 
human c -myc oncogene (Stone et al, 1987) were previously inserted into the 
retroviral expression vector pMV6 and transfected into the packaging cell line `Y2 
(Stone et al, 1987; Mann and Mulligan, 1983). Helper -free ecotropic retoviral stocks 
were then harvested from the medium above transfected T2 cells and were used to 
infect Rat 1 A cells according to the procedure outlined by Brown and Scott (1987) 
and stable incorporation of the vector was selected for on the basis of neomycin 
resistance (Penn et al, 1990; Stone et a1, 1987). 
The Rat- IA/mycA145 -262 cell line is a pool of 150 -250 neomycin resistant colonies 
derived from Rat-1A cells infected with retroviruses encoding the c- mycA145 -262 
deletion mutant. This mutant has been shown to be fully active in autosuppression of 
endogenous c -myc expression (Penn et al, 1990), co- operation with Ha -ras in 
transformation of Rat -1A fibroblasts (Stone et al, 1987) and is capable of inducing 
apoptosis in Rat-1A cells upon serum depletion (Evan et al, 1992). Rat 1 A/mycA106- 
143 cells express high levels of mRNA transcripts of the deletion mutant c- mycA106- 
143 but this mutant shows no autosuppression, cotransformation or apoptotic activity 
(Evan et al, 1992; Stone et a1, 1987; Penn et al, 1990). 
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Table 3.2 Summary of Cell Lines 









Rat - l AlmycA 145- 
262 




neor Stone (1987) 
Penn (1990) 
Rat- I A/mycA 106- 
143 





neor Stone (1987) 
Penn (1990) 








r REF early passage Fisher rat embro fibroblasts 
+ active c -myc - myc. 145 -262: crippled c -myc = myc. 106 -143: Tn5 -neor = neomycin resistance gene from bacterial transposon 5 
$ Tx - transfection: Cat(PO4) = calcium phosphate coprecipitation metho 
d 
§ neor neomycin (G118) resistance 
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3.2.3 Morphological Analysis of Cell Lines. 
3.2.3.1 Phase Contrast Microscopy 
Phase contrast microscopy was used to investigate the cellular morphology of 
fibroblasts adherent to the substratum and to examine the cultures for apoptotic cell 
death under the various experimental conditions described below. Monolayers of cells 
were examined at medium power (x100) and at high power (x320) using an inverted 
phase- contrast microscope (Leitz). 
3.2.3.2 Transmission Electron Microscopy 
Clone 6 cells were seeded in duplicate flasks and grown at 37°C for 24 hours. At this 
point one flask was moved to the 32°C incubator and cells in a duplicate flask were 
fixed in .situ with 3% glutaraldehyde in 0. I M sodium cacodylate for 1 hour, and then 
washed and stored at 4°C in a 5% sucrose / sodium cacodylate pH 7.4 buffer for no 
longer than 48 hours. After 24 hours at 32°C cells were similarly fixed, washed and 
stored overnight. All cells were then post -fixed in situ with 1% osmium tetroxide in 
sodium cacodylate. Cells were then removed from the flasks by scraping and 
suspended in cacodylate buffer. A pellet containing cells from each sample was 
prepared by centrifugation. Pellets were dehydrated through graded alcohols to 
absolute ethanol, incubated twice in propylene oxide for 20 minutes and then 
impregnated with grades of araldite to 100% araldite. Samples were maintained at 
room temperature overnight in 100% araldite before polymerisation of the araldite at 
56°C. Representative ultrathin (40 -50nm) sections were cut on an ultramicrotome and 
stained with uranyl acetate and lead citrate. Specimen grids were examined using a 
transmission electron microscope (JEM -I 00: Jeol). 
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3.2.4 Evaluation and Quantitation of Apoptotic Cell Death 
3.2.4.1 Morphological Evaluation of Apoptotic Cell Death 
Apoptotic cells were recognised under the phase contrast microscope as rounded, 
highly refractile, spherical bodies. This assertion was confirmed by acridine orange 
fluorescence and by electron microscopy (data not shown). Attached apoptotic bodies 
were defined as those refractile bodies that appeared to be almost perfectly spherical 
and could not be induced to migrate across the field by gentle tapping of the 
microscope stage. 
3.2.4.2 Quantitation of Cell Number and Apoptosis. 
Reference points (3 per flask) were used to count directly the number of cells in x100 
field using a 10 x 10 graticule. This permitted sequential counts at 20, 28 and 42h. 
after plating at 32 °C or 37 °C. Apoptotic cells adherent to the monolayer were counted 
at each time point as well as cell number. The apoptotic cells were recognised by 
virtue of their spherical, highly refractile appearance under phase contrast. These cells 
showed the classical appearances of apoptosis and were confirmed by electron 
microscopy and acridine orange fluorescence microscopy (Arends and Harrison, 
1994). 
Both the total number of cells per field and the total number of apoptotic bodies 
adherent to the monolayer were counted as described above using the phase contrast 
microscope. Clusters of very small apoptotic bodies were considered to have 
undergone fragmentation and were assumed to have derived from one cell. Spherical 
refractile bodies that occurred in pairs were suspected to be mitotic and, unless they 
were perfectly spherical and failed to exhibit anchoring pseudopodia, were ignored. 
The prevalence of apoptosis in the fields was expressed as the number of apoptotic 
(attached, non -mitotic, refractile) bodies as a percentage of the number of live cells 
per field ( "percentage apoptosis"). 
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3.2.5 Treatment of Cells with DNA Damaging Agents 
Clone 6 cells were plated at a density of 2 x 104 cells /cm2 and grown for 24 hours at 
37°C. One group of cells was then removed to a 32°C incubator while treatment with 
drugs (dissolved in the appropriate vehicle) began with the cells at 37°C. Drug 
treatment of cells at 32°C was commenced 24 hours after the temperature shift. All 
procedures were carried out at the appropriate temperature with previously 
equilibrated reagents. It was assumed that washing effectively removed drug from the 
cells. 
3.2.5.1 Etoposide 
The dimethylepipodophyllotoxin, etoposide (VP -16), has been shown to cause 
double -stranded breaks in DNA by interfering with the breakage- reunion reaction of 
the enzyme topoisomerase II, resulting in stabilisation of enzyme -drug -DNA cleavable 
complexes (Liu, 1989). The level of cellular expression of topoisomerase II activity is 
dependant upon position in the cell cycle and determines the levels of drug- induced 
DNA cleavage and cell death (Long el al, 1986). However, the complexes and DNA 
breaks are reversible upon removal of the drug (Long el al, 1985) and there is 
dissociation between maximal topoisomerase II activity (G2/M) and maximal 
cytotoxicity (S phase)(Chow and Ross, 1987). It has been suggested that cells may be 
triggered to die by an interaction between the epipodophylloyoxin stabilised cleavable 
complexes and other cellular processes such as DNA and RNA synthesis or 
illegitimate recombination (Bae el al, 1988). Upon removal of etoposide, cells 
undergo a transient cell cycle arrest and and accumulate in G2 which correlates with 
inhibition of p34cJc2 kinase activity (Lock and Ross, 1990b). Upon recovery of p34`k2 
activity to abnormally high levels (after 12 -24 hours in CHO cells), many cells enter 
mitosis and subsequently die by apoptosis after abnormal segregation of chromosomes 
(Lock and Ross, 1990a). 
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A stock solution of etoposide (VP -16; 100mM in DMSO)(Sigma) was diluted fresh 
for each experiment to 10mM in PBS. This suspension was added to the medium 
above the experimental cells to a final concentration of either 1011M or 50µM. After 1 
hour, the medium was removed and the cells washed three times with PBS before 
adding fresh medium to each flask. Control cells were treated similarly with an 
equivalent volume of 10% DMSO in PBS. 
3.2.5.2 Bleomycin. 
Bleomycin sulphate is a mixture of complex glycopeptides produced by Streptomyces 
verticillus, bleomycinA2 and bleomycinB2 being the main constituents (Crooke and 
Bradner, 1976). Bleomycin has a portion that binds divalent metal ions such as Cu(II) 
and Fe(II) and a region that binds to DNA at specific sequences (eg, 5' -GC -3' and 5'- 
GT-3'; (Mirabelli et al, 1983; Mirabelli et al, 1982). Single and double strand breaks 
are made in DNA when bleomycin -Fe(II) -02 complexes bind to DNA and catalyse the 
reduction of 02 to hydroxyl and superoxide radicals (Burger et al, 1986; Lown and 
Sim, 1977). Active or relaxed chromatin is more susceptible to bleomycin- induced 
strand breaks (Kuo, 1981). Bleomycin causes an accumulation of cells in G2 (with 
many cells exhibiting chromosomal abnormalities) (Watanabe et al, 1974; Hittleman 
and Rao, 1974; Nagatsu et al, 1972; Tobey, 1972) and apoptosis (Kuo and Hsu, 
1978). 
A stock solution of 1 unit / ml bleomycin (Sigma) in PBS was prepared (1 U = 1 mg 
bleomycin A2) and added to the medium above experimental cells to a final 
concentration of 151.1U /ml. After one hour cells were washed three times with PBS 
before adding fresh medium to the flask. Control cells were treated with an equivalent 
volume of PBS. 
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3.2.6 Cell Cycle Analysis 
An EPICS CS (Electronically Programmable Individual Cell Sorter; Coulter 
Electronics) flow cytometer was used to provide a measure of the DNA content of 
Clone 6 cells under experimental conditions. Nuclei were isolated and stained with 
propidium iodide (Vindelov et al, 1983), and 1 x 104 cells were analysed on the flow 
cytometer. Histogram analysis was performed using the Easy 2 Software. No doublets 
were seen. Bromodeoxyuridine incorporation analysis was carried out using the 
Amersham Cell Proliferation Kit (cat. #: RPN20). 
3.2.7 Stable Transfection of Plasmid DNA into Mammalian Cells 
Two methods of the stable introduction of plasmid DNA into fibroblast cell lines were 
used. The calcium phosphate co- precipitation technique (Graham and van der Eb, 
1973; Wigler el al,, 1977; Wigler et al, 1979) was used to co- transfect Rat l A- derived 
fibroblast cell lines with plasmids containing mutant p53 sequences and plasmid DNA 
containing the hygromycin B resistance gene (pHMR272). The electroporation 
method (Neumann et al, 1982) was used to introduce plasmids pMV7 and pMV7- 
MER, into Clone 6 cells. 
Plasmids were linearised before transfection in order to maximise efficiency of 
incorporation of vector into recipient genomic DNA (Szostak et al, 1983; OrrWeaver 
et al, 1981). 
Selection was performed with the appropriate antibiotics (G418 or hygromycin B; see 
Chapter 2 for details) added to the medium for a period of at least 1 -2 weeks in order 
to select for cells with stably -incorporated vector sequences. In all transfection 
experiments, two samples of cells were similarly treated, one sample without the 
addition of DNA in order to confirm the efficiency of the selection conditions. 
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3.2.7.1 Linearisation and Ethanol Precipitation of Plasmid DNA 
20 -30µg of each plasmid was linearised by exhaustive digestion with the appropriate 
restriction enzyme. Candidate enzyme sites occurring only in non -essential portions of 
the vectors were shown to cut only in these regions by digestion of small samples of 
plasmid DNA and analysis of the resulting restriction fragments by agarose gel 
electrophoresis (Table 3.3 and Figs. 3.1 to 3.6). 
A small sample of each digestion reaction was retained for electrophoresis in order to 
check that complete digestion had indeed occurred. Once digestion was confirmed, 
the DNA was precipitated with 2 volumes of absolute ethanol at 4°C for 30 minutes. 
The DNA was collected by microcentrifugation at 4°C for 20 minutes at 13000 rpm 
and briefly air -dried in a sterile laminar flow hood before use in transfection protocols. 
3.2. 7.2 Transfection: HEPES-based Calcium- Phosphate Coprecipitation Method 
Graham and van der Eb (1973) described the optimal conditions for the uptake of 
coprecipitates of calcium phosphate (125mM) and DNA (5- 30µg/ml) at pH 7.05 into 
adherent cells. It is thought that co- precipitated particles of appropriate size enter the 
cytoplasm by pinocytosis and may be transferred to the nucleus by an unknown 
mechanism. The calcium phosphate co- precipitation method can be used to establish 
stably transfected cell lines with multiple, integrated copies of vector DNA 
(Sambrook et al 1989). 
Cells were harvested 24 hours before transfection, washed in PBS and drawn through 
a fine needle with a syringe to form a single cell suspension. Cells were plated at a 
density of 1 x 105 cells /cm2 onto 100mm x 20mm tissue culture compatible Petri 
dishes (Costar) in 10m1 GMEM /10% HINCS and placed in a humidified 5% CO2 
incubator at 37°C. Four hours before transfection the medium was changed and 
returned to the incubator. Linearised plasmid DNA (20 -30µg of one p53- containing 
plasmid together with 2 -3µg linearised pHMR272) was ethanol -precipitated (2.5.1) in 
a sterile microfuge tube, dried briefly in a sterile laminar flow hood and dissolved in 
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0.5m1 0.1 x TE (pH8.0) / calcium phosphate (250mM) solution. This solution was 
added drop -by -drop, with constant gentle mixing to 0.5ml 2 x HEPES buffered saline 
(2 x FIBS: appendix A) in a sterile Falcon 2059 tube (Becton Dickinson). The mixture 
was then incubated at room temperature for 20 -30 minutes to allow the DNA -calcium 
phosphate precipitate to form before addition of the entire mixture to the medium 
above the cells to be transfected. The dish was gently rocked to ensure complete 
mixing of the precipitate with the medium and the dish was returned to the incubator. 
After 16 hours the medium was aspirated, cells were washed with PBS and fresh 
medium applied. The cells were allowed a further 24 hours incubation before replating 
at 2 x 104 cells /cm2 in selection medium. 
3.2.7.3 Transfection: Electroporation Method 
Electric field pulses applied across cellular suspensions are believed to facilitate DNA 
uptake into cells by direct entry into the cytoplasm and nucleus by formation of 
transient pores in cellular membranes. In this way single copies of cloned genes can be 
incorporated into eukaryotic cells (Boggs et al, 1986). On this basis, linearised 
plasmid vectors were transfected into fibroblasts by electroporation (Neumann et al,, 
1982) using a Bio -Rad Gene Pulser and Capacitance Extender. 
Plasmid DNA (20 -30µg of each construct) was linearised by exhaustive restriction 
digestion with the appropriate enzyme, ethanol precipitated in a sterile microfuge tube 
and allowed to dry briefly in a sterile laminar flow hood before dissolving in 0.8ml 
sterile PBS. Approximately 107 fibroblasts grown to 70 -80% confluence were 
harvested by trypsinisation, washed in PBS, centrifuged at 1000 rpm at 20°C for 5 
minutes and then resuspended in the DNA / PBS solution. The resulting DNA / cell 
suspension was then transferred to a Gene Pulser cuvette (a chamber, two opposing 
sides of which are constructed from sheets of metal and act as parallel electrodes). 
Two discharges of an electric field of 0.23kV with a capacitance of 50011F (McMahon 
and Bradley, 1990) were applied across the DNA / cell suspension at ambient 
temperature. Cells were allowed to recover for 10 minutes before being drawn 
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through a fine needle with a syringe to form a single cell suspension (to help prevent 
co- operation between adjacent cells in selection) and seeded at an approximate 
density of 2 x 104 cells /cm2 into 25cm2 flasks or onto 10cm x 20mm tissue culture 
compatible Petri dishes (Costar) with an appropriate volume of GMEM /10% HINCS. 
Cells were selected and cloned as described in the General Materials and Methods 
section (Chapter 2). 
Table 3.3. Restriction Analysis of Plasmids 










9.8kb EcoR I 
BamH I 
Xhol and KpnI 
9.8kb 
2.1 kb, 7.7kb 
1.1kb, 1.65kb, 7.05kb 
Sal I 
pLTRp53cGXK 7.05kb EcoRI 




pHMR272 4.1 kb HindIII 
EcoR I 
4.1 kb 
0.3kb, 0.5kb, 3.3kb 
Hind III 
pMV7 -MER 10.4kb EcoR I 
Xhol 




1.0kb, 1.4kb, 2.0kb, 
5.97kb 
XhoI¶ 
pMV7 7.97kb EcoR I 
XhoI 






Xhol cuts twice in p \t\'7 and releases a 3.8kb fragment containing pl3R322 derived sequences. The larger fragment contains retrosiral sequences. IIS \Yk -ncor, 
and the unique EcoR I cloning site into which the myc -ER construct has been inserted in pMV7-MER 
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3.3 Results 
3.3.1 Cellular Morphology 
3.3.1.1 Phase contrast Microscopy 
The majority of Clone 6 cells grown at 37°C in plastic culture flasks appeared as 
elongated spindle- shaped, slightly refractile cells with visible nuclei and multiple (3 -5) 
nucleoli. A minority of cells at 37oC appeared more broadened, irregularly shaped and 
were less refractile (Fig. 3.7a). Nuclei were, in general, round or oval shaped, but 
some cells exhibited slightly irregular outlines. Rare, atypically large cells appeared to 
contain more than one nucleus per cell or contained one nucleus that was noticeably 
larger than cells of usual appearance. Mitoses were visible at a rate of about 3 -5% in 
subconfluent cultures. When grown to confluence, the cells tended to overlap each 
other and eventually formed into foci (Fig. 3.10) 
Most Clone 6 cells incubated at 32°C for a least 24 hours were larger, broader and 
much less refractile than at 37°C (Fig. 3.7b). These cells exhibited an abundance of 
criss- crossing, filamentous densities strewn about the cytoplasm. Mitotic cells were 
extremely rare after 24 hours incubation at 32°C. Cells kept at this temperature did 
not increase in number and did not become confluent. Few apoptotic cells were seen 
at either temperature in the monolayer or supernatant. 
1 n contrast, Rat -1 A/mycA ] 45 -262 and Rat -1 A/mycAl 06 -143 cells showed no change 
in morphology and only a small reduction in growth rate when placed at 32°C. There 
were an abundance of spherical, highly refractile cellular bodies, both attached to the 
monolayer and suspended in the medium above the Rat-1 A/mycA145 -262 cells 
(3.13b). These bodies were demonstrated to be apoptotic by the observation of 
nuclear fragmentation in samples of these bodies when stained with acridine orange 
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thus shows a moderate rate of apoptosis, but its induction is not temperature 
sensitive. 
3.3.1.2 Transmission Electron Microscopy 
Samples of Clone 6 cells previously incubated at either 37 °C or 32 °C were fixed in 
situ and processed for electron microscopy. Nuclei usually possessed one large, dense 
nucleolus, which sometimes contained some unusual, highly electron -dense 
inclusions. It was considered that there may have been less endoplasmic reticulum 
and less prominent nucleoli in cells incubated at 32 °C than in cells incubated at 37 °C. 
Otherwise, there were no obvious ultrastructural differences at the two temperatures 
(Fig 3.9). 
3.3.2 Growth Properties and Serum Dependence 
Cells from all three lines were seeded at equal density, grown in wells of a 24 -well 
tissue culture plate for 24 hours (37 °C, GMEM / 10% HINCS) and subsequently 
incubated in either a 37 °C or a 32 °C incubator in GMEM supplemented with 10 %, 
0.01% or 0% HINCS. The degree of viability of each cell line was estimated 
qualitatively in order to determine whether apoptosis could be induced in the cell 
lines under conditions of serum deprivation. Cells grown in the presence of 10% 
serum had the typical morphology and growth characteristics of cells grown as 
monolayers in the stock flasks. All the cell lines maintained their basal apoptotic rate 
and proceeded to confluence within 2 -4 days. 
As previously observed by Evan et al (1992), Rat- lA/myc0145 -262 cells showed an 
increase in apoptotic rate when placed in reduced serum conditions. Rat - 
lA/mycd106 -143 cells did not show this effect. In addition both cell lines maintained 
these characteristics when the experiment was repeated at 32 °C 
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Fig. 3.7a : Clone 6 cells grown at 3700. Cells are elongated, slightly refactile and possess prominent nuclei. 
Phase contrast: Left: x 100; Right x 320. 
I ? .%' ,i . :; q 
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Fig. 3.7b : Clone 6 cells incubated at 3200. Cells are spread out over the substratum and contain criss- crossing 
filamentous densities in the cytoplasm. 
Phase contrast Left x 100; Right: x 320. 
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Fig. 3.9a : Clone 6 cells grown at 37°C. 
TEM: x 4000 
o 
Fig. 3.9b : Clone 6 cells incubated at 32°C. Note electron dense inclusions in nucleolus. 
TEM: x 3000. 
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Fig. 3.10: Clone 6 cells grown to confluence. Cells are highly refractile and grow on top of each other. 
Phase contrast: Above: x 100; Below: x 320. 
Fig. 3.11: Clone 6 cells at 37°C 24 hours after treatment with 50µM etoposide. Note abundant apoptotic 
bodies. 
Below: Phase contrast: x 320. 
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Fig. 3.12a : Rat1A/mycM106 -143 at low density. Cells are elongated, retractile and slighlty overlapping. 
Observe the spherical, retractile properties of the apoptotic bodies. 
Phase contrast: x 100. 
Fig. 3.12b : Clone 6 cells at low density. Note while some cells are elongated, others are broader and less 
retractile. 
Phase contrast: x 100. 
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Fig. 3.13a : RailA/myc0106 -143 cells grown to confluence. Cells are elongated, form fascicular arrays and do 
not overlap. 
Phase contrast: Left x 100; Right x 320. 
Fig. 3.13b : RatlA/mycM145 -262 cells grown to confluence. Cells are polygonal and refractile. Note the 
abundance of apoptotic bodies. 
Phase contrast: Left: x 100; Right: x 320. 
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3.3.3 Clone 6 cells are Growth Arrested at 32°C. 
Exponentially growing cells were shifted to a 32 °C incubator. In three independent 
experiments cells ceased to show increase in cell number at 32 °C (Fig. 3.14). There 
was no increase in apoptosis in the presence of p53 with wild type configuration (see 
Figs. 3.17 to 3.18 controls). At 37 °C, with mutant conformation p53, there was a 
three -fold increase in cell number over the same period, confirming the original 
observations of Michalovitz and colleagues (1990). DNA flow cytometry showed 
both diploid and tetraploid peaks at permissive and nonpermissive temperatures. At 
32 °C there was in increase in the diploid GO /1 peak (Fig 3.15), and cells did not take 
up bromodeoxyuridine consistent with this state (data not shown). This growth arrest 
was reversible by transferring cells to 37 °C, even after 2 weeks, or more. By contrast, 
RcGphel32.4 cells continued to grow at a slightly reduced rate at 32 °C in keeping 
with the previous observations of Michalovitz and colleagues (1990)(data not shown). 
3.3.4 Clone 6 cells with Wild -Type p53 are Resistant to both Etoposide and 
Bleomycin. 
At 37 °C, in the presence of mutant conformation p53, there was a progressive 
increase in apoptosis starting 6 -10h. after pulsing with drug. The increase was dose 
dependent: etoposide at 10µM induced a maximum of 6% apoptosis whereas at 
50µM the maximum was greater than 30% apoptosis. By contrast, cells maintained at 
32 °C with p53 in the wild type conformation showed no increase in percentage 
apoptosis, nor in cell number (Figs. 3.16 and 3.17). Treatment with bleomycin 
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Fig. 3.14: Growth properties of Clone 6 cells at 37oC (filled circles) and at 32oC (open circles). 
Each point represents the mean number of cells per field (n =3) in one flask at each time point. Note 














Fig. 3.15. Cell cycle analysis of Clone 6 cells. (a) Exponentially growing cells at 37 °C. untreated 
(GO/G1 fraction : 46.56 %). (b) Following incubation at 32 °C for 24 hours, the GO /G1 peak is 
enlarged (72.51 %) and there is a marked decrease in the proportion of cells between the GO /GI and 
G2/M peaks (S- phase). (c) At 37 °C. 24 hours after etoposide treatment (504M) cells accumulated in 
G2/M with only 10.18% of cells occupying the GO/G1 position. (d) At 32 °C. 24 hours after treatment 
with 50µM etoposide (GO /G1 fraction: 38.51 %). Abscissa: DNA content (propidium iodide 
fluorescence). 
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RcGphe132.4 cells are sensitive to apoptosis induced by etoposide and bleomycin at 
32 °C and 37° C: We considered the possibility that these differences in cell 
proliferation and apoptosis in response to DNA damage might be due simply to 
altered pharmacokinetics at the different temperatures. The RcGphe132.4 cell line 
was derived from the same parental stock as Clone 6, but contains a temperature - 
insensitive mutant p53; hence in this cell line wild type p53 is excluded from function 
at both 32 °C and 37 °C. At 37 °C Clone 6and RcGphe132.4 cells show closely similar 
entry into apoptosis: 24h after treatment with 501...tM etoposide the incidences were 
18.0% and 19.4% respectively. In contrast, at 32 °C the incidence of apoptosis in 
RcGphel32.4 cells was 9.5 %, but had fallen to less than 2% in Clone 6 cells. Very 
similar results were obtained following treatment with bleomycin. At 37 °C incidence 
of apoptosis in Clone 6 cells was 19.8 %, but fell to less than 3% at 32 °C. In contrast, 
RcGphe132.4 cells showed 10.3% apoptosis at 37 °C and 8.9% at 32 °C. Thus the 
profound inhibition of apoptosis in Clone 6 cells at 32 °C is dependent upon the altered 
configuration of p53 to wild -type and is not explicable solely on the basis of 
temperature effects on pharmacokinetics. 
In order to investigate whether p53- induced growth arrest is capable of preventing 
apoptosis by allowing time for recovery from DNA damage, cells were incubated at 
32 °C for 24 hours before treatment with 5011M etoposide, 15µU /ml bleomycin or 
equivalent volumes of either DMSO or PBS as described above and replacement into 
the 32 °C incubator. At various times after treatment (2,6,12,24 hours), cells were 
shifted to 37 °C. Cells and apoptotic bodies were counted at various time points after 
treatment. Cells shifted to 37 °C 2 hours after treatment with bleomycin showed a 
similar, though delayed increase in percentage apoptosis. However, after shifting to 
37 °C after 12 or 24 hours after drug- treatment, no increase in percentage apoptosis 
was seen (Fig. 3.19). This pattern was also seen with etoposide- treated cells (data not 
shown). The duration of wild -type p53 expression and the associated Gl /S arrest may 
therefore determine the susceptibility of Clone 6 cells to undergo DNA damage - 
induced apoptosis. 
166 
0 5 10 15 
Time / Hours 
20 25 
Fig. 3.16 : Treatment of Clone 6 cells with 1011M etoposide at 37 °C (filled circles) for 1 hour 
results in substantial apoptosis, whereas treated cells at 32 °C (filled squares) and untreated controls 
(unfilled symbols) do not show this increase. Note the latent period during induction of apoptosis at 
37 °C. Each line represents a separate experiment (performed in triplicate and expressed as a mean For 
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Fig. 3.17: Treatment of Clone 6 cells with 501.1.M etoposide for 1 hour induces substantial apoptosis 
when cells are incubated at 37 °C (filled circles). At 32 °C treated cells (filled squares) and in control 
cells treated with an equivalent volume of DMSO vehicle (unfilled symbols) do not show an increase 
in percentage apoptosis. Each line represents a separate experiment (performed in triplicate and 
expressed as a mean. For low values range was 2% and for high values was up to 22 %). 
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Fig. 3.18 : Clone 6 cells treated with 15µU /ml bleomycin sulphate for 1 hour at 37°C (filled 
circles) and at 32 °C (filled squares). Note that treated cells incubated at 37 °C undergo substantial 
apoptosis whereas treated cells at 32 °C and untreated controls (open symbols) do not show an 
increase in percentage apoptosis. Each line represents a separate experiment (performed in triplicate 
and expressed as a mean. For low values range was 2% and for high values range was up to 12 %). 
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Fig. 3.19: Clone 6 cells were incubated at 32 °C for 24 hours before treating with 15µU /ml 
bleomycin sulphate for 1 hour. Cells were then incubated for various periods of time at 32 °C before 
shifting to 37 °C. Cells incubated at 32 °C for 2 hours (filled circles) and 6 hours (unfilled 
circles) underwent substantial apoptosis after temperature shift. In contrast cells incubated 
for 12 hours (filled squares), 24 hours (unfilled squares) and untreated controls (filled diamonds) did 
not show this increase in apoptosis. (mean and SEM; n =3). 
170 
L- mimosine (Sigma) was included in the medium at 37 °C for 24 hours before and 
during some drug experiments in order to mimic the reported wild -type p53- induced 
late GI /S phase block to the cell cycle (Ryan el al, 1993; Lalande, 1990). At 
concentrations reported to induce cell cycle arrest, however, mimosine directly 
affected cell viability during the time course of these experiments: drug- treated cells 
underwent apoptosis at rates indistinguishable from control cells. Cells treated at 32 °C 
also showed a loss of viability in the presence of mimosine. As a result, the general 
role of a G1 /S phase block in the prevention of apoptosis of cells at 37 °C could not be 
determined with this cell line. 
3.3.5 Low efficiency of transfection of Clone 6 cells with mvc-containing 
plasmids 
Plasmid linearisaton sites were identified and plasmid identity was confirmed by 
restriction analysis (Table 3.1 and Figs. 3.1 to 3.6) Results of transfection experiments 
are shown in Table 3.4. Co- transfection experiments with pHMR272 using the 
1 -TEPES -based calcium phosphate co- precipitation technique produced no antibiotic - 
resistant colonies, but colonies of transfected Clone 6 cells formed after 
electroporation with neomycin- resistant expression vectors. These results are 
consistent with the observation that electroporation techniques are useful for cell lines 
which have been found to be refractory to transfection by other techniques (Neumann 
el al, 1982). Only 0.018% of the number of colonies that formed after transfection 
with the empty vector control plasmid pMV7 were recovered from Clone 6 cells 
electroporated with pMV7 -MER (containing the mycER insert) under identical 
conditions. These data are consistent with an hypothesis that cells containing both 
p53va1135 and mycER expressed under the control of strong exogenous promoters 
results in loss of viability of such cells. This suggests that breakthrough gene activity 
can occur when using temperature- sensitive alleles or oestrogen -sensitive fusion 
proteins and that this may confound experiments when genes of interest are capable of 
inducing apoptosis under certain conditions. 
ov't 
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3.4 Discussion 
Expression of wild -type p53 has been shown to induce apoptosis in some cell types 
(Yonish -Rouach et al, 1991; Ryan et al, 1993; Shaw et al, 1992), G1 arrest and 
survival in others (Kuerbitz et al, 1992; Kastan et al, 1991; Mercer et al, 1990; Baker 
et al, 1990; Diller et al, 1990; Michalovitz et al, 1990). In addition, wt p53 has been 
shown to be an essential intermediate in a signal transduction pathway between the 
effects of DNA damaging agents (DNA strand breaks) and either apoptosis or G1 
arrest (Malcomson et al, 1996; Kuerbitz et al, 1992; Kastan et al, 1992; Lowe et al, 
1993; Clarke et al, 1993). In this way p53 seems to play a critical role in deleting 
certain cell types that have sustained DNA damage (eg. thymocytes (Clarke et al, 
1993), lymphocytes (Gottleib et al, 1994; Howie et al, 1994b) and myeloid 
progenitor cells (Lotem and Sachs, 1993)) or in establishing a state of G1 arrest, 
possibly permitting DNA repair (Bakalkin et al, 1994; Lane, 1993). 
The finding that p53 function is lost in many authentic human and experimentally 
induced animal tumours has led to the assumption that p53 loss of function is 
causally associated with resistance to anticancer therapy (Lowe et al, 1993a). In this 
study, the importance of p53 status on the sensitivity of cells to apoptosis induced by 
two anticancer drugs and by co- expression of c -myc was addressed. 
In this work, a fibroblast cell line transformed with activated Ha -ras and 
temperature- sensitive p53 transgenes was used to show that wild type p53 can lead to 
G1 arrest and at the same time resistance to the DNA damaging agents bleomycin 
and etoposide. By contrast, in the presence of mutant conformation p53, cells 
underwent apoptosis associated with a relative accumulation in G2 /M, a common 
response to DNA injury in yeast and mammalian cells (Hartwell and Weinert, 1989). 
Mimicry of a GO /G1 arrest in Clone 6 cells at 37 °C by either mimosine treatment or 
serum starvation was not informative in the case of Clone 6 cells as these treatments 
caused the death of the cultures. It was therefore impossible, using this cell line, to 
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show directly that a growth arrest in GO /G1, independent of p53, was protective 
against DNA damage. 
These findings apparently contrast with published work in which temperature - 
sensitive p53 was expressed in the M1 myeloid leukaemic (Ml; Yonish -Rouach et al, 
1993) and murine erythroleukaemic (MEL; Ryan et al, 1993) cell lines where 
apoptosis was induced upon incubation at 32 °C (ie. with wild -type p53). MEL cells 
underwent G1 arrest prior to undergoing apoptosis, but in Ml cells, no growth arrest 
could be observed at any position in the cell cycle. Other cell types (including rat 
fibroblasts) have been shown to undergo G1 arrest but not apoptosis in response to 
wild -type p53 induction (Michalovitz et al, 1990; Diller et al, 1990; Mercer et al, 
1990; Kastan et al, 1992). In cell lines derived from clinically- sensitive human 
tumours, DNA -injury induced wild -type p53 was held to be responsible for decreased 
clonogenicity following ionising radiation and this effect could be reversed by 
transfection of a dominant negative mutant p53. (McIlwrath et al, 1994). While 
bleomycin and etoposide maximally kill cells in S phase, where replication forks are 
forced to negotiate either cleaved complex / double strand breaks (etoposide; Bae et 
al, 1988) or double -strand breaks resulting from free radical attack (bleomycin; Kuo, 
1981), they can damage and kill cells in GO /GI (Clarke et al, 1993; Roy et al, 1992; 
Evans et al, 1994). The simplest explanation of the data presented here is that the G1 
arrest mediated by p53 facilitates survival of ras- transformed fibroblasts by allowing 
effective DNA repair and prevents entry into S phase, a stage when cells are often 
most susceptible to DNA damage. 
Depending upon the cell system chosen, induction of p53 can cause either G1 arrest, 
apoptosis or both apoptosis and G1 arrest (Michalovitz et al, 1990; Ryan et al, 1993; 
Yonish -Rouach et al, 1993; Debbas and White, 1993; Wu and Levine, 1994). The 
mechanisms by which decisions are taken that favour either of these endpoints are 
poorly defined but these decisions can be affected by specific growth factors 
(Yonisch -Rouach et al, 1991; Gottleib et al, 1994; Canman et al, 1995). In particular, 
it is not known how p53 can mediate apoptosis in the thymocyte but not in the 
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fibroblast. The recognition of DNA damage (possibly involving the ataxia 
telangiectasia gene products; Kastan et al, 1992) leads, via p53, to the control of the 
cell cycle at the G1 checkpoint. We have shown this pathway to be protective in 
fibroblasts. Our results complement that of Lowe et al, (1993) who showed that p53- 
normal fibroblasts were susceptible to anticancer treatment as a result of abrogation 
of the p53- mediated G1 arrest by adenovirus EIA expression. Further, IL6 protects 
M1 cells from undergoing p53- mediated cell death (Yonish -Rouach et al, 1991, 
1993) and this protection also correlates with the induction of a stable GO/G1 arrest. 
This supports the supposition that activation of wild -type p53 can result in different 
response depending upon other modifying factors such as cell lineage and the trophic 
environment. (Levy et al, 1993). 
Using a different mutated p53 (proline substituted at residue 193) under its 
physiological promoter, Bristow and colleagues (1994) have shown that co- 
transfection of activated Ha -ras and mutated p53 into a primary rat embryonal 
fibroblast cell line resulted in enhanced clonogenicity in vitro and tumorigenicity in 
SCID mice after irradiation compared with cell lines containing ras alone. This effect 
was dependent on the level of mutant p53 expression, presumably as a result of 
competition with endogenous wild type p53. However they did not directly assess the 
proportion of cells undergoing proliferation, growth arrest or cell death. Experiments 
similar to those in Bristow et al, (1994) with ionising radiation sources could not be 
carried out here as it was found that reproduciblity of results could not be maintained 
if there were fluctuations in temperature of Clone 6 cells before or during 
experiments. Indeed, clonogenicity of Clone 6 at 32 °C was negligible. 
Our in vitro experiments with DNA damaging drugs (including the radiomimetic 
bleomycin) show that, under certain circumstances, overexpression of wild type p53 
can protect a cell which has suffered DNA injury against death rather than kill it, by 
causing the cell to growth arrest in G1. The corollary in vivo is that wild type p53 in 
an appropriate cellular context could confer a state of increased drug resistance. The 
significance of mutated p53 oncosuppressor gene in clinical drug resistance is likely 
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to be both complex and variable depending on the existence of other pathways of cell 
cycle activity control and response to injury. 
Very recently, a study of tetracycline- inducible p53 in p53 null immortalised mouse 
embryonic fibroblasts revealed an slight anti -apoptotic activity of p53 that was only 
apparent at very low levels of p53 expression (Lassus et al, 1996). However the 
authors drew a distinction between a protective effect of the enforced growth arrest 
caused by overexpression of wild -type p53 seen here (published as Malcomson et al, 
(1995)) and their protective effect that was elicited without sufficient p53 expression 
to cause growth arrest. The basis of this effect is not known. 
It was shown here that death of fibroblasts induced by etoposide and bleomycin 
occurs independently of wild -type p53 function. This confirms work by Strasser et al, 
(1994) which showed that thymic lymphoma cells from p53 -/- mice underwent 
apoptosis by p53- independent mechanisms following irradiation. Tumours which 
contain cells with mutated p53 initially may be more susceptible to cell death caused 
by therapy. However in the absence of G1 arrest caused by wild type p53, and 
therefore in the presence of continuing cell cycle activity, combined with karyotype 
instability (Yin et al, 1992; Livingstone et al, 1992), clones resistant to therapy may 
appear thus conferring a clinical state of "drug resistant" disease. 
Wafl (Cip1 / Sidl, p21), a gene product which is induced by wt p53, has potent 
inhibitory activity on cyclin E / cdk2 complexes in cells undergoing radiation - 
induced G1 arrest (Dulic et al, 1994; ElDeiry et al, 1994; ElDeiry et al, 1993). Wafl 
is therefore a major regulator of cell cycle progression at the Gl /S interface. The 
expression of Wafl in cell types that undergo apoptosis following activation of the 
p53 pathway has suggested that it may be active in both arrest and death mechanisms. 
The decision of a cell to die may therefore be determined by other lineage- dependent 
messages or growth factors (Canman et al, 1995). Recently, it has been shown that 
apoptosis of thymocytes from p21 W``1 " mice underwent normal p53- dependent 
apoptosis following irradiation. Therefore it is unlikely that p53 mediates apoptosis 
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through its transcriptional upregulation of p21. Further, these mice do not show an 
increased rate of neoplasia similar to that suffered by the p53 -/- mice (Deng et al, 
1995; Brugarolas et al, 1995). 
It therefore seems that the growth -arresting property of p21 is not the chief 
mechanism of p53 -medated tumour suppression. Other functions of p53, including 
apoptosis, may therefore be critical for tumour suppression by p53. Moreover, 
emerging data from the analysis of various activities of p53 mutants has 
demonstrated that induction of apoptosis and suppression of transformation (in 
suitable test cell lines for each function) by p53 can be separated from transcriptional 
activation of p21 and growth arrest. It appears, however, that some of these mutants 
that are defective for induction of apoptosis (but not for induction of p21 expression) 
are nevertheless unable to activate transcription from the Bax or IGF- binding protein - 
3 (IGF -BP3) promoters (Rowan et al, 1996; Friedlander et al, 1996; Ludwig et al, 
1996). It has been postulated that these and other downstream transcriptional targets 
of p53 (such as Fas (OwenSchaub et al, 1995)) mediate its apoptotic function. 
However, this is not necessarily the case in all cellular situations as evidenced by the 
normal p53- dependent apoptotic response in Bax -/- mice (Knudson et al, 1995) and 
by observations that p53 mediated apoptosis can occur without detectable changes in 
Bax expression (Allday et al, 1995; Canman et al, 1995; Rowan et al, 1996). 
However, pathways of gene activation leading from p53 to apoptosis may be 
redundant and this may explain differential usage of such pathways in various 
cellular contexts. Nevertheless, a p53 protein that has no transcriptional activity as a 
result of the so- called 22/23 mutation in the trans -activation domain has been used to 
show that, in rodent kidney cells, transcriptional activation by p53 is essential for 
induction of apoptosis, whereas in HeLa cells trans -activation by p53 is entirely 
dispensable (Haupt et al, 1995; Sabbatini et al, 1995). 
Clearly, the cellular context in which p53 is expressed is important for determining 
the consequences of p53 activation within a given cell type. As discussed above, the 
growth factor milieu and cell lineage have important bearings upon this. In addition 
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to factors that affect general susceptibility to apoptosis, such as the Bcl -2- related 
proteins (Guillouf et al, 1995; Chiou et al, 1994; Wang et al, 1995; Schott et al, 
1995; Debbas and White, 1993) expression of mitogenic oncogenes appears to alter 
the susceptibility to p53- mediated apoptosis. The Clone 6 cells used for this study 
were transformed with activated c- Ha -ras. It is known that ras- overexpression can 
inhibit responses to apoptotic stimuli (Lin et al, 1995; Arends et al, 1993)and may 
therefore play a part in determining the response to wild -type p53 in this cell line. 
However, the presence of ras does not appear to affect p53- independent apoptosis of 
Clone 6 cells at 37 °C in response to bleomycin or etoposide. Of particular note, on 
the other hand, is the observation made here that serial transfection of myc -ER and 
p53val135 into rat fibroblasts did not result in stable expression, either in the 
presence or absence of activated ras expression. After initial slow colony formation, 
such transfectants were not expandable into stable cell lines. This is a common 
observation in experiments where cells are transfected with plasmids containing 
constitutively- expressed genes that cause apoptosis (Lowe et al, 1993a). Given that 
complete control of the temperature- sensitive p53 and myc -ER activities is unlikely 
(M.Oren, personal communication; Danielian et al, 1993; Berry et al, 1990) , even 
under the cell culture conditions used, this observation is consistent with the 
hypothesis that p53 and c -myc co- operate to induce apoptosis in cells that do not 
normally undergo apoptosis in response to wild -type p53 induction. This is supported 
by observations that apoptosis induced by serum starvation of c- myc -transfected 
mouse embryo fibroblasts is dependent upon the presence of functional p53 alleles 
(Hermeking and Eick, 1994; Wagner et al, 1994). Likewise, overexpression of the 
transcriptional regulator E2F -1 that is involved in cell cycle progression into S phase 
can co- operate with wild type p53 to induce apoptosis (Wu and Levine, 1994) and 
the apoptosis inducing functions of both E2F -1 and the adenovirus El A oncogene are 
blocked by disruption of both p53 alleles (Lowe et al, 1994; Kowalik et al, 1995). 
The inability to produce stable cell lines expressing both c -myc and wild -type p53 by 
the methods used in this chapter made it impossible to confirm, at that stage, 
speculation that co- expression of these two genes was synergistic and could trigger 
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apoptosis by default under normal culture conditions. It was thought possible that 
these assumptions could be tested in vitro if greater control was exerted over the 
expression of apoptosis -promoting genes at the transcriptional, rather than at the 
post -translational level. Therefore, inducible expression systems were evaluated for 
use with apoptosis -promoting genes as described in the following chapter. 
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Chapter 4. 
4. Evaluation of Inducible Expression Systems for 
the Study of Apoptosis- Related Genes. 
4.1 Introduction 
As discussed in the previous chapters, generation of stably- transfected cell lines 
constitutively expressing genes that force cells to undergo either a cell cycle arrest or 
apoptosis is not possible. In the situation described in Chapter 3, where several 
attempts were made to produce cell lines co- expressing a temperature- sensitive p53 
mutant and myc -ER, it was surmised that the leak- through activity, however small, 
from both these transgenes was sufficient to have a profound effect upon cell 
viability. The inability to produce such lines made it difficult to investigate a possible 
co- operative interaction between p53 and c -myc using this approach. Such an 
interaction would be significant, given the high prevalence of alterations of both 
these genes in many human cancers. Detailed analysis of such an interaction could 
provide valuable information regarding the relationship between cell cycle control 
and apoptosis. It was therefore decided to persist with attempts to generate such 
lines, but by using a different strategy. This was to utilise the properties of inducible 
gene expression systems so that the transcription of the test gene mRNAs could be 
kept as low as possible during transfection, selection and cloning of stable cell lines. 
Induction of the test genes could then be controlled by the addition of an exogenous 
chemical, ideally without toxic side -effects affecting the expression of endogenous 
genes. A survey of available inducible expression systems was carried out, the results 
of which appear in Chapter 1. Two systems were investigated. The first, the 
Lacswitch system based upon the lac operator- repressor interaction was chosen 
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because of the high affinity of the lac repressor for its cognate recognition sequence; 
the low toxicity and rapid uptake of its inducer, IPTG; and for the ability of lacI to 
greatly decrease expression from a strong viral promoter whilst retaining inducibility 
of up to 100 fold. The second system, involving the VP16GalER`m tamoxifen- 
dependent transcriptional activator, was chosen so that a comparison could be made 
between repression of an otherwise constitutive promoter in the absence of inducer 
and specific activation of a synthetic promoter occurring only in the presence of 
exogenous ligand. In order to make the testing of these two systems as stringent as 
possible for the purpose of investigating apoptosis genes, both of these systems were 
used to control expression of mouse Nedd2, an ICE -like protease known to cause 
apoptosis, in addition to the development of similar vectors for the expression of c- 
myc, p53 and p21 WAFT /CIPI 
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4.2 Materials and Methods 
4.2.1 Vector Construction 
Detailed vector maps for intermediates in construction strategies are given in 
alphabetic order in Appendix C. 
4.2.1.1 .Alterations to Existing Expression Vectors. 
4.2.1.1.1 Lac Vectors 
The CAT gene was removed from pOPRSVICAT by digestion with NotI and 
recircularisation with T4 DNA polymerase to generate pOPRMT. The G418 
resistance cassette in pOPRMT was replaced in pOPRMTBg1II by a Bg1II linker 
following digestion with AatII and SacI and treatment with T4 DNA polymerase. The 
puromycin resistance cassette from pPUR (de la Luna, 1988) was cloned into the 
BglII site of pOPRMTBg1II as a 1.4kb PvuII/BamHI fragment (pOPRpuro). Because 
of a difficulty in preparing sufficient quantities of plasmid pPUR for transfection 
experiments, plasmid pPURO (Fig. 4.14) was derived from pOPRpuro by removal of 
the RSV LTR by digestion with BstXI and NotI and recircularisation following 
treatment with T4 DNA polymerase. The NotI site was regenerated. pPURO plasmid 
contains the ampicillin resistance gene and ColE1 origin of replication, both derived 
from pBluescript and appears to replicate more efficiently in XL1B1ueMRF'cells 
than pPUR, which is based upon pBR322, a lower copy number plasmid. 
The NotI site of pOPI3CAT was converted to a Bcll site in pOPI3N -Bc1I. This was 
achieved by linearisation of pOPI3CAT with NotI, blunt- ending with T4 DNA 
polymerase and adding phosphorylated Bcll linkers. As BclI restriction is inhibited 
by dam methylation, pOPI3N -Bc1I DNA was maintained in the dam -deficient E. coli 
strain SCSI 10. Plasmid pOP 13N -BclI contains an intron containing three lac 
operator sites in a 485bp BglII /Bc1I fragment. 
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4.2.1.1.2 Gal -4 Responsive Vectors 
Versions of pSP65GC (Figs. 2.6 and 4.1a) were made that provided either puromycin 
(pSP65GCpuro) or hygromycin (pSP65GChygro) resistance. The puromycin 
resistance (PAC) gene under the control of an SV40 early region promoter /enhancer 
and followed by an SV40 polyadenylation signal was excised from pPUR (also 
referred to as pBSpacAP) (de la Luna, 1988) using PvuII and BamHI, blunt -ended 
with T4 DNA polymerase and subcloned into a blunt -ended SphI site of pSP65GC. 
The orientation of the puromycin resistance cassette in pSP65GCpuro was 
determined relative to the Ga14- responsive promoter by digestion with PstI which 
produced a 1068óp fragment. Similarly, a hygromycin resistance gene under the 
control of phosphoglycerate kinase (PGK) gene control elements contained within a 
1960bp BglII fragment was subcloned blunt -ended from pPGKhygro into the blunted 
SphI site of pSP65GC. Orientation of the hygromycin resistance cassette in 
pSP65GChygro was confirmed by digestion with EcoRI (586bp) (Figs 4.lb,c and 
4.2). 
4.2.1.2 p53 Plasmids 
In order to generate a wild -type murine p53 cDNA that could be easily subcloned 
into expression vectors, p53 sequences from two plasmids were combined. The first 
plasmid, pSV53C (Jenkins et al, NAR 12 1994), which contains a full length, murine 
pseudo- wild -type p53 cDNA from bases 19 to 1377 (numbered according to 
GenEMBL x00741) in an SV40 expression cassette. This sequence was originally 
cloned as pP53 -5 from an SV40- transformed murine fibroblast cell line (SVA31E7) 
and contains 4 mutations in the non -conserved 5' end of the coding sequence: Arg48 
(CGA), Gln79(CAG), Trp80(TGG), del 81. The second plasmid, pMSVc1 -ala (Finlay 
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Fig. 4.1a: pSP65GC. M: Life Tech. 1kb ladder. Lane 1: uncut plasmid; Lane 2: BamHI; Lane 3: 
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Fig. 4.1b: pSP65GCpuro. M: Life Tech. 1kb ladder. Lane 1: uncut plasmid; Lane 2: BamHI; Lane 
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Fig. 4.1c: pSP65GChygro. M: Life Tech. 1kb ladder. Lane 1: uncut plasmid; Lane 2: BamHI; 
Lane 3: EcoR1; Lane 4: Hindu; Lane 5: EcoRV; Lane 6: Sall; Lane 7: PvulI. 
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Fig.4.2: pSP65GCpuro and pSP65GChygro. AmpR: prokaryotic ampicillin resistance gene. 
pA, PolyA: polyadenylation signal. PAC: puromycin resistance gene. PGK: phosphoglycerate 
kinase. 
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The MCS of pBKCMV was altered so that it contained a BgIII site 3' of the EcoRl 
site in order to be able to clone in the p53C cDNA in such a way as to retain the 
cloning sites so that this sequence could be easily excised for subcloning into other 
plasmids. pBKBglll was constructed by insertion of 8 -mer Bglll linkers into the Smal 
site in the multiple cloning site (MCS) of pBKCMV. In addition, a KpnI site that lies 
3' of the newly inserted Bglll site was destroyed in order to facilitate, in a later 
cloning step, a direct swap of wild -type p53 sequence into the gap created by 
digestion with XhoI and KpnI, whose restriction sites lie within the cDNA sequence. 
pBKBg1IIAK was constructed by treatment of KpnI cut pBKBglII DNA with T4 
DNA polymerase and subsequent religation. 
To generate the wild type p53 sequence (Fig. 4.3), the entire p53 sequence from 
pSV53C was subcloned in a single 1358bp EcoRIBglII fragment into pBKBgIAK 
between the EcoRI and Bg1II sites (pBK53C). 11/12 white colonies on 
Xgal /IPTG/Kanamycin plates were recombinant. The 606bp Xhol/Kpnl fragment 
between the XhoI and KpnI site of pBK53C which contains the four mutations was 
replaced with a 609bp Xhol/Kpnl fragment from pMSVc1 -ala so that the p53 open 
reading frame (ORF) consisted of wild -type p53 sequence (pBK53wt). The sequence 
of the p53 gene in plasmid pBK53wt was confirmed as wild -type by sequencing (with 
the T3 promoter primer and dITP labelling mixes) plasmids from individual colonies 
containing unidirectional nested deletions from the EcoRI site of pBK53wt that were 
generated as described in the methods section (Figs. 4.4 and 4.5). 
To generate plasmid pBKOP53wt (Fig. 4.6), pBK53wt was cut with Nhel and 
Bam1-11 and recircularised (pBK53wtN/B) regenerating the BamHI site. A c.400bp 
Bglll/Bcll fragment from pOPI3N -Bc1I containing an intron with three lac operator 
sites was cloned into the BamHI site of pBK53wtN /B. Orientation of the intron was 
confirmed by sequencing with the BKCMV primer (Stratagene) (Fig. 4.7). The 
sequence of the p53 gene in pBKOP53wt was checked using the panel of sequencing 
primers P1 -P6 (Table 4.1). 
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Fig. 4.4. A). Strategy for the generation of unidirectional nested deletions from the EcoNJ site of 
pBK53wt. CMV: CMV promoter. Arrows: T3 promoter primer binding site. B). Generation of 
deletions of pBK53wt. M: Life Tech 1 kb ladder. Lanes 1 -12: increasing lengths of time (in 10 
second intervals) of digestion with exonuclease III. Arrow: kb ladder spiked with undigested 
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Fig. 4.5: pBK53wt (Bottom). Labels as in previous figures. Table: Regions of the p53 gene in 
pBK53wt sequenced using clones containing nested deletions. 
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Fig. 4.6: Construction strategy for pBKOP53wt. (Detailed maps for intermediates in Appendix 
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Table 4.1. Mouse p53 sequencing primers. 
Primer Sequence p53 position (bp) 
P1 5'-CTGTAGGTAGCGACTCACGT-3' 32-41 
P2 5'-CTTCCTCCAGAAGATATCC-3' 207-225 
P3 5'-CCCTGTCATCTTTTGTCCCT-3' 385-404 
P4 5'-AGAAGTCACAGCACATGACG-3' 601-620 
P5 5'-GGCTCTGAGTATCCACCAT-3' 786-805 
P6 5'-AAGTCCTTTGCCCTGAACTG-3' 988-1007 
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To generate plasmid pOPRp53wt (Fig. 4.8), pBK53wt was linearised with EcoRI and 
Bglli, blunt -ended with T4 DNA polymerase and ligated to 10 -mer phosphorylated 
Noti linkers. Following digestion with Notl the 1376bp fragment was isolated from a 
1% agarose gel and ligated to Noti cut, dephosphorylated pOPRMT. Orientation of 
the p53 insert was checked by digestion with SacI which generated a 1167bp 
fragment. Plasmid pSP65GCp53wt was constructed by blunt -end subcloning of the 
1.4kb EcoRI /Bglil fragment from pBK53wt into the EcoRV site (treated with T4 
DNA polymerase) of pSP65GC. To generate a plasmid (pSP65GCp53wtpuro) which 
contains a puromycin resistance cassette in the opposite orientation to the Ga14 -p53wt 
expression cassette a single blunt -ended 1.4kb PvuII/BamHI fragment from pPUR (de 
la Luna, 1988) into the SphI site (treated with T4 DNA polymerase) of 
pSP65GCpuro. All fusion sites were destroyed in the cloning procedure. The 
orientation of the puromycin resistance cassette was determined by digestion with Psti 
which produced a 915bp diagnostic fragment. To generate a Ga14- responsive p53 
expression vector containing a hygromycin resistance cassette, a blunt -ended BglII 
fragment of approximately 1960bp in length was subcloned from pPGKhygro into the 
Sphl site (blunt -ended with T4 DNA polymerase) of pSP65GCp53wt. Orientation of 
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Fig. 4.9a. pSP65GC53wthygro mini -preps: Lanes 1-6 (2 correct), EcoRI. pSP65GChygro mini - 
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Fig. 4.9b. pSP65GC53wthygro maxi -prep DNA.M: Life Tech. 1kb ladder. Lane 1: uncut plasmid; 
Lane 2: EcoRl; Lane 3: BamHI; Lane 4: Hind1II; Lane 5: EcoRV; Lane 6: Sall; Lane 7: PvuI. 
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Fig. 4.9c. pSP65GCp53wtpuro maxi -prep. M: Life Tech. 1kb ladder. Lane 1: uncut plasmid; Lane 
2: BamHI; Lane 3: EcoRI; Lane 4: HindIII; Lane 5: Sall; Lane 6: EcoRV; Lane 7: Pstl; Lane 8: 
PvuII; Lane 9: SphI. 
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4.2.1.3 Myc Plasmids 
4.2.1.3.1 Lac System 
The c- myc -ER fusion construct was subcloned as a 2.4kb EcoRl fragment from 
pMV7 -MER into the EcoRI site in the MCS of pBKCMV (pBKMER). The 
orientation of the insert was determined by digestion with BamHI which produced a 
1.4kb fragment in recombinant plasmid clones that have the mycER sequence in the 
same orientation as the CMV promoter in the vector. To generate a CMV -mycER 
construct containing three lac operator sites in an intron between the CMV promoter 
and the mycER gene (CMV- OP -MER) (Fig. 4.11), pBKMER was linearised with 
NheI and Sall and blunt- ended. Into this blunt -ended vector fragment, the intron from 
pOPI3N -Bc1I was inserted as a blunt -ended 485bp BglII /Bc1I fragment from 
pOP 13N -BclI DNA grown in the dam -negative SCS 110 E. coli strain. Orientation of 
the intron within pBKOPMER was determined by sequencing from the CMV 
promoter into the intron using the BKCMV primer (Stratagene). Two clones out of 
had the in correct To 
with the CMV- OP -MER construct which would also contain a puromycin resistance 
cassette, a 3.2kb NsiI/NotI fragment was subcloned as a blunt -ended fragment from 
pBKOPMER into blunt- ended, BstXI/NotI vector fragment from pOPRpuro 
(pCMVOPMER). Orientation of the insert was determined by digestion with HindIII 
(Figs. 4.12 to 4.14). 
4.2.1.3.2 Tamoxifen- Inducible System 
To isolate a wild -type c -myc cDNA, total RNA from the A549 human lung epithelial 
cell line was isolated, reverse transcribed and subjected to PCR with 
oligodeoxyribonucleotide primers designed to amplify a 1343óp fragment 
corresponding to bases 554 -1879 of human c -Myc cDNA (GenEMBL accession 
number: v00568) which encompasses the ORF encoding c -MYC protein. The 5' 
primer (5987: myc5'; 5'- CCGAATTCGACGATGCCCCT -3', overlaps the c -Myc 
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translation initiation codon (underlined) and incorporates a synthetic EcoRI restriction 
half -site (Bold). The 3' primer (3212: myc3'; 5'- GGCCGCTTACGCACAAGAGTT - 
3', overlaps the translational stop codon (underlined). The PCR products were cloned 
into pGEM -T (Promega) at the equivalent of the EcoRV site in pGEM- 5Zf( +). 
pGEMmyc was sequenced using the PCR primers and T7 and Sp6 primers and by 
subcloning each of two Pstl fragments into the Pstl site of pGEM- 5Zf( +) and using 
the T7 and Sp6 primers. (pGEMmycS and pGEMmycL). A cytosine to adenosine 
mutation was detected at base 1440 of sequence v00568 which conserves the amino 
acid sequence of the c -MYC protein. The remainder of the sequence was identical to 
v00568. 
To generate a Ga14- responsive expression vector (pSP65GCmyc) containing the c- 
myc cDNA, a single 1350óp EcoRI/Notl fragment pGEMmyc (blunt -ended with T4 
DNA polymerase) was subcloned from into the EcoRV site of pSP65GC. Orientation 
of the myc gene was determined with PstI which produced a 784bp fragment. A 
puromycin resistance cassette was added to produce plasmid pSP65GCmycpuro by 
subcloning the 1.4kb PvuIUBamHI fragment (blunt- ended) from pPUR (de la Luna, 
1988) into the Sphl site (also blunt- ended) of pSP65GCmyc. The orientation of the 
puromycin resistance cassette was determined to be in the opposite direction to the 
Ga14 -myc expression cassette by digestion with Pst! which produced a I 774bp 
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Fig. 4.13b. pCMVOPMER minipreps, HindlII. Lane 1 nonrecombinant, Lanes 2, 4, 5, 6, 7, 8, 10, 
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Fig.4.13c. pCMVOPMER (lanes 1 to 6) and pPURO (lanes 7 to 10) maxi- preps: M: Life Tech. 
1kb ladder. Lane 1: uncut DNA; Lane 2: XhoI; Lane 3: BamHI: Lane 4: HinduI; Lane 5: BstXE: 
Lane 6: NotI; Lane 7: uncut pPURO DNA; Lane 8: HindIII; Lane 9: BstXI; Lane 10: Not'. 
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Fig. 4.15. pSP65GCmycpuro. Maxi -prep (above): M: Life Tech. 1kb ladder. Lane 1: uncut plasmid; 
Lane 2: BamHI; Lane 3: EcoRI; Lane 4: HindIII; Lane 5: Sall; Lane 6: EcoRV; Lane 7: Pst1; Lane 
8: PvuII. 
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4.2.1.4 Plasmids containink p21 wapic;pr 
4.2.1.4.1 Full- length p21. 
The open reading frame from the 2nd and 3rd exons (amino acids 1 to 159 and stop 
codon (TGA) of murine p21 WAF1 /CIP1 (u09507: bases 201 -639) was amplified by 
high fidelity RTPCR from 129 /Sv /ola total murine liver RNA using primers WAF5' 
(G5650: 5'- CAGGATCCATGCCAATCCTGGT -3'; which overlaps the p21 
translation initiation codon (underlined) and incorporates a synthetic BamHI 
restriction half -site (bold)) and WAF23 (15027: 5'- 
GGCACTTCAGGGTTTTCTCTTGC-3' ; and includes the stop codon (codon 160: 
underlined) (Fig. 4.16a). The PCR products were cloned as a 496bp fragment into 
pGEM -T at the equivalent of the EcoRV site in pGEM5Zf( +) (Promega). The 
resulting plasmid, pGEMWAF 1 -160 (Fig 4.16b), was sequenced using the PCR 
primers, primer WAF 5'Q (2645), and the T7 promoter primer which bind within the 
vector. No alterations from the published p21 sequence were found 
4.2.1.4.2 Truncated p21. 
Total RNA from 129 /Sv mouse liver was isolated and reverse transcribed and 
subjected to PCR with oligodeoxyribonucleotide primers designed to amplify a 
446bp fragment corresponding to bases 200 -639 of the second exon of murine 
p21 WAF 1 /CIP 1 cDNA (GenEMBL accession number: u09507) which encodes the 
first 143 amino acids of p21. The 5' primer (G5650: WAF5'), 5'- 
CAGGATCCATGCCAATCCTGGT-3', overlaps the p21 translation initiation 
codon (underlined) and incorporates a synthetic BamHI restriction half -site (bold). 
The 3' primer (G5649: WAF3'), 5'- TCGGTACCTGTCAGGCTGGT -3', contains 
codon 143 (underlined) and a synthetic KpnI restriction half -site (bold). The PCR 
products (Fig 4.16a) were cloned into pGEM -T at the equivalent of the EcoRV site in 
pGEM5Zf( +). A stop codon was inserted following codon 143 by site -elimination 
(KpnI) site -directed mutagenesis using the mutagenic /selection oligonucleotide W26. 
Eight individual colonies from the mutagenesis reaction were sequenced with the 
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primer WAF 5'Q and all (100 %) were found to contain the inserted stop codon 
(TGA) at codon position 143 (pGEMWAF1 -143) (Fig. 4.16c). The rest of the waf -1 
reading frame was sequenced using the PCR primers and the T7 and Sp6 promoter 
primers. A conservative mutation (T to G) was found at base 581 (numbered 
according to u09507) of the p21 sequence. 
4.2.1.4.3 Lac system 
A 512bp BamHI/NotI fragment was subcloned from pGEMWAF1 -160 (blunt -ended 
with T4 DNA polymerase) into the (blunt) NotI site of pOPRMT to generate plasmid 
pOPRWAF1-160. Orientation of the insert was confirmed by EcoRI/SmaI (901 bp) 
digest. All fusion sites were destroyed in the cloning process (Fig. 4.17). 
pGEMWAFl -143 was digested with BamHI, blunt -ended and ligated to 1Omer NotI 
linkers. The resulting 520bp NotI fragment was then subcloned into the NotI site of 
pOPRMT. In a recombinant clone that was designated pOPRWAF1 -143, the 5' NotI 
site was destroyed (Appendix C.). 
4.2.1.4.4 Tamoxifen- inducible system. 
The 512bp BamHI/NotI fragment from pGEMWAF1 -160 (blunt -ended with T4 
DNA polymerase) was subcloned into the EcoRV site of pSP65GCpuro to generate 
pSP65GCWAF1- 160puro. Orientation of the insert was confirmed by digestion with 
PstI (1350bp) (Figs. 4.18a and 4.19). 
To generate plasmid pSP65GCWAF1- 143puro, a 464óp BamHI/NotI fragment 
(blunt -ended with T4 DNA polymerase) was subcloned from pGEMWAF1 -143 into 
the EcoRV site of pSP65GCpuro. Orientation of the insert was verified using PstI 
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Fig. 4.16a. Left: p21WAF (Full- length: codons 1 -160) Hi- fidelity RT -PCR, M; Life Tech. lkb ladder. 
Lane 1: OmM MgCL2; Lane 2: 0.5mM; Lane 3: 0.75mM; Lane 4: 1.00mM; Lane 5 1.25mM; Lane 6: 
1.5mM. Right: p21WAF (Truncated: codons 1 -143) RTPCR Mv: Boehringer Mannheim Marker V. 
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Fig. 4.16b. pGEMWAF1 -160 maxi -prep. M: Life Tech. lkb ladder. Lane 1; uncut plasmid: Lane: 2: 
BamHl; Lane 3: PstI. 
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Fig. 4.17. pOPRWAF1 -160. Above: Maxiprep DNA. M; Life Tech. 1kb ladder. Lane 1: uncut DNA; 
Lane 2: BamHI; Lane 3: EcoRI; Lane 4: HindiI; Lane 5: PstI; Lane 6: SmaI; Lane 7: EcoRUSmaI. 
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Fig. 4.18a. pSP65GCWAF1- 160puro maxi-prep DNA. M: Life Tech. 1kb ladder. Lane 1: uncut 
plasmid; Lane 2: BamHI; Lane 3: EcoRl; Lane 4: HindIII; Lane 5: Sall; Lane 6: EcoRV; Lane 7: Pstl; 





M 1 2 3 4 5 6 7 8 9 
Fig. 4.18b. pSP65GCWAF1- 143puro maxi-prep DNA. M: Life Tech. 1kb ladder. Lane 1: uncut 
plasmid; Lane 2: BamHI; Lane 3: EcoRl; Lane 4: Hind111; Lane 5: Sal; Lane 6: EcoRV; Lane 7: PstI; 
Lane 8: Pvui. Lane 9: Sphl. 
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4.2.1.5 Nedd2 Plasmids. 
The open reading frame encoding murine Nedd2 (GenBank accession no: d28492) 
was amplified from 129 /Sv /Ola mouse liver cDNA using the oligonucleotide primers 
designed to amplify a 1365óp fragment corresponding to bases 4 -1369. The 5' primer 
(3444: Nedd2 5'), 5'- AAATGGCGGCGCCGAGCGGGAGGTCGCAGT -3', 
overlaps the nedd2 translation initiation codon (underlined) and corresponds to bases 
5 -34 of the mRNA. The 3'- primer (3445: Nedd2 3') 5'- 
GGCGGCATCACGTGGGT-3', is complementary to bases 1353 -1369 and overlaps 
the translational stop codon (underlined). The resulting PCR products were cloned 
into pGEM -T (pGEMNedd2). pGEMNedd2 was linearised with SacII, blunt -ended 
with T4 DNA polymerase) and ligated to lOmer NotI linkers. The resulting NotI 
fragment was cloned into the NotI site of pOPRMT (pOPRNedd2). Orientation of the 
Nedd2 gene was confirmed by Sall (997óp) digest. (Fig. 4.20). The Nedd2 insert in 
pOPRNedd2 was sequenced using the PCR primers and primers N1 to N6 (Table 
4.2). 
Four separate mutations were found. An A to C at d28492 position 415 resulted in an 
predicted amino acid change from a threonine to a proline at codon 136. A G to A at 
position 478 caused a predicted change from aspartate to asparagine at codon 158. A 
C to A at position 485 resulted in a predicted change from threonine to a lysine at 
codon 160 (Fig. 4.21a). The fourth mutation, a C to T at position 114 did not result in 
a change in the predicted amino acid sequence (Fig. 4.20c). The first three mutations 
were corrected in pOPRNedd2 by side directed mutagenesis using primers N29 and 
N30 with the selection primer NEO as described in the methods section. Twenty -one 
individual colonies from the mutagenesis reaction containing all three primers were 
sequenced with primer N1 and ran on S2 sequencing gels until the xylene cyanol 
reached the bottom of the gels. Twelve (57.1 %) of the colonies had the position 136 
mutation corrected to the wild -type and twelve had the second and third mutations 
corrected (57.1%). Ten of the colonies had all three mutations corrected (47.6 %). 
One clone (clone 10) was selected and maxiprep DNA from clone 10 was sequenced 
210 
using the panel of sequencing primers described above. No deviations from the 
published wild -type sequence were detected. Clone 10 was designated 
pOPRNedd2(10). In order to sequence the 5' region of the Nedd2 insert, plasmid 
pOPRNedd2(10) was treated with BamHI, recircularised (pOPRNedd2BamHI) and 
sequenced using the BKRSV primer (Stratagene) which binds to a region at the 3' 
end of the RSV LTR. Again, no deviations from the wild type sequence were 
detected. 
By subcloning a blunt -ended NotI fragment from pOPRNedd2(10) into the EcoRV 
site of pSP65GC, the plasmid pSP65GCNedd2 was generated. The orientation of the 
Nedd2 gene was checked with SalI which produced a 1008bp diagnostic fragment 
length. The puromycin resistance cassette from pPUR (Clontech) (de la Luna, 1988) 
was subcloned as a 1392bp PvuII/BamHI blunt -ended fragment into the SphI site of 
pSP65GCNedd2 (Figs. 4.21 b and 4.22). Recombinant plasmids contained the 
puromycin resistance cassette in the same orientation as the Ga14 -Nedd2 cassette (as 
confirmed by an HindlIl digest which produced a 1671 bp fragment) and were 
designated pSP65GCNedd2puroSD (Fig. 4.22). 
Table 4.2. Nedd2 sequencing primers. 
Primer Sequence Nedd2 position (bp) 
N1 5'-GGCAGTTTCAGCCAGAATGT-3' 241-260 
N2 5'-TCCCTTTCTCGGTGTGTGA-3' 422-450 
N3 5'-TTGGCACTGGTGCTGAGCAAT-3' 604-624 
N4 5'-TTGCACAGTTACCTGCACAC-3' 776-795 
N5 5'-AGCATGTCGTGGAGATGAGA-3' 957-976 
N6 5'-GCCTTAAAGGTAATGCTGC-3' 1108-1127 
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Fig. 4.21a. Correcting Mutagenesis of pOPRNedd2. Clone 1 contains all three mutations that alter the 
protein sequence. Clones 2 and 10 are wild -type as a result of incorporation of both the correcting 
mutagenic oligonucleotides. Clone 9 retains a mutation at position 415 (T136P) and represents a clone 
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Fig. 4.21b. pSP65GCNedd2 Maxi-prep DNA. M: Life Tech. 1kb ladder. Lane 1: uncut plasmid; Lane 2: 
BamHI; Lane 3: EcoRl; Lane 4: HindIIf; Lane 5: Sall; Lane 6: EcoRV; Lane 7: Pstl; Lane 8: Pvull; 
Lane 9: Sphl. 
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4.2.2 Transfection. 
4.2.2.1 Optimisation of Transfection Conditions 
4.2.2.1.1 Antibiotic Sensitivity of Ratl fibroblasts. 
0.5 x 106 cells were plated onto 10cm diameter tissue culture plates in non -selective 
medium and allowed to attach to the substratum for 24 hours. The medium was then 
replaced with complete medium containing hygromycin B, G418, or puromycin at 
various concentrations. Medium was replaced every three days. After 10 days, plates 
were scored for cell survival. (Table 4.3). The lowest dose of each antibiotic which 
killed 100% of cells was chosen for selection of transfected cells. 
Therefore, transfected cells were selected in 2501.1g /m1 hygromycin B, 3501g /ml 
G418 or 21.tg/m1 puromycin where appropriate. In the case of selection with 
puromycin, cells died much more rapidly than in the presence of hygromycin or 
G418, cell death was easily detectable 24 hours following addition of puromycin. A 
similar level of death in hygromycin or G418 selections occurs only after 3 to 4 days. 
In a pilot experiment with plasmid pPURO (Suggested in (de la Luna and Ortin, 
1992)), it was noticed that many more clones of transfected cells survived puromycin 
selection at 2µg /ml if the transfected cells were split into medium containing 
puromycin at 11,1g /m1 and allowed to attach to the substratum for 24 hours before 
increasing the puromycin concentration to 2.tg/ml. This procedure was followed in 
all subsequent puromycin selections. 
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Cells Surviving in 
Hygromycin B. 
Cells Surviving in 
G418. 
Cells Surviving in 
puromycin. 
0 + ++ + ++ + ++ 
1 N/D N/D + 
2 N/D N/D - 
3 N/D N/D - 
4 N/D N/D - 
5 N/D N/D - 
50 ++ ++ N/D 
100 ++ ++ N/D 
150 + ++ N/D 
200 + ++ N/D 
250 - + N/D 
300 - + N/D 
350 - - N/D 
400 - - N/D 
500 - - N/D 
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4.2.2.1.2 Determination of Optimal pH of 2xBBS. 
The optimal conditions for transfection of DNA into monolayer cultures of 
mammalian cells by the calcium phosphate coprecipitation method as modified by 
Chen and Okayama (Chen and Okayama, 1987) lie within narrow limits. 
Transfection efficiency is affected by a number of factors including the pH of the 2 x 
BBS solution, the initial pH of the medium, the age and concentration of CaC12 and 
DNA preparations and the CO2 concentration in the incubator. If the overall pH of 
the medium is too acidic following addition of the BBS /CaC12 /DNA mixture, very 
little precipitate forms. Alternatively if it is too alkaline the precipitate clumps 
together rapidly following addition to the medium. Consequently, parallel batches of 
2xBBS solution were made up and the pH was adjusted close to pH 6.95 which was 
judged to be optimal in the experiments of Chen and Okayama. Transfections of 
plasmid pPURO were thus carried out with 20µg of DNA and 2xBBS solutions 
ranging from pH 6.95 to pH 6.98. Cells were split 1 in 10, 24 hours after transfection 
into replicate 10cm culture plates and selected in puromycin. Surviving colonies were 
fixed, stained with Giemsa and counted after 10 days. The optimal batch of 2 x BBS 
was that adjusted to pH 6.97. (Figs. 4.23 and 4.24) This pattern was confirmed in two 
independent experiments. 
4.2.2.1.3 Determination of Optimal Plasmid DNA Concentration. 
The quality of the calcium phosphate / DNA precipitate that develops during the 
overnight incubation step is markedly affected by the amount of plasmid DNA used. 
Too little DNA results in a coarse, flocculent precipitate. Too much DNA results in a 
very fine precipitate. The optimal DNA concentration results in an even, granular 
precipitate that is visible at x100 magnification (Chen and Okayama, 1987). In order 
to determine the optimal DNA concentration for pPURO, 10, 15, 20, or 25 pg of 
DNA was transfected using the optimal 2 x BBS buffer (pH6.97). Fig. 4.26 shows 
the morphology of the precipitates. The photograph of cells transfected with 20 µg of 
pPURO show an even granular precipitate that most resembles that of Chen and 
Okayama (Chen and Okayama, 1987). At this DNA concentration, the transfection 
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efficiency (as measured by average colonies per plate) was the highest by at least 2 to 
3 fold (Figs 4.25 and 4.27). This pattern was also found in two independent 
experiments. 
From these data it can be concluded that DNA concentration has a much more 
marked effect upon the transfection efficiency in Rat 1 cells than small changes in the 
pH of the 2x BBS buffer. Therefore, similar experiments were carried out for other 
expression constructs to determine whether there was any variation in the optimal 
amount of plasmid DNA from construct to construct. As it was expected that some of 
the expression vectors might inhibit colony formation, it was assumed that the quality 
of the precipitate was related to the transfection efficiency. Table 4.4 details the 
concentration of expression plasmids that produced precipitates with an even, 
granular appearance. 
The optimal plasmid concentration could not be predicted from the size of the 
plasmid, nor from the series of vectors to which any particular plasmid belonged. It 
may be that variations in the quality or age of the plasmid preparations may affect the 
quality of the precipitate. However, all plasmids used for transfection were prepared 
using Qiagen columns, were less than 6 months old and had OD260/280 ratios of 
between 1.70 and 1.80. Alternatively, pipetting or DNA quantitation errors may 
account for variations in optimal DNA concentration between plasmids. 
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Fig. 4.23: Optimisation of calcium phosphate -mediated transfection (Chen and Okayama, 
1987): 2xBBS pH: Colonies stained with Giemsa following transfection with pPURO and selection 
in 2µg/m1 puromycin. (Bottom to Top Rows) Control transfection with non -relevant selectable 
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Fig. 4.24. Mean number of colonies per plate ( +SEM) following transfection of pPURO in a 2xBBS 
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Fig. 4.25. Mean numbers of colonies per plate ( +SEM) following transfection with pPURO with 
various amounts of DNA. 
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Fig. 4.26: Appearance of calcium phosphate /plasmid DNA precipitate (Chen and Okayama 
method) on Ratl cells following overnight incubation. Top left: 101.1g pPURO; Top right: 151.1,g; 
Centre: untransfected cells. Bottom left: 201.1,g; Bottom right: 25µg. 
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Fig. 4.27: Optimisation of calcium phosphate -mediated transfection (Chen and Okayama, 
1987): Mass of DNA: Colonies stained with Giemsa following transfection with pPURO and 
selection in 21.ig/ml puromycin. (Bottom to Top Rows) Control transfection with non -relevant 
selectable marker (pBKCMV); Transfections with pPURO: 10µg; 1511g; 204g; 25µg. 
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Table 4.4. Optimal Plasmid DNA Concentrations. 
Plasmid Optimal Mass of DNA (µg) 
pPURO 20 






pSP65GCWAFI- 143puro 30 
pCMV -ßgal + pPURO 20 (5 + 15) 
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4.2.2.1.4 Estimation of Transfection Efficiency. 
0.5 x 106 cells were plated 24 hours prior to transfection with 201.1g of pPURO with 2 
x BBS at pH 6.95. The precipitate was washed off and the cells were incubated in 
normal medium for 24 hours. The cells were then split 1 in 10 and replated in 
selective medium. In parallel, 1 x 103 transfected cells were plated in replicate plates 
in normal medium in order to determine the plating efficiency. Colonies were fixed 
and stained after 10 days in culture. The transfection efficiency was calculated 
according to the following formula: 
Transfection Efficiency = Mean Number of Colonies x Dilution Factor 
Number of cells Transfected x Plating Efficiency 
= 513 x 10 
0.5 x 106 x 0.683 
0.0150 = 1.5% 
The transfection efficiency under optimal conditions with pPURO in Rat1 using the 
Chen and Okayama version of the calcium phosphate coprecipitation method was 
therefore estimated to be 1.5 %. This is in close agreement with transient transfection 
experiments with pCMV -ßgal in which cells were fixed and stained with X -gal 24 




4.3.1 Evaluation of the lac repressor / operator vector system. 
4.3.1.1 Generation of Ratl cells expressing LacI -NLS. 
As an initial step towards lacI- regulable expression of genes such as p53, 
p21 WAF1 /CIP1' c -myc and nedd2, the Rat 1A fibroblast cell line was engineered to 
express the modified LacI -NLS repressor protein. It was expected that the expressed 
protein would be identifiable by immunofluorescence microscopy and localised to 
the nucleus of transfected cells. Plasmid p3'SS, the expression vector that contains 
the lacI -NLS construct, was transfected into Ratl cells and stable transfectants were 
selected for on the basis of hygromycin resistance. Individual clones were picked, 
expanded and analysed for expression of the LacI protein by immunofluorescence 
microscopy. Each of the clones was scored for total Lacl expression and for 
subcellular distribution (Table 4.5). Fig. 4.28 shows one clone (RatlRep54) with 
strong nuclear staining using the anti -Lacl antibody. Other sub -lines also had nuclear 
staining but RatlRep54 was chosen as the recipient line for as it qualitatively showed 
the best nuclear localisation and strongest antibody staining of the 19 lines tested. 
4.3.1.2 Transfection of IPTG- inducible vectors into RatlRep54 cells. 
4.3.1.2.1 Attem s ted ! eneration o lac -re ! ulable .21 WAF1 -143 ex.ressin Ratl 
cells. 
In order to test whether the Lacswitch system was capable of controlling the 
expression of a gene known to inhibit cell growth such that a reversible growth arrest 
could be induced in Rat1 cells, attempts were made to generate stable cell lines that 
expressed the truncated p21WAFI 
/CIPI insert containing only the cyclin -CDK- 
inhibitory domain under the Iacl -NLS fusion protein. Plasmid pOPRWAF1-143 was 
transfected into RatlRep54 cells and selected for on the basis of G418 resistance in 
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the absence of IPTG. However, clones were generally very small (less than 50 cells 
per clone) and often consisted of large, poorly packed, flat cells. Very few mitotic 
cells were identified. Attempts were made to expand individual clones but these did 
not result in the generation of any stable cell lines. 
4.3.1.2.2 Attempted generation of lac- regulable myc -ER expressing Ratl cells. 
In order to generate Ratl cells engineered to overexpress c -myc under the 
transcriptional control of an inducible promoter, attempts were made to generate cell 
lines expressing the mycER fusion gene dependent upon the presence of IPTG in the 
medium. Such a cell line would be expected to exert tight regulation of c -myc activity 
owing to control at both the transcriptional (IPTG) and post -transcriptional ((3- 
oestradiol) levels. Accordingly, pCMVOPMER (containing the mycER fusion gene 
under the control of a lacl- regulable CMV promoter) was transfected into Rat 1Rep54 
cells and selected for upon the basis of puromycin resistance. The transfection 
efficiency of such transfection experiments was unexpectedly very low. Only a few 
(5 -8) colonies formed on each plate and although these colonies appeared healthy in 
normal culture medium and increased in size during selection, attempts to expand 
these in medium containing charcoal- stripped neonatal calf serum purchased from 
Sigma resulted in no stable cell lines. These results may be interpreted as indicating 
that the lac control of myc -ER expression was incomplete and possibly lead to a 
reduction of cell viability under the stressful conditions of selection and cloning in 
tissue culture. However, the above experiments should be regarded as inconclusive as 
it was subsequently found that the plating efficiency of Ratl cells in the batch of 
serum used was observed to be very low at low plating densities: similar conditions 
to which cells subjected to selective antibiotics are exposed (data not shown). 
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Fig. 4.28: Lacl Immunofluorescence of Ratl cells stably -transfected with p3'SS (clone: 
Rat lRep54). Note that the majority of LacI -NLS expression is localised to the nucleus. 
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Table 4.5. Lacl Immunofluorescence. 
Clone Total Lacl staining Nuclear 
localisation 
Rat I Rep3 weak + 
Rat 1 Rep6 weak ++ 
Rat 1 Rep? weak +++ 
Rat 1 Rep30 weak ++ 
Rat I Rep54 v. strong + ++ 
Rat 1 Rep56 strong +++ 
Rat I Rep58 strong ++ 
Rat I Rep3.1 strong ++ 
Rat 1 Rep3.2 strong ++ 
Rat I Rep3.4 strong + ++ 
Rat l Rep3.5 strong + 
Rat l Rep3.7 weak - 
Rat IRep3. 8 weak ++ 
Rat I Rep3.9 weak + 
Rat 1 Rep3.10 weak + 
Rat 1 Rep3.12 strong + 
Rat I Rep3.13 weak - 
Rat 1 Rep3.15 weak ++ 
Rat 1 Rep3.18 strong + ++ 
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4.3.1.2.3 Attempted generation of lac -regulable p53 expressing Ratl cells. 
Pilot transfection experiments showed that plasmid pOPRp53wt was capable of 
forming colonies following transfection of RatlRep54 cells and selection with G418. 
Colonies appeared to be healthy by phase contrast microscopy and were able to be 
expanded. It was expected that overexpression of p53 would cause alteration of cell 
cycle activity in rat fibroblasts. In order to test the ability of LacI protein to suppress 
expression of p53 from vectors containing lac operator sites, either of two vectors, 
pOPRp53wt or pBKOP53wt, which contain 2 or 3 operator sites respectively, were 
transfected into either RatlRep54 or the parental Ratl cell line. If p53 expression 
was suppressed by Lacl expression, it was expected that more colonies would form 
following transfections of RatlRep54 cells than in transfections of RatI cells. 
Accordingly, colonies on replicate plates were stained with Giemsa and counted 14 
days following transfection. Table 4.6 shows the results of these experiments. There 
was no statistically- significant difference between the number of transfectant 
colonies derived from ladI- expressing RatlRep54 and parental Ratl cells in 
experiments with either of the two inducible p53 expression vectors. 
It was noted that pBKOP53wt consistently produced fewer colonies following 
selection than pOPRp53wt. There was no significant difference between the number 
of colonies obtained by transfection of RatlRep54 cells and Ratl cells with either 
pOPRp53wt or pBKOP53wt. Although p53 mRNA or protein levels were not 
measured in this work, it is possible that repression of expression of wild -type p53 
does not affect the efficiency of colony formation of Ratl cells. 
Table 4.6. Number of colonies (±SEM) derived from transfections with IPTG -inducible p53 expression vectors. 
Cell line pOPRp53wt pBKOP53wt 
Ratl 45.5 + 8.7 17.2 ± 5.1 
n=6 n=6 
RatlRep54 51.8 + 5.4 12.0 ± 3.75 
n=6 n=6 
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4.3.1.2.4 Repression of expression ofNedd2 bti^ lad-NB is not complete. 
In order to test whether repression by IacI -NLS of an ICE -like protease gene (Nedd2) 
under the control of a promoter containing lac operator sites was sufficient to allow 
construction of stable cell lines, plasmid pOPRNedd2 or a control vector (pOPRIVIT) 
lacking the Nedd2 expression cassette was transfected into RatlRep54 cells. Cells 
transfected with the control plasmid formed large, easily expandable colonies upon 
selection with G418 at a transfection efficiency of 0.41 %. However, cells transfected 
with pOPRNedd2 formed only a few small, colonies (less than 100 cells per colony) 
which contained many gaps with apoptotic cells and which did not survive extensive 
attempts at expansion. In a transient transfection assay, Nedd2 mRNA expression 
was detected by RT -PCR after 9 hours in DNase- treated, total RNA samples from 
cells transfected with pOPRNedd2 in both the presence or absence of IPTG (Fig. 
4.29a). It was concluded that cells transfected with pOPRNedd2 were killed by the 
expression of Nedd2 caused by incomplete repression of transcription by Lacl. 
4.3.2 Evaluation of the Tamoxifen- Sensitive Ga1ER Expression System 
4.3.2.1 Generation of Ratl Sublines Expressing the VP16GalERtm Transactivator. 
The first stage of the construction of cell lines designed to express exogenous genes 
conditional upon the addition of 4- hydroxytamoxifen to the medium was to create a 
subclone of the Ratl cell line that expressed the VP16GalERtm transactivator. 
Accordingly, pBabeNeoVP16GalERtm was transfected into Rat 1 cells and selected by 
G418 resistance. Six sublines were tested for expression of the VP 16Ga1ERtm fusion 
transcript by Northern blotting. (Fig. 4.29b). Note that although 101,tg of total cellular 
RNA was loaded in each lane, only a weak signal from the 4.4kb RNA transcript was 
detectable in 4 out of the 6 clones. Clone Rat1 /4.7, which expressed the 
VP16GaIERtm RNA at intermediate levels was chosen for further study with Ga14- 
inducible vectors. Clone Ratl /4.12, which showed the highest levels of expression, 
grew relatively slowly in culture and was not used further. 
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Fig. 4.29a: Nedd2 RT -PCR of RatlRep54 and Rati cells transiently transfected with 
pOPRNedd2. Note that nedd2 mRNA is detected in all lanes. Control (untransfected cells or no 
cDNA template) PCR reactions were blank (on a separate portion of the gel). .M: Life Tech. 1kb 
ladder. Lane 1: RatlRep6.4 cells transfected with pOPRNedd2, -IPTG; Lane 2: RatlRep6.4 cells 
transfected, +IPTG; Lane 3: Ratl cells transfected , -IPTG. Lane 4: Ratl cells transfected , +IPTG. 
4.4kb> 
Rat 1 4.1 4.2 4.7 4.9 4.12 Blank 
Fig. 4.29b: Northern analysis of Ratl cells stably -transfected with pBabeNeoVP16GalER`m An 
Hindlll probe internal to the VP16GalER°n insert was generated from pBabeNeoVPI6GalERti" and 
was used to probe a total RNA Northern blot of Ratl cells and transfectants. Although the signal was 
generally weak, several clones were positive and clones 4.12 and 4.7 showed the greatest expression of 
VP16GalER`n RNA. 
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4.3.2.2 Testing of Gal4- inducible constructs in Ratl cells. 
It was hypothesised that, if the expression of test genes was tightly regulated in the 
tamoxifen- inducible system, there would be no significant difference in the number 
of transfectants recovered from Ratl /4.7 cells (expressing the VP16GalERtm 
transactivator) with Gal -4- responsive constructs containing p53, p21 or c -myc genes 
as compared to control experiments performed with an empty vector. Pilot 
transfection experiments of Ratl /4.7 cells with vectors pSP65GCp53wtpuro, 
pSP65GCmycpuro, pSP65GCWAF1- 143puro and pSP65GCWAFi- 160puro all 
produced similar numbers of healthy, expandable clones to that of transfections with 
pSP65GCpuro, a control vector not containing an inserted gene (approximately 40 -50 
colonies per plate). Similarly, transfections of pSP65GCp53wthygro produced 
similar numbers of colonies to pSP65GChygro. These data indicate that there is no 
selection against colony formation by Ga14- inducible vectors containing apoptosis or 
growth inhibitory genes in the absence of active VP16GalERtm transactivation. 
4.3.2.3 Dose -Response Relationship of 4- hydroxytamoxifen upon Ratl Cell 
Toxicity. 
It is important for the validity of experiments with inducible expression systems 
designed to express apoptosis promoting genes to be sure that the inducing agent 
does not itself possess toxic properties. Accordingly, a dose -response toxicity 
relationship for 4- hydroxytamoxifen in Ratl cells was carried out. 1 x 105 cells were 
plated into replicate wells of a 6 well tissue culture plate and allowed to attach to the 
substratum for 24 hours. The medium was then replaced with medium containing 
various concentrations of 4- hydroxytamoxifen (4 -OHT) (Sigma). The proportion of 
live cells after a further 24 hours in culture was determined by counting of cells in 
several fields from each well by phase contrast microscopy. Because serum 
deprivation experiments with vectors expressing c -myc were planned, the experiment 
was performed in parallel with medium containing 0.1% serum. (Fig. 4.30). At the 
concentration of 4 -OHT used for induction experiments (800nM), there appeared to 
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Fig. 4.30. Toxicity of 4- hydroxytamoxifen. (Arrow: concentration 








0 1 2 4 
4-OHT /µM 
6 8 10 
-0- 10% FCS 
-f-0.1% FCS 
233 
4.3.2.4 Generation of Ratl sub -lines with tamoxifen -inducible Nedd2 
Rat1 /4.7 cells expressing the VP16GalER`m fusion gene were transfected with 
pSP65GCNedd2SDpuro and selected with puromycin for up to 2 weeks. These 
clones were large and could be expanded as single colonies. RNA and protein were 
extracted at 6 hour intervals from pools of clones induced with 800nM 4- 
hydroxytamoxifen (Sigma). Induction of Nedd2 expression was monitored by RT- 
PCR of DNAse -treated RNA samples (Fig. 4.31a). Nedd2 mRNA was detected 
within 6 hours. At later time points RNA samples showed evidence of degradation 
(not shown) although mRNA was still detectable by RT -PCR at 36 hours. 
4.3.2.5 Tamoxifen- induced Nedd2 expression causes apoptosis of Ratl cells. 
It was hypothesised that induction of Nedd2 expression from the tamoxifen- regulable 
vectors would be sufficient to induced apoptosis in doubly -transfected Ratl cells. 
Accordingly, twelve day old colonies derived from transfection of Rat1 /4.7 cells with 
pSP65GCNedd2puroSD were induced with 800nM 4- hydroxytamoxifen. Individual 
colonies were photographed at 0, 6, 12, 18, 24 and 36 hours following addition of the 
tamoxifen (Fig. 4.32). Within approximately 75% of the clones, cells were seen to 
round up and detach from the substratum between 6 and 12 hours. At the 18 hour 
time point the majority of cells in these clones had detached and formed spherical, 
highly refractile apoptotic bodies. By 24 hours all cells in these clones were dead. 
Apoptosis was confirmed as the mode of cell death by acridine orange staining (not 
shown) or electron microscopy of dead cells collected from the medium (Fig 4.3 l b). 
Clones that showed no initial response to tamoxifen were unaffected and continued 
to increase in size throughout the experiment. At the dose of tamoxifen used, 
untransfected Ratl, Rat1 /4.7 cells or Ratl /4.7 cells transfected with empty vector 
pSP65GCpuro were unaffected by addition to the medium of 800nM 4- 
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Fig. 4.31a: RT -PCR analysis of 4- hydroxytamoxifen- induced nedd2 expression in 
Rat1/VP16GaWERb1 cells (Rat14.7) transfected with pSP65GCNedd2puroSD. M: Life Tech. 1 kb 
ladder. Lane 1: PCR positive control (reaction spiked with 1pg pSP65GCNedd2puroSD plasmid 
DNA). Lane 2: PCR blank (no cDNA template); Lane 3: cDNA from uninduced cells (0 hours). Lane 
4: 6 hours post induction. Lane 5: 12 hours; Lane 6: 18 hours; Lane 7: 24 hours. 
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Fig. 4.31b: Transmission electron microscopy of Ratl 4.7 / pSP65GCNedd2puroSD 
transfectants induced with 4- hydroxytamoxifen. (osmium tetroxide post -fix; uranyl acetate / lead 
citrate stain) 1: Early stage apoptotic nucleus showing marginated, condensed chromatin and 
nucleoli. (x800) 2: Apoptotic body with condensed nuclear fragment. Note the whorls of membrane 
and dilated endoplasmic reticulum in the cytoplasm. (x600). (Contrast in size with normal cell at 
same magnification in 4.) 3: Late stage apoptotic cell with fragmented, condensed nucleus and 
secondary necrosis with rupture of the cell membranes. (x620). 4: Normal Rat1 cell. (x 600). 
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Fig. 4.32: Phase contrast microscopy of Ratl 4.7 / pSP65GCNedd2puroSD transfectant 
colonies induced with 800nM 4- hydroxytamoxifen. Top left: Untreated (x100); Top right: 6 hours 
(x40); Bottom left: 12 hours (x40). At 24 hours all cells had rounded -up and detached (Bottom 
right). Centre: Rat1 4.7 cells transfected with empty vector (pSP65GCpuro) treated with 800nM 4- 
hydroxtamoxifen, 24 hours (x100). 
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4.4 Discussion. 
A modification of the Gal -ER inducible expression system was used here to control 
expression of the ICE -related protease Nedd2 in Rat1 fibroblasts. Nedd2 transcripts 
were not detectable by an RT -PCR assay in the uninduced state but were detected six 
hours following addition of 4- hydroxytamoxifen to the medium. This induction of 
Nedd2 expression coincided with the onset of a wave of apoptosis that resulted in 
complete involution of transfected colonies by 24 hours. The colonies that showed no 
initial response continued to be unaffected during the course of the experiment. It is 
likely that in these surviving colonies, integration of the Nedd2 expression construct 
may have resulted in disruption of the Nedd2 coding sequence. 
In contrast to the tamoxifen- inducible system, it was not possiible, under similar 
culture conditions, to produce stable clones of cells with Nedd2 or p21 WAPUCIPI under 
the control of the Rous sarcoma virus long terminal repeat in vectors designed to be 
repressible by a modified lac repressor protein. This suggests that such a system is 
inherently too leaky to be of use in demanding situations such as with the stable 
expression of cell death or cell cycle inhibitory genes. Surprisingly, transfection with 
myc -ER expression vector, pCMVOPMER, also did not produce stable clones in 
`oestrogen -free' conditions, although this was eventually ascribed to the inability of 
the batch of charcoal- stripped serum used to support growth of Rat -1 cells. An 
unexpected result was that there was no significant difference between the number of 
colonies produced in repressor positive or repressor negative Rat1 cells upon 
transfection with lac operator- containing p53 expression plasmids pOPRp53wt or 
pBKOP53wt. Wild -type p53 has an inhibitory effect upon cell growth or survival in 
most cells and it seemed plausible that enforced p53 expression in the absence of 
repressor from these vectors would substantially decrease the transfection efficiency 
relative to repressor positive cells. There are several possible explanations for this 
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observation. Firstly, the vectors may contain mutant p53 as a result of a cloning 
artifact. This possibility was rejected by sequencing the p53 inserts in the two 
vectors. Secondly, even if p53 -transfected Rat -1 cells do overexpress p53, p53 
expression may have no effect upon cell growth or apoptosis. This may be because of 
the species difference between the exogenous murine p53 and the rat cells used. 
However, murine p53 has previously proven to be effective in rat embryo fibroblasts 
(Michalovitz et al, 1990). Alternatively, as it known that Rat -1 cells possess 
endogenous wild -type p53, it is possible that these cells have mutations in other 
genes, downstream or at the activation of p53, that may cause these cells to be 
unresponsive to the addition of exogenous p53. However, the one previous report in 
which Rat -1 cells have been transfected with constitutive murine p53 expression 
constructs (in co- transfections with separate plasmids containing a selectable neo 
gene), exogenous wild -type p53 reduced the numbers of clones surviving selection 
relative to parallel transfections with point or deletion mutants. Exogenous wild -type 
p53 protein was not detected in the surviving clones, most of which did not contain 
an integrated copy of the p53 expression vector or had less than one copy per cell 
(Finlay et al, 1989). If indeed p53 mRNA was expressed from the vectors in Rat -1 
cells, a third possibility is that p53 translation was inhibited. The p53 cDNA used 
contains the full 5' untranslated region of the endogenous mRNA which has been 
suggested to form an extensive stem loop secondary structure, thereby inhibiting 
translation (Mosner et al, 1995). The exogenous p53 protein may therefore be under 
the same translational control as endogenous protein and therefore expressed at low 
levels in Rat -1 cells. Activation of the exogenous p53 may therefore require a 
stimulus such as DNA damage or oncogene activation in order to alter protein 
stability and therefore p53 protein concentration. This could be tested by comparing 
both the mRNA and protein levels in the transfectants with that in untransfected Rat - 
1 cells. 
A similar repression system to the lac operon, based upon the tet- repressor, tetR, has 
not been used in mammalian cells as it is believed that steric inhibition of RNA 
polymerase- mediated strand elongation alone is not sufficient to control transcription 
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effectively in the case of low tetO occupancy. Higher occupancy rates are not 
achievable in mammalian cells as tetR is toxic at greater concentrations than are 
generally achievable (Gossen and Bujard, 1993). The lac -repressor protein used here 
can be expressed at easily detectable levels and is localised mainly in the nucleus as a 
result of fusion with an SV40 nuclear localisation signal peptide. Therefore, operator 
occupancy by LacI -NLS is unlikely to be the limiting factor in this case. The data 
presented here suggests that inhibition of transcription by the lac repressor at 
operator sites placed within and (or) downstream of a strong viral promoter is 
incomplete. Indeed, following transient transfection of pOPRNedd2 into cells 
expressing LacI -NLS, Nedd2 mRNA was detected by RT -PCR even in the absence 
of the inducer, IPTG. 
The production of clonal cell lines with tamoxifen- inducible Nedd2 expression will 
allow biochemical dissection of the mechanisms by which Nedd2 causes apoptosis. 
In particular, these cell lines may provide a tool to identify substrates that are 
specifically cleaved by the Nedd2 cysteine protease activity. Although not shown in 
this work, it is likely that cells stably -transfected with inducible constructs for ICE - 
related proteases are likely to achieve induced protease molecule concentrations at 
least 1000 -fold lower than that in experiments where loading of cells with proteases 
such as trypsin or proteinase K resulted in cell death resembling apoptosis as a result 
of non -specific cleavage of many cellular proteins (Williams and Henkart, 1994). 
This much lower final concentration of protease in transfected cells is much more 
likely to result in apoptosis as a result of cleavage of substrates at specific sites. 
Further work will be needed to determine whether, like tTA- inducible expression, 
tamoxifen- inducible Nedd2 protein levels can be titrated by varying the inducer 
concentration. If this is indeed the case, then the VP16GalER`m cell lines developed 
here may provide a means to circumvent artifacts resulting from non -specific 
cleavage of substrates by the gratuitous overexpression of ICE -like proteases. 
One potential side -effect of the use of the strong VP16 trans- activation domain in 
fusion proteins is squelching of transcription factors acting at endogenous genes. 
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Both Ga14 -VP16 and VP16 -ER proteins, when transiently transfected, have been 
shown to inhibit transcription from promoters not containing Gal -4 binding sites 
(Gilbert et al, 1993; Sadowski et al, 1988). The VP16 domain is common to both the 
VP16GalER and tTA transactivators as well as chimaeric lac repressors containing 
the VP16 moiety (Bairn et al, 1991). Therefore work needs to be done to determine 
whether these proteins cause squelching in stable transfectants. Squelching could 
account for the barely detectable levels of VP16GalER``n mRNA in transfected Ratl 
cells. Use of tetracycline trans- activator vectors in mammalian cells invariably 
results undetectable tTA expression and requires laborious characterisation of 
individual candidate tTA lines by transient transfection with a tetracycline inducible 
reporter gene. Luckily, this was not required here as transient transfection efficiency 
of Ratl cells was no higher than 1% when determined by histochemical staining for 
ß- galactosidase. Repeated attempts to measure the activity of CAT in such transient 
assays failed to achieve levels much above background. 
Notwithstanding the comments above, the tamoxifen- inducible system described here 
provides sufficiently tight regulation of gene expression to allow generation of stable 
cell lines with apoptosis -promoting genes. Charcoal- stripping of steroid hormones 
from serum was not a requirement to maintain transfected cells in the uninduced 
state. The use of the tamoxifen- sensitive mutant oestrogen receptor is therefore a 
major refinement of the VP16Ga1 -ER trans -activator that will enhance its utility in 
transgenic animals where the normal high concentration of endogenous oestrogenic 
steroids would otherwise result in significant background expression of the 
transgene. This is particularly important if the result of expression of the transgene is 
likely to result in ablation of the tissues where the transgene is expressed. The use of 
the tamoxifen- inducible system should therefore facilitate the study of apoptosis. 
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Chapter 5. 
5. Concluding Discussion. 
Evidence was presented here to suggest that, at least in one particular cellular 
context, expression of wild -type p53 can protect cells from the lethal effects of the 
DNA damaging agents etoposide and bleomycin. This was probably mediated by 
enforcement of a GO /G1 cell cycle arrest, thus allowing time for recovery from the 
insult. As certain cell types, including fibroblasts, undergo a prolonged growth arrest 
following DNA injury, the p53- dependent growth arrest is likely to provide enough 
time for DNA repair to proceed to completion. In contrast, in the presence of mutant 
p53 expression, the fibroblast cell lines studied here underwent apoptosis associated 
with an accumulation of cells in G2 /M. The p53- independent apoptosis in this 
situation may be the cellular response to abortive attempts to undergo mitosis with 
unrepaired DNA. 
The response to induction of wild -type p53 activity in other cellular situations does 
not always result in cell survival and growth arrest. Often cells become committed to 
undergoing apoptosis, with or without passing through a state of growth arrest. The 
irradiated thymocyte is a good example of this. In the absence of p53, thymocytes 
often give rise to thymic lymphomas in vivo and are unresponsive to irradiation in 
vitro (Clarke et al, 1993; Lowe et al, 1993). Moreover, this death pathway can be 
separated from the growth arrest pathway. This is exemplified by the defect in DNA 
damage -induced fibroblast growth arrest but not thymocyte apoptosis in mice 
deficient for the p53- inducible p21 gene (Brugarolas et al, 1995; Deng et al, 1995). 
Therefore the response to p53 is determined by cell lineage. 
Other factors may affect the outcome of activation of wild -type p53 including 
availability of certain growth factors or the expression of other genes, especially 
oncogenes. It is known that activated ras can alter susceptibility to apoptotic stimuli 
(Arends et al, 1993). For this reason, myc and p53 co- transfection experiments were 
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attempted in both the ras- transformed Clone 6 cell line and the spontaneously 
immortalised, but non -transformed cell line, Rat l. However, there was no obvious 
difference in results between the two cell lines in these experiments. In this report, 
data was presented that expression of wild -type p53 in fibroblasts could result in 
reduced viability if co- transfected with plasmids expressing c -myc, suggestive of a 
co- operative relationship in the control of cell death. This is supported by 
observations by others that apoptosis induced by mitogenic genes, including c -myc, 
E2F -1 and adenovirus El A cannot occur in cells deficient for p53 (Kowalik et al, 
1995; Lowe et al, 1994; Hermeking and Eick, 1994; Wagner et al, 1994). Therefore, 
p53- dependent apoptosis is likely to be a more important determinant of tumour 
suppression than p53- dependent growth arrest, acting to delete cells of probably all 
lineages that carry activated oncogenes. This is evidenced by the unexpectedly very 
low rate of neoplasia in p21 -/ -mice (Brugarolas et al, 1995; Deng et al, 1995) and by 
the observation that certain mutant p53 alleles that are unable to induce apoptosis 
when overexpressed in an appropriate test line also have lost the ability to suppress 
cellular transformation, despite retaining the ability to cause transcriptional 
activation of p21 and growth arrest (Friedlander et al, 1996; Ludwig et al, 1996; 
Rowan et al, 1996). 
Inducible expression systems should allow the detailed analysis of deleterious genes 
in stable cell culture lines. In this project a Nedd2 cDNA was cloned as a test gene 
downstream of two different inducible promoters: one containing lac operator sites in 
which expression is downregulated by binding of a repressor protein until the 
addition of IPTG; and a second promoter that becomes active only in the presence of 
4- hydroxytamoxifen. Whilst the lac -repressor -based system was leaky, resulting in 
only transient expression, the VP16GalERtm provided sufficiently tight control of 
expression to enable the propagation of stably -transfected cells which underwent 
apoptosis upon induction with 4- hydroxytamoxifen. Little is known of the substrate 
preferences of this relatively poorly characterised protease. The tamoxifen- inducible 
system and the Nedd2 cell lines generated here are therefore a powerful tool for the 
study of apoptosis effector mechanisms. 
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Scientific method involves making perturbations in identified factors in order to learn 
about the normal from those alterations. In molecular cell biology this can often 
require manipulations that cause the overexpression of a particular gene product or 
mutation that eliminates or alters the function of a gene. A common strategy for 
specific genetic manipulation is gene knockout by vector -directed homologous 
recombination in totipotent embryonic stem cells. This is the first step in the 
derivation of recombinant animals that have a targeted deletion at a particular 
genomic locus. This strategy has been useful for determining the effects of absence 
of particular genes. However ideal this strategy appears to be as a tool of science, the 
function of a knocked -out gene can only be inferred by careful analysis of the 
phenotype of the targeted animals and their cells in comparison with normal animals. 
Indeed, many gene knockouts result in remarkably similar phenotypes or are 
embryonic lethal. Further, deletion of a gene whose function is redundant in vivo can 
result in a normal phenotype. Therefore, in the real scientific world, information 
about a particular gene, by necessity, is drawn from several sources including 
expression experiments. Despite arguments that overexpression is an artificial 
situation, the ability to exogenously supplement the expression of a gene is still of 
equal scientific value and as much ingenuity as has been poured into gene targeting 
techniques is required to develop expression technology. Expression techniques are, 
after all, the basis of future gene specific therapies. 
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Appendix A: Solutions 
TE 
10 mM Tris (p118.0) 






in 1 litre DDW pH7.4 autoclaved 
(x10) TAE 
48.4g Tris 
11.42 ml stock glacial acetic acid 
3.72g EDTA 
make up to 1 litre with DDW (pH 8). 
(x10) TBE 
108g Tris 
55g boric acid 
40 ml 0.5M EDTA 
make up to 1 litre with DDW (pH 8). 
dNTP mix. 
l01.11 of each 100mM stock dNTP. 
To l00111 with DDW. 
Store at -20 °C. 
(x10) gel loading buffer 




20g Bacto -tryptone 
5g Bactro -yeast extract 
0.5g NaC1 
in 1 litre DDW autoclaved 
SOC medium 
1 litre SOB 
5 ml 2M MgC12 
20 ml 1M glucose 
filter sterilise (0.2µm filter) 
LB medium 
10g Bacto- tryptone 
5g Bacto -yeast extract 
l Og NaC1 
in 1 litre DDW 
pH7.5 autoclaved 
LB agar 
7.5g bacto agar 
500 ml LB medium 
autoclave 
cool to 50 °C 
add antibiotic (e.g. 100N.g/ml 
ampicillin) 
2xYT Broth 
l Og NaC1 
! 0g Yeast Extract 
16g tryptone 
to 1 litre with DDW (pH 7.5 with 
NaOH), autoclave. 
Miniprep Cell resuspension solution 
50 mM Tris -HCI pH7.5 
10 mM EDTA 
100gg/m1 RNaseA 
Miniprep Cell lvsis solution 
0.2M NaOH 
1% SDS 
Miniprep Neutralization solution 
1.32M Potassium acetate pH4.8 
Miniprep Column wash solution 
200 mM NaC1 
20 mM Tris -HC1 pH7.5 
5 mM EDTA 
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dilute with 95% ethanol to a final 
ethanol concentration is 55% 
Maziprep resuspension buffer: Pl 
100µg/m1 RNaseA 
50 MM tris/HCl 
10 mM EDTA pH8.0 
P2: lvsis buffer 
200 MM NaOH 
1% SDS 
P3: neutralisation buffer 
3M KAc pH5.5 
OBT: equilibration buffer 
750 mM NaCl 
50 mM MOPS 
15% ethanol pH 7 
0.15% triton X -100 
OC: wash buffer 
M NaCI 
50 mM MOPS 
15% ethanol pH8.5 
OF: elution buffer 
1.25M NaCl 
50 mM tris/HCl 
15% ethanol pH8.5 
2x BES- buffered solution (BBS) 
50 mM N,N- bis(2- hydroxyethyl) -2 
aminoethanesulfonic acid (BES) 
280 mM NaC1 
1.5 mM Na2HPO4 pH 6.95 
800 ml DDW 
adjust to appropriate pH (6.95 - 6.98) 
with NaOH 
filter sterilise and freeze in 20 ml 
aliquots at -20 °C 
2.5M CaCl2 
183.7g CaC12 dihydride 
DDW to500m1 
filter sterilise and store in 10 ml 
aliquots at -20 °C 
10x MOPS running buffer 
1.8g MOPS (3 -N 
Morpholinopropanesulphonic acid) 
3.72g EDTA (Disodium salt) 
4.1g Sodium acetate 
to 1 litre with DEPC treated water 
pH 7.0 
0.2µm filter 
10x Ligase buffer 
300mM Tris -Hel, pH 7.8 
100mM MgC12 
100mM dithiothreitol (DTT) 
10mM adenosine triphosphate (ATP) 
10x Mutagenesis buffer 
100mM Tris -acetate (pH 7.5) 
100mM MgOAc 
500mM KOAc (pH 7.5) 
6% denaturing polvacrvlamide gel. 





Stir until urea dissolves and store at 
4 °C. 
Add l00µ1 TEMED and 100m1 25% 
ammonium persulphate per 100m1 gel, 
mix and pour immediately. 
100 ml formaldehvde/agarose gel 
1 g agarose 
20 ml 10x MOPS 
62 ml DEPC treated water 
boli by microwaving 
cool to 60° and add 18 ml 
formaldehyde - pour immediately 
RNA sample buffer 
240µ1 formaldehyde 
750µl deionised formaldehyde 
50111 10x MOPS running buffer 
store at -20 °C 
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RNA Loading Buffer 
50% glycerol 
1 mM EDTA 
0.25% bromophenol blue 
0.25% xylene cyanol 
Northern Prehybridisation solution 
2.5 ml 20x SSPE 
1 ml 50x Denhart's solution 
0.1 ml (10 mg/ml) Calf thymus DNA 
5 ml formamide 
to 10 ml with DEPC- treated DDW 
Northern Hybridisation solution 
2.5 ml 20x SSPE 
1 ml Denhart's solution 
0.1 ml Calf thymus DNA 
5 ml 10% dextran sulphate in 
formamide to 10 ml with DEPC- 
treated DDW 
Deionised Formamide. 
5g Mixed bed resin per 100m1 
formamide. Stir 1 hour. Add more 
resin if required. Filter. Store at -20 °C. 
20x SSC 
175.3g NaC1 
88.2g Na citrate 





to 1 litre with DDW (pH 7.4) 
100x Denhardt's Solution. 
20g polyvinyl pyrolidine 
20g Ficoll 
20g BSA 
To 1 litre with DDW 
Store at -20 °C 
DNA -DNA Hybridisation Buffer. 
5g Dextran sulphate in 25m1 DDW, 
(65 °C) 
15m120xSSC 
2.5ml 20% SDS 
0.8ml 5mg/ml heat denatured salmon 
sperm DNA. 
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Appendix B: E. coli Strain Genotypes. 
Strain Genotype 
XL1Blue recAl endAl gyrA96 thi-1 hsdR17 supE44 relA 1 
lac {F' proAB Iac19ZAM15 Tn10 (Tet`)]° 
XL1B1ueMR A(mcrA)183 0(mcrCB-hsdWR-mrr)173 endA1 
supE44 thi-1 recAl gyrA96 relAl lac° 
XLIB1ueMRF' A(mcrA)183 A(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recAl gyrA96 relAl lac [F' proAB 
laclgZAM15 Tn10 (Tee)]` 
XLmutS Kan' A(mcrA)183 A(mcrCB-hsdSMIt-mrr)173 endAl 
supE44 thi-1 recAl gyrA96 relAl lac 
mutS.: Tn10 (Tet`) [F' proAB Iac14ZAM15 Tn5] 
SCSI 10 rpsL (Strt) thr leu endA thi-1 lacY gaK galT ara 
tonA tsx dam dcm supE44 A(lac-proAB) [F' 
traD36 proAB laclgZAM15] 
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Appendix C: Additional Plasmid Maps. 
F1 ORI 
P(BLA) 
Nsi I (4307) 
SV40 pA 
3'splice 
Nsi I (4235) LacZ 
SV40 Early Promoter T7 
5' splice 
Kpn I(1015) 
NEO(R) Bgl II (1024) 
Not I(1053) 
Sac II (1053) 
Xho I (1072) 
Hind III (1078) 
`ÉcoR I (1087) 
::BamH I (1096) 
Spel(1102) 
Sal I (1108) 
,Pst I (1118) 
Sac I (1130) 
T3 
CMV IE Promoter 
Nsi I (1904) 
P(BLA) F1 ORI 





Apa LI (2267) 
Nsi I (4181) 







Bgl II (970) 
Not I (999) 
Sac II (999) 
Xho I(1018) 
Hind III (1024) 
,EcoR I (1033) 
ré,BamH I (1042) 
",'Spe I (1048) 
Sal I (1054) 
Pst I (1064) 
Sac I (1076) 
T3 
CMV IE Promoter 
Nsi I (1850) 
TK pA 
COLEI ORI 




.Vsi I (5522)_.____ 









Bgt II (1020) 
Sac H (1289) 
Kpn I(1635) 
p53C 
Apa LI (1913) 
Pst I (1946) 
Pst I(2074) 
Sac I(2080) 
Eco RV (2175) 
.1.7,o I (2233) 
Sac I(2234) 
Eco RV (2244) 
EcoR I (2374) 




Apa LI (3554) 
.Vsi I(3191) 
CMV IE Promoter 
P(BLA) 
Nsi I (6637) 
Nsi I (6565) 




. 1pa 1.1(4597) 
T3 











Bst XI (1024) 
NotI(1045) 
rho I (1064) 
Hind III (1070) 
EcoR I (1079) 
Sac I(1095) 
Pst I (1395) 
Ns) I (4234) 
CMV IE Promoter 
T3 
Sac I (3460) Pst I (3448)i¡ff: 
Sal I (3438J' 
J 
SpeI(3432)1 
Barn H I (3426)/ 
EcoR I (3417) 
Sac I(3415) 
Pst I (1566) 
hER Steroid- binding domain 
Hind III (1864) 
11 c -myc 
Bam I (2042) 
1 i 
1\ Pst I 
(2818) 
Fco RV (3206) 
Pst I (3232) 
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P(BLA) 
Nsi I (6934) 
Nsi I (6862) 




Apa 11 (4894) 
Nsi I (4531) 
CMV E Promoter 
Hind III (3921) 
Lac OP 








/ Sma I(1022) 
i Bst XI (1024) 
/Nor I (1045) 
Sac II (1045) 
XhoI(1064) 
Hind III (1070) 
pBKOPMER 
7153 bp 
Apa LI (3411) 
AmpR 
Sal I (3786) 
Lac OP 
Sal I (3743) 
Bam H I (3712) r 
Bam H I (3489) 
Hind III (3454) 
Spe I (3432) 
Pvu II (4242) 
, EcoR I (1079) 
Sac I(1095) 
Pst I (1395) 
Pst I(1566) 
hER Steroid- binding domain 
Bgl II (1612) 
Hind III (1864) 
Barn H I (2042) 
c-myc 
Pst 1(2818) 
Sac II (2854) 
Eco RV (3206) 
Pst I (3232) 
Sac I (3415) 
EcoR I (3417) 
BamH I (3426) 
TIP Aar II (21) 
Sac II (47) 
EcoR I (56) 
Pst 1(195) 
Pvu II (367) 
Sac II (571) 
pGEMmyc 
4351 bp 
Pst I (609) 
c-myc 
Cla I (858) 
SP6 P 
_NotI(1411) 
Pst I (1422) 
P(LAC) Sal I (1424) 
Sac I (1443) 
, Nsi I (1461) 
i 
Apa LI (2165) 
1 
i Lac OP 
Pvu II (1675) 
250: 
Apa LI (2876) 
AmpR 
Apa u (2477) 
Pvu 11 (3707) 
17 P 
Aal II (21) 
Sph I (27) 
Sac 11 (47) 
Eco RV (52) 
_ 
-Not I (63) _. 
____ 
____ 1(74) 
Cla I (323) 
mycl- 
Not I (876) 
Pst I (887) 





¡vu 11 (3308) 
\ ac 1(908) 
Nsi 1(926) 




Sph I (27) 
Sac II (47) 
Eco RV (52) 
Not 1(63) 
' Pst I (74) 
:i :7/ . Eco RV (96) 
Fi ORI Pvu 11 (246) mycS 
_ - - - - - - - 
Sac 11 (450) 
Pst I (488) 
Sal I (490) 
Sac I (509) 
Nsi I (527) 
AmpR 
Lac OP 
Pvu 11 (741) 
P(LAC) 
Apa 11 (1231) 
251 
Apa LI (3448) 
AmpR 
Apa LI (2510) 
F1 ORI 
T7 P 
Sph I (27) 
I Nco I (38) 
Sac II (47) 
-TNsi I (153) 
Sac I(273) 
Apa LI (674) 
EcoR I (701) 
Nedd2 
Hind III (752) 
- Sal I(1037) 
EcoR I (1325) 
_Spe I (1441) 
Not I (1448) 





Apa LI (2202) 
T7 P 
Pwu II (3341) 
P(LAC) 
AatII (21) 
Sac II (47) 
Bain H I (56) 
. SacI(1480) 
Nsi I (1498) 
Lac OP 
p21 Waf1 1-143 
F1 ORI Pst I (363) Sma I (438) 
Not I (510) 
SP6 P 
\__'Pst I (521) 
Sal I (523) 







Pvu II (774) 
Apa LI (1264) 
252': 
Apa LI (2559) 
Pine II (3390) 
T7 P Aat II (21) 
Sac II (47) 
Bam H I (56) 
F1 ORI 
p21 WAF1/CIP1 pst I(363) - -" Sma I (438) 
Not I (559) 
Pst I 
SP6 P .. Sal I(572(570) 
Sac I (591) 
pGEMWAF1-160 } ' Nsi I(609) 
3499 bp 
AmpR 
Bg! II (4372) 
Bg! II (4364) 
PGK enhancer 
Sac II (3741) 
Apa LI (3543) 
HY9re gene 
Pst I (3298) 
Apa LI (3241) 
EcoR I (3204) 
PGK promoter 
Lac OP 
P(LAC) / 'pu II (823) 
Apa LI(1313) 
EcoR I (2422) 
Cla I (241'7)________- -_ 
Bg! II (2404) 
SP6 T/C [NIT' j 
Apa LI (2308) 
SP6 P 

















Aat II (6235) 
Apa LI (5980) 
Apa LI (4734)- 





Not I (3895) 
Nco I (3660) 
EcoR I (3359) Hind III (2634) 
Sal I (2726) 
Sal I (2769) 
Sal I (2812) 
BamH I (2843) 
Ham H I (3066) 
IHind III (3101) 
'Bcl I (3113) 
COLEI ORI 
Apa LI (4001) 




Pst I (1055) 
EcoRI(1144) 
Sac I(2054) 
i r Sac II (2061) 
Bst XI (2062) 
EcoR I (2541) 
Apa LI (2621) 
'Bgl II (2628) 
P(BLA) 
Apa LI (5247) Aat II (36) 





Pst I (958) 
Pst I (1155) 
HSV TK promoter 
EcoR I (1244) 
pOPRMT 
5466 bp 
F1 ORI ( -) 
Sac I (2154) 
Hind III (3155) ` 
Sac II (2161) 
'Bst XI (2162) 
BamH I (3120) 
Lac OP ,r ¡ RSV LTR 
Sal I (3058) Intron' 
EcoR I (2641) 
Lac OP 
BamH I (2854) 
Hind III (2774) 
I (2715) 
Apa LI (2764) 
256 
Bg1 II (3347) 
Pst I (3347)\ Sac II (8) 
P(BLAL___ Bst XI (9) 




EcoR I (488) 
Lac OP 
ti Sal I(562) 
'1 Apa LI (611) 
i Hind IH (621) 




BamH I (967) 
COLEI ORI 
Apa Lí(1848) 
TK pA 3'splice 




Apa LI (6624) Apa LI (248) 




COLEI ORI .''Pst I (1125) 
Apa LI (5378) o(PR Nedd2 
\HSV TK promoter 
EcoR I (1214) 
NcoI(4848) 
TK pA'` 
EcoR I (4416) 
Hind III (3843)__ 
Nedd2 
EcoR I (3792) 
Apa LI (3765) 
F1 ORI ( -) 
RSV LTR 
EcoR I (2611) 
- -Lac OP 
Apa LI (2734) \ 
Hin d III (2744) 
BamH I (2824) 
Intron 
Lac OP 
; Bam H I (3090) 
3'splice 
Hind HI (3125) 
257' ' 




SV40 Early Promoter 
Nco I (236) 
III (345) 
- Pst I (361) 
Sma I (488) 
PAC Gene 
NcoI(1084) 
Sma I (1108) 
SV40 pA 
Cla I (1399) 
RSV LTR 
EcoR I (1893) 
COLEI ORI _ 
Apa LI (3253) 
Nco I (2723) f ____Lac OP 
TK pA - - Apa 11 (2016) 
Hind III (2407) \ "Hind III (2026) 
3'splice BamH I (2106) 
COLE1 ORI 




Bam H I (2372) 
P(BLA) 
/ 
Aat II (36) 
Apa LI (5709) Apa LI (278) 
AmpR ° pA 
NEO(R) 
Psi I (958) 
Pst I(1155) 
HSV TK promoter 
EcoR I (1244) 
Not I (3624) \ 
Sma I (3548L\ 
pOPRWAF1-143 
5928 bp 
F1 ORI ( -) 
Sac I(2154) 
Sac II (2161) 
Pst I(3473).----, 
p21 WAF1/CIP codons 1 -142_. BstXI (2162) 
Hind III (3155__ -:- -ï RSV LTR 
3'sphce EcoR I (2641) 
Bam I (3120) / 
LacOP/ Lac OP 
Sal I (3058) i i 1A Sal I (2715) 
Intron i Apa LI (2764) 
Hind III (2774) 
BamH I (2854) 
258 
BcunH I (1) 
Synthetic PoIyA 
Cla I (58) 
SP6 P 
GaI4 Hind DI (170) 
Ga14-Responsive Promoter 11 EcoR I (118)7V ATTGG 
Gal4 Gall/ TATA 
Sph I (4562) - +1 Sal I (257) 
Apa LI (4.460) EcoR I (274) 
Aal II (4218) 
Apa LI (3963) 
pSP65GCmyc 
5008 bp 
Apo LI (2717) 
Bam [1 1 (1), 
Ga14-Responsive Promoter 
ORI 1 
Pvu 11 (2227) 
SV40 pA 
Synthetic PolyA 
C/ci I (58) 
Ga14 
Gal4 
EcoR I (118) Hind DI (170) +1 
--Pst 
Pst I (413) 
Eco RV (435) 
Pvu 11 (585) 
Sac 11 (789) 
Pst I (827) 
N 
c-myc 
Cla I (1076) 
1(1647) 
EcoR I (1663) 
Intron 
10- 
\ ' Unknown sequence , 
Hind Ili (1953) 
I \ \ Sma I (1968) 
EcoR I (1972) 
Cla I (1980) 
TATA I 
Xho I (406) Apa (4453) 




,---i Unknown sequence : 
ORI 
SV40 pA 
Cla I (19'73) 
EcoR I (1965) 
Sac 1(413) 
Sac I (567) 
Pa. I (573) 
'SS 
Pst I (704) 
Apa U (729) 
\ 
Kpn I (1015) 
\\ Sac (1359) 






Hind III (1946) 
Sma I (1961) 
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p53- independent death and p53- induced protection against apoptosis in 
fibroblasts treated with chemotherapeutic drugs 
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Summary Many recent studies have implicated p53 in the cellular response to injury and induction of cell 
death by apoptosis. In a rat embryonal fibroblast cell line transformed with c- Ha -ras and a mutant 
temperature -sensitive p53 (va1135), cells were G, arrested at the permissive temperature of 32 °C when 
overexpressed p53 was in wild -type conformation. In this state cells were resistant to apoptosis induced by 
etoposide (at up to 50 pm) or bleomycin (15 µU ml -1). Cells at 37 °C with overexpressed p53 in mutant 
conformation were freed from this growth arrest, continued proliferating and showed dose -dependent increases 
in apoptosis. This death is independent of wild -type p53 function. Control cells containing a non- temperature- 
sensitive mutant p53 (phel32) were sensitive to both etoposide and bleomycin after 24 h at 32 °C and 37 °C, 
indicating that the results are not simply due to temperature effects on pharmacokinetics or DNA damage_ 
Our data show that induction of a stable p53 -mediated growth arrest renders these cells much less likely to 
undergo apoptosis in response to certain anti -cancer drugs, and we conclude that the regulatory role of p53 in 
apoptosis is influenced by the particular cellular context in which this gene is expressed. 
Keywords: p53; ras; apoptosis; etoposide; bleomycin; cell cycle; fibroblasts 
Many tumours are resistant to chemotherapy, either intrinsic- 
ally or following an initial partial response. A number of 
pharmacokinetic explanations may account for this, including 
overexpression of the multidrug resistance gene mdrl, overex- 
pression of drug detoxication enzymes, or alteration of the 
drug target, for example topoisomerase II isoform. However 
despite intensive study of drug - target interactions, and drug 
metabolism, it is clear that in many instances drug resistance 
is associated with a failure of induction of apoptosis, even 
after an appropriate triggering event. Since many anti -cancer 
drugs and ionising radiation damage DNA, the response of 
the cell in recognising injury and proceeding to repair or 
apoptosis is of paramount importance (Hickman, 1992; Har- 
rison, 1995). 
Entry to apoptosis is regulated by a number of genes (see 
Bellamy et al., 1995 for general review), each of which may 
show abnormal expression or function in cancer. In Rat -1 
fibroblasts cell cycle arrest or serum deprivation in the 
presence of constitutive expression of the c -myc oncogene can 
cause apoptosis (Evan et al., 1992). By contrast, overexpress- 
ion of bc1-2 directly inhibits apoptosis in both normal and 
neoplastic cells (Hockenberry et al., 1990; Sentman et al., 
1991; Miyashita and Reed, 1992, 1993; Veis et al., 1993) and 
prevents c- myc -driven apoptosis (Wagner et al., 1993). More 
recently evidence has accumulated implicating the tumour - 
suppressor gene p53 in an injury- response pathway leading to 
apoptosis. Thymocytes and myeloid progenitor cells from 
p53 knockout mice, fail to undergo induced apoptosis in the 
absence of a wild -type p53 allele following etoposide or 
ionising radiation treatment but not apoptosis associated 
with ageing in vitro or non -clastogenic insults such as dex- 
amethasone treatment. (Clarke et al., 1993; Lotem and Sachs, 
1993; Lowe et al., 1993a). Furthermore overexpression of 
wild -type p53 in a variety of cancer- derived cell lines such as 
M1 myeloid leukaemia (Yonish -Rouach et al., 1991), marine 
erythroleukaemia (Ryan et al., 1993) and HT29 colon car- 
cinoma (Shaw et al., 1992) resulted in an increase in spon- 
taneous apoptosis. 
By contrast, studies of p53 null fibroblasts grown in 
primary culture have failed to detect alteration in cell sur- 
vival characteristics after DNA damage as compared with 
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normal primary fibroblasts (Slichenmeyer et al., 1993). In the 
latter experiments, cells were isogenic apart from p53 status. 
This suggests that other factors, including cell lineage and 
expression of oncogenes may modulate the effects of p53 on 
cellular physiology. In both experimental and human tumori- 
genesis p53 inactivation is believed to be a late event and is 
therefore superimposed on a series of progressive genetic 
abnormalities, such as activation of ras oncogenes (Fearon 
and Vogelstein, 1990). 
In this study we have used a rat embryonal fibroblast line 
(Clone 6) transformed with activated Ha -ras and a temper- 
ature- sensitive p53 mutant as a model of the role of p53 in 
anti-cancer drug therapy in the presence of other genetic 
alterations. We report that induction by wild -type p53 of a 
GI arrest protects Clone 6 cells from apoptosis caused by the 
anti -cancer drugs etoposide and bleomycin. Our data imply 
that wild -type p53 provides a mechanism of resistance of cells 
to chemotherapy but by allowing continued proliferation p53 
mutations may nonetheless contribute to the development of 
drug resistance. 
Materials and methods 
Clone 6 cells and RcGphe132.4 cells 
Clone 6 cells are rat embryonic fibroblasts constitutively 
expressing a human mutationally activated c -Ha -rasl gene 
and a marine, temperature- sensitive p53 mutant, p53va1135. 
At the permissive temperature of 32 °C the p53 protein is 
found predominantly in wild -type configuration but at 37.5 °C 
it adopts mutant conformation and function (Michalovitz et 
al., 1990). RcGphe132.4 cells contain a temperature- stable 
p53phe132 mutation in addition to activated c -Ha -rasl. The 
level of p53 expression in these two cell lines is similar. All 
manipulation of cell lines and counting was performed at the 
selected temperature to minimise the risk of inadvertent p53 
conformational shifts. 
Cell culture 
Cells were plated in duplicate flasks at a density of 2 x 104 
cells cm' in Glasgow modified Eagle's medium (GMEM) 
supplemented with 10% fetal bovine serum (FBS) and 
antibiotics. 
Quantitation of cell number and apoptosis 
Reference points (three per flask) were used to count directly 
the number of cells in x 100 field using a 10 x 10 graticule. 
This permitted sequential counts at 20, 28 and 42 h after 
plating at 32 °C or 37 °C. Apoptotic cells adherent to the 
monolayer were counted at each time point as well as cell 
number. The apoptotic cells were recognised by virtue of 
their spherical, highly refractile appearance under phase con- 
trast. These cells showed the classical appearances of apop- 
tosis and were confirmed by electron microscopy and acridine 
orange fluorescence microscopy (Arends and Harrison, 1994). 
Effects of bleomycin and etoposide 
Twenty four hours after plating at 37 °C cells were either 
moved to a 32 °C incubator or maintained at 37 °C for a 
further 16 h. Etoposide (10, 50 gm) or bleomycin sulphate 
(15µU ml -': 1 U = 1 mg bleomycin A2) were added for 1 h 
and then washed with phosphate buffered saline (PBS). Cont- 
rols were performed using equal concentrations of dimethyl 
sulphoxide (DMSO) or PBS vehicles. 
The number of viable and apoptotic cells was counted at 
intervals up to 50 h following drug treatment. The mean 
number of apoptotic bodies per field was expressed as a 
percentage of the mean adherent cell number (`percentage 
apoptosis'). RcGphe132.4 cells were counted 24 h after drug 
treatment. 
Cell cycle analysis 
Nuclei were isolated and stained with propidium iodide 
(Vindelov et al., 1983), and 1 x 104 cells were analysed on an 
EPICS CS flow cytometry (Coulter). Histogram analysis was 
performed using the Easy 2 Software. No doublets were seen. 
Bromodeoxyuridine incorporation analysis was carried out 
using the Amersham Cell Proliferation Kit (cat no. RPN20). 
Results 
Clone 6 cells are growth arrested at 32°C 
Exponentially growing cells were shifted to a 32 °C incubator. 
In three independent experiments cells ceased to show inc- 






0 I I I I I 
0 10 20 30 40 50 
Time (h) 
Figure 1 Growth properties of Clone 6 cells at 37 °C () and at 
32 °C (0). Each point represents the mean number of cells per 
field (n = 3) in one flask at each time point. Note that the cells 
incubated at 32 °C do not increase in number consistent with a wt 
p53- induced growth arrest. 
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rease in apoptosis in the presence of p53 with wild -type 
configuration (see Figure 2 controls). At 37 °C, with mutant 
conformation p53 there was a 3 -fold increase in cell number 
over the same period, confirming the original observations of 
Michalovitz et al. (1990). DNA flow cytometry showed both 
diploid and tetraploid peaks at permissive and non -perm- 
issive temperatures. At 32 °C there was in increase in the 
diploid G011 peak (Figure 3), and cells did not take up 
bromodeoxyuridine consistent with this state (data not 
shown). This growth arrest was reversible by transferring 
cells to 37 °C, even after 2 weeks, or more. By contrast 
RcGphe132.4 cells continued to grow at a slightly reduced 
rate at 32 °C in keeping with the previous observations of 
Michalovitz et al. (1990). 
Clone 6 cells with wild type p53 are resistant to both etoposide 
and bleomycin 
At 37 °C, in the presence of mutant conformation p53, there 
was a progressive increase in apoptosis starting 6 -10h after 
pulsing with drug (Figure 2). The increase was dose depen- 
dent: etoposide at 10 gm induced a maximum of 6% apop- 
tosis whereas at 50 µm the maximum was greater than 30% 
apoptosis (Figure 4). By contrast, cells maintained at 32 °C 
with p53 in the wild -type conformation showed no increase 
in percentage apoptosis, nor in cell number (Figures 2 and 4). 
Treatment with bleomycin showed similar effects (Figure 5). 
RcGphe132.4 cells are sensitive to apoptosis induced by 
etoposide and bleomycin at 32 °C and 37 °C. We considered 
the possibility that these differences in cell proliferation and 
apoptosis in response to DNA damage might be due simply 
to altered pharmacokinetics at the different temperatures. 
The RcGphe 132.4 cell line was derived from the same paren- 
tal stock as Clone 6, but contains a temperature -insensitive 
mutant p53; hence in this cell line wild -type p53 is excluded 
from function at both 32 °C and 37 °C. At 37 °C Clone 6 and 
RcGphe132.4 cells show closely similar entry into apoptosis: 
24 h after treatment with 50 gm etoposide the incidences were 
18.0% and 19.4% respectively. In contrast, at 32 °C the 
incidence of apoptosis in RcGphe132.4 cells was 9.5 %, but 
had fallen to less than 2% in Clone 6 cells. Very similar 
results were obtained following treatment with bleomycin. At 
37 °C incidence of apoptosis in Clone 6 cells was 19.8 %, but 
fell to less than 3% at 32 °C. In contrast, RcGphe132.4 cells 
10 15 20 25 
Time (h) 
Figure 2 Treatment of Clone 6 cells with 10 µm etoposide at 
37 °C () for I h results in substantial apoptosis, where as treated 
cells at 32 °C () and untreated controls (unfilled symbols) do not 
show this increase. Note the latent period during induction of 
apoptosis at 37 °C. Each line represents a separate experiment 
(performed in triplicate and expressed as a mean, for low values 
the range was less than 0.6% and for higher value the range was 
up to 2 %). 
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showed 10.3% apoptosis at 37 °C and 8.9% at 32 °C. Thus the 
profound inhibition of apoptosis in Clone 6 cells at 32 °C is 
dependent upon the altered configuration of p53 to wild -type 
and is not explicable solely on the basis of temperature 
effects on pharmacokinetics. 
Discussion 
Expression of wt p53 has been shown to induce apoptosis in 








1992; Ryan et al., 1993), GI arrest and survival in others 
(Baker et al., 1990; Diller et al., 1990; Mercer et al., 1990; 
Michalovitz et al., 1990; Kastan et al., 1991; Kuerbitz et al., 
1992). In addition, wt p53 has been shown to be an essential 
intermediate in a signal transduction pathway between the 
effects of DNA damaging agents (DNA strand breaks) and 
either apoptosis or G1 arrest (Kastan et al., 1992; Kuerbitz et 
al., 1992; Clarke et al., 1993; Lowe et al., 1993a). In this way 
p53 seems to play a critical role in deleting certain cell types 
that have sustained DNA damage e.g. thymocytes (Clarke el 






Figure 3 Cell cycle analysis of Clone 6 cells. (a) Exponentially growing cells at 37 °C, untreated (Go /Gi fraction: 46.56 %). (b) 
Following incubation at 32 °C for 24 h, the Go /GI peak is enlarged (72.51%) and there is a marked decrease in the proportion of 
cells between the G0/01 and G2/M peaks (S- phase). (c) At 37 °C, 24 h after etoposide treatment (50 µM) cells accumulated in G2/M 
with only 10.18% of cells occupying the Go /G, position. (d) At 32 °C, 24 h after treatment with 50 µM etoposide (Go/G, fraction: 
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Time (h) 
Figure 4 Treatment of Clone 6 cells with 50 µM etoposide for 
1 h induces substantial apoptosis when cells are incubated at 37 °C 
(D). At 32 °C treated cells (M) and in control cells treated with an 
equivalent volume of DMSO vehicle (unfilled symbols) do not 
show an increase in percentage apoptosis. Each line represents a 
separate experiment (performed in triplicate and expressed as a 
mean. For low values range was 2% and for high values was up 






10 20 30 40 
Time (h) 
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Figure 5 Clone 6 cells treated with 15 µU ml -' bleomycin sul- 
phate for 1 h at 37 °C () and at 32 °C ( ). Note that treated 
cells incubated at 37 °C undergo substantial apoptosis whereas 
treated cells at 32 °C and untreated controls (open symbols) do 
not shown an increase in percentage apoptosis. Each line 
represents a separate experiment (performed in triplicate and 
expressed as a mean. For low values range was 2% and for high 
values range was up to 12 %). 
1994; Griffiths et al., 1995) and myeloid progenitor cells 
(Lotem and Sachs, 1993) or in establishing a state of G, 
arrest, possibly permitting DNA repair (Lane, 1993; Bakalkin 
et al., 1994). Clearly the cellular context in which p53 is 
expressed is important. Murine fibroblasts or primary rat 
kidney cells can be induced to undergo apoptosis by p53 in 
response to disruption of growth control by coexpression of 
c -myc (Wagner et al., 1994) or adenovirus EIA (Debbas and 
White, 1993) respectively. 
The finding that p53 function is lost in many authentic 
human and experimentally induced animal tumours has led 
to the assumption that p53 loss of function is causally 
associated with resistance to anti -cancer therapy (Lowe et al., 
19936). In this study we have addressed the importance of 
p53 status on the sensitivity of cells to apoptosis induced by 
two anti -cancer drugs. 
We have shown here, in a fibroblast cell Ene transformed 
with activated Ha -ras and temperature- sensitive p53 trans - 
genes that wild -type p53 leads to G, arrest and at the same 
time resistance to the DNA damaging agents bleomycin and 
etoposide. By contrast, in the presence of mutant conforma- 
tion p53, cells underwent apoptosis associated with a relative 
accumulation in GZ/M, a common response to DNA injury 
in yeast and mammalian cells (Hartwell and Weinert, 1989). 
We were unable to produce a Go /G, arrest in Clone 6 cells at 
37 °C by either mimosine treatment or serum starvation as 
these treatments caused the death of the cultures. We were 
thus unable to show directly that a growth arrest in Go /G,, 
independent of p53, was protective against DNA damage. 
Our findings apparently contrast with published work in 
which temperature- sensitive p53 was expressed in the MI 
myeloid leukaemic (M1; Yonish - Rouach et a1.,1993) and 
murine erythroleukaemic (MEL; Ryan et al., 1993) cell lines 
induced apoptosis upon incubation at 32 °C (i.e. with wild - 
type p53). MEL cells underwent G, arrest before undergoing 
apoptosis, but in M I cells, no growth arrest could be 
observed at any position in the cell cycle. In addition, other 
cell types (including rat fibroblasts) have been shown to 
undergo G1 arrest but not apoptosis in response to wild -type 
p53 induction (Diller et a /., 1990; Mercer et al., 1990; 
Michalovitz et a /., 1990; Kastan et al., 1992). While 
bleomycin and etoposide maximally kill cells in S- phase, 
where replication forks are forced to negotiate either cleaved 
complex / double strand breaks (etoposide; Bae et al., 1988) 
or double -strand breaks resulting from free -radical attack 
(bleomycin; Kuo, 1981), they can damage and kill cells in 
Go /G, (Roy et al., 1992; Clarke et al., 1993; Evans et al., 
1994). In cell lines derived from clinically sensitive human 
tumours, DNA injury- induced wild -type p53 was held to be 
responsible for decreased clonogenicity following ionising 
radiation and this effect could be reversed by transfection of 
a dominant negative mutant p53. (Mcllwrath et al., 1994). 
The simplest explanation of our data is that the G, arrest 
mediated by p53 facilitates survival of ras- transformed fibro- 
blasts by allowing effective DNA repair and prevents entry 
into S- phase, a stage when cells are often most susceptible to 
DNA damage. 
Depending upon the cell system chosen, induction of p53 
can cause either G, arrest, apoptosis or both apoptosis and 
G, arrest (Michalovitz et al., 1990; Debbas and White, 1993; 
Ryan et al., 1993; Yonish -Rouach et al., 1993; Wu and 
Levine, 1994). The mechanisms by which decisions are taken 
that favour any of these end points are poorly defined but 
these decisions can be affected by specific growth factors 
( Yonish- Rouach et al., 1991; Gottleib et al., 1994; Canman et 
al., 1995). In particular, it is not known how p53 can mediate 
apoptosis in the thymocyte but not in the fibroblast. The 
recognition of DNA damage (possibly involving the ataxia 
telangiectasia gene products; Kastan et al., 1992) leads, via 
p53, to the control of the cell cycle at the G, checkpoint. We 
have shown this pathway to be protective in fibroblasts. Our 
p53 and cell death in fibroblasts 
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results complement those of Lowe et al. (1993b) who showed 
that p53 -normal fibroblasts were susceptible to anti -cancer 
treatment as a result of abrogation of the p53 -mediated G, 
arrest by adenovirus EIA expression. Further, interleukin 6 
(IL6) protects M 1 cells from undergoing p53- mediated cell 
death (Yonish -Rouach et al., 1991, 1993) and this protection 
also correlates with the induction of a Go /G, arrest. (Levy et 
al., 1993). 
Wafl (Cipl / sid1, p21), a gene product which is induced 
by wt p53, has potent inhibitory activity on cyclin E / cdk2 
complexes in cells undergoing radiation -induced G, arrest 
(El -Deiry et al., 1993, 1994; Dulic et al., 1994). Wafl is 
therefore a major regulator of cell cycle progression at the 
G, /S interface. The expression of Wafl in cell types that 
undergo apoptosis following activation of the p53 pathway 
suggests that it may be active in both arrest and death 
mechanisms. The decision of a cell to die may therefore be 
determined by other lineage- dependent messages or growth 
factors (Canman et al., 1995), although the activity of Wafl 
as an apoptosis- inducing gene has not yet been directly 
tested. One such determinant may be the level of activity of 
the transcriptional regulator E2F -1. When constitutively 
overexpressed in the presence of wild -type p53 this triggers 
death in fibroblasts (Wu and Levine, 1994). 
Using a different mutated p53 (proline substituted at 
residue 193) under its physiological promoter, Bristow et al. 
(1994) have recently shown that co- transfection of activated 
Ha -ras and mutated p53 into a primary rat embryonal fibro- 
blast cell line resulted in enhanced clonogenicity in vitro and 
tumorigenicity in severe combined immunodeficient (SCID) 
mice after irradiation compared with cell lines containing ras 
alone. This effect was dependent on the level of mutant p53 
expression, presumably as a result of competition with 
endogenous wild -type p53. However they did not directly 
assess the proportion of cells undergoing proliferation, 
growth arrest or cell death. We could not carry out 
experiments similar to those of Bristow et al. (1994) with 
ionising radiation sources as we found that reproducibility of 
results could not be maintained if there were fluctuations in 
temperature of Clone 6 cells before or during experiments. 
Indeed, clonogenicity of Clone 6 at 32 °C is negligible. 
Our in vitro experiments with DNA -damaging drugs (inc- 
luding the radiomimetic bleomycin) show that, under certain 
circumstances, overexpression of wild -type p53 can protect a 
cell which has suffered DNA injury against death rather than 
kill it, by causing cell growth to arrest in G,. The corollary in 
vivo is that wild -type p53 in an appropriate cellular context 
could confer a state of increased drug resistance. The 
significance of mutated p53 oncosuppressor gene in clinical 
drug resistance is likely to be both complex and variable 
depending on the existence of other pathways of cell cycle 
activity control and response to injury. We show here that 
death of fibroblasts induced by etoposide and bleomycin 
occurs independently of wild -type p53 function. This 
confirms work by Strasser et al. (1994) which showed that 
thymic lymphoma cells from p53 - / - mice underwent apop- 
tosis by p53- independent mechanisms following irradiation. 
Tumours which contain cells with mutated p53 initially may 
be more susceptible to cell death caused by therapy. However 
in the absence of G, arrest caused by wild -type p53, and 
therefore in the presence of continuing cell cycle activity, 
combined with karyotype instability (Livingstone et al., 1992; 
Yin et al., 1992), clones resistant to therapy may appear thus 
conferring a clinical state of `drug- resistant' disease. 
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Cell death in health and disease: the biology and regulation 
of apoptosis 
Christopher O.C. Bellamy, Roger D.G. Malcomson, David J. Harrison and Andrew H. 
Wyllie 
Apoptosis is a morphologically stereotyped form of cell death, 
prevalent in multicellular organisms, by which single cells are 
deleted from the midst of living tissues. Recognition of the 
cellular corpses and their removal by phagocytosis occurs 
without disturbance to tissue architecture or function and 
without initiating inflammation. Apoptosis is regulable and 
is of fundamental importance to tissue development and 
homeostasis. Cellular susceptibility to apoptosis is determined 
by a variety of signals, of both extracellular and internal 
origin, including pmliferative status. Dysregulated apoptosis 
is important in the pathogenesis of several important human 
diseases including neoplasia, and recognition of the defects 
involved is prompting development of new therapeutic 
strategies. 
Key words: apoptosis / genetic regulations / homeostasis 
PHYSIOLOGICAL CELL. DEATH iS an inconspicuous yet 
prevalent phenomenon in complex multicellular 
organisms. It is characterized by the deletion of 
scattered, single cells from the midst of a living tissue 
without disturbance to the continuity of tissue archi- 
tecture or function. With few exceptions cellular 
death is accomplished by a process with a structural 
stereotype, termed apoptosis, that strongly suggests a 
common underlying effector mechanism.' Apoptosis 
is observed in circumstances as diverse as embryoge- 
nesis, normal adult tissue turnover and organ atrophy; 
it is also fundamental to the regulation and operation 
of pathophysiological processes such as the immune 
response, inflammation and the elimination of cells 
after genotoxic injury (Figure 1). The realisations that 
apoptosis represents an innate cellular defence 
against carcinogenesis, that the regulatory pathways to 
apoptosis (but not the effector mechanisms) are 
frequently disabled in malignant neoplasms and that 
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many cancer chemotherapeutic agents may act by 
induction of apoptosis have stimulated intense inves- 
tigation into the underlying molecular controls. 
The structural changes of apoptosis 
In apoptosis coordinated changes occur in the 
nucleus, the cytoplasm and at the cell surface (Figure 
2).2 The time to onset of apoptosis after a lethal 
stimulus is variable but the changes are rapid (a few 
minutes duration): cells lose contact with their neigh- 
bours and round up. The endoplasmic reticulum 
dilates and superficial cisternae fuse with the plasma 
membrane. Other cytoplasmic organelles remain 
largely unaffected. At the same time there is a striking 
loss of cell volume, apparently due to voiding of water 
and ions with consequent compaction of the organ- 
elles and an increase in cell density. The nucleus 
condenses and chromatin marginates to form dense 
granular caps under the intact nuclear membrane. 
The nucleolar fibrillar centre dissociates from its 
transcriptional complexes. The cell surface starts to 
bleb violently and time lapse phase contrast studies 
show an extraordinary bubbling appearance.3 Around 
this time the nucleus breaks up into several mem- 
brane- bound fragments. The cell itself then splits into 
multiple membrane -bound `apoptotic bodies', some 
of which contain nuclear fragments. The apoptotic 
bodies are phagocytosed almost immediately by 
neighbouring cells or by macrophages without elicit- 
ing an inflammatory reaction, in contrast to necrosis 
as described below. Apoptotic bodies in phagosomes 
remain recognizable by light microscopy for up to a 
few hours and are consequently the predominant 
form of apoptosis recognized in tissue sections. In 
epithelia or cultured monolayers apoptotic bodies can 
instead be shed into lumina or the culture medium 
where they degenerate within a couple of hours: they 
gradually lose membrane integrity (becoming perme- 
able to vital dyes) and metabolic activity ceases. 
Apoptosis is not the only possible mode of cell 
death. Necrosis is a non - specific term for a variety of 
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Figure 1. Prevalence of apoptosis in physiological and disease contexts (modified and reproduced 
with permission of John Wiley and Sons, Chichester, UK). 
other modes of death in which, in contrast to 
apoptosis, the cell plays only a passive role while it is 
destroyed. Cell lysis during necrosis releases intra- 
cellular contents into the extracellular space, result- 
ing in inflammation and further secondary tissue 
damage. Necrosis typically involves contiguous cells 
and is associated with tissue architectural disruption 
whilst apoptosis generally affects scattered single cells 
and preserves the tissue architecture (except in 
special circumstances such as embryonic remodel - 
ling),I Necrosis is always pathological whereas apopto- 
sis is a physiological process that may also be triggered 
in pathological situations. 
Kinetic considerations 
The `gold standard' for identification of apoptosis is 
Figure 2. (A) Transmission electron micrograph showing late stage apoptotic fibroblast with 
fragmentation of the cell into membrane -bound apoptotic bodies. (B) Early apoptosis showing 
distinct peripheral chromosome condensation against the intact nuclear membrane. (C) 
Phagocytosed apoptotic body within a phagosome. (D) Cell surface changes in apoptosis: scanning 
electron micrograph of an apoptotic thymocyte, showing loss of microvilli and gaping cisternal 
pits, formed by fusion of dilated endoplasmic reticulum with the surface. (Reproduced with 
permission of Kluwer Academic Publishers, Dordtrecht). 
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morphological assessment. A comment on methods of 
evaluation of apoptosis has been given elsewhere4 but 
the importance of quantitation is worth stressing. The 
speed of apoptosis and the rapidity of clearance of 
apoptotic bodies in vivo (a few hours at most)5 mean 
that the identification of only a few apoptotic bodies 
in a tissue section can represent a considerable degree 
of cumulative cell loss. Numerically small differences 
in `apoptotic indices' (Le. the percentage of cells that 
are apoptotic) can therefore be of great biological 
import. For example, an intravenous bolus of anti- 
CD4 antibody increases the apoptotic index in murine 
lymph nodes from 0.06% to 1.33 %, and this is 
sufficient to halve the total cell count of the lymph 
nodes within 48 h.6 Unfortunately studies of this 
nature require that large numbers of cells be counted 
in order to achieve running means for apoptotic 
indices and allow statistical evaluation of differences. 
Furthermore, to be able to ascribe changes in tissue or 
tumour size to altered rates of apoptosis, parallel 
quantitative evaluation of cell proliferation is neces- 
sary. Other factors such as the rate of disposal of 
apoptotic bodies will also affect the perceived apopto- 
tic index. 
Underlying cell biology of the effector 
processes 
Cytoplasmic events 
The abrupt increase in cell density is due to voiding of 
water and ions, possibly channelled to the cell surface 
through the endoplasmic reticulum.2 As yet no 
mechanism has been identified to account for this 
profound and sudden fluid shift. The cell size and 
shape changes during apoptosis require major cytos- 
keletal reorganization that is still largely uncharac- 
terized, although actin polymerization (in part stimu- 
lated by protein kinase C) is essential for the budding 
that generates apoptotic bodies.? Some apoptotic 
cells, e.g. hepatocytes, also activate tissue trans - 
glutaminase to produce an insoluble shell of cross - 
linked protein.8 Although increased transcription of 
specific mRNAs frequently precedes apoptosis (see 
below), a site -specific endogenous RNAse activity late 
in apoptosis is suggested by the rapid degradation of 
ribosomal and messenger RNA in apoptotic cells.910 
The role of proteolysis (e.g. of terminin proteins)11 is 




As mentioned above, the nuclear membrane is not 
lost during apoptosis, unlike mitosis. However the 
subjacent nuclear lamina (which anchors chromatin) 
is dissassembled by depolymerization of constituent 
lamin filaments.12,13 Lamin phosphorylation and 
depolymerization also occurs during mitosis, catalysed 
by cdc2 kinase, and it is possible the same mechanism 
operates during apoptosis.14 That elements are com- 
mon to mitosis and apoptosis is as likely to reflect a 
general role in regulation of nuclear structure as to 
indicate any deeper similarity between these distinct 
processes. In contrast to mitosis the depolymerized 
lamins subsequently undergo proteolysis in apoptosis, 
perhaps making lamina dissassembly irreversible.l3 
Ubiquitin conjugation of nuclear proteins appears to 
be important in some (but not all) examples of 
apoptosis, and has been suggested to regulate some of 
the chromatin structural changes.15 A specific feature 
of apoptosis is rapid DNA cleavage. Initially large 
transient 50 kbp and 300 kbp fragments are detect- 
able that probably represent chromatin loops and 
rosettes detached from the anchoring nuclear 
matrix.16 In many cell types there is further rapid and 
extensive double strand cleavage of internucleosomal 
DNA to yield a series of oligonucleosome chains of 
180 -200 bp multiples (180 bp is the length of DNA in 
a single nucleosome). These are visualised as the 
characteristic `DNA ladder' on agarose gel electro- 
phoresis.2 The DNA cleavage is not sequence specific 
and the precise identity of the nuclease (s) responsible 
is still unknown (see ref 17, A. Eastman this issue, 
pp45 -52, for a detailed discussion). It is sufficient to 
say here that nuclease is constitutively present in some 
cell types but is induced in others prior to apoptosis. 
The nuclear changes of apoptosis can occur without 
oligonucleosome generation (e.g. TGF (31- induced rat 
hepatocyte apoptosis), which when present may be a 
very late event, after chromatin margination.16,18,19 Of 
note is that mitochondrial DNA is not fragmented in 
apoptosis, indicating that DNA fragmentation is a 
specific nuclear event.2o.21 
Surface changes 
A key property of apoptotic bodies is their rapid 
recognition and phagocytosis by adjacent cells or 
professional phagocytes. Cell surface changes during 
apoptosis that promote recognition are best charac- 
terized for apoptotic inflammatory cells, and include 
loss of sialic acid (thereby exposing glycoprotein side- 
C.O.C. Bellamy et al 
chain sugars) and exposure of membrane phosphati- 
dylserine.22 A third mechanism involves thrombo- 
spondin secreted by macrophages to form a 
molecular bridge between apoptotic cell and macro- 
phage surface CD36 or a3(35 integrin.22 Importantly 
phagocytosis of apoptotic cells does not activate 
macrophages to produce an inflammatory 
response.' 
Organization of effector events 
An ordered set of molecular events underlies the 
phenomena of apoptosis. To what extent these events 
are organized as a linear cascade or as parallel 
independent processes at multiple subcellular sites is 
unclear. It is of interest however that the nucleus is 
not essential for the cytoplasmic changes of apopto- 
sis.2s The degree of redundancy built into effector 
mechanisms is also unknown, although no obligate 
gene (i.e. without which apoptosis cannot occur at all) 
has yet been identified. Expression of effector mole- 
cules in non- apoptotic cells is variable: thymocytes 
must synthesize protein and RNA in order to undergo 
apoptosis in response to some stimuli,24 but other cell 
types constitutively possess the effector molecules, as 
demonstrated by apoptosis in the presence of protein 
or RNA synthesis inhibitors. For other cells inhibition 
of protein synthesis itself triggers apoptosis, suggest- 
ing the presence of a short -lived protein inhibitor of 
cell death. These observations have led to the concept 
of states of readiness (`priming') for apoptosis, 
determined by the dynamic activity of regulatory 
pathways to induce or deplete effector molecules.2 
Cellular ligands, e.g. fas ligand, 
CD40 ligand. 
Cytokines, e.g. TGF ß, TNF 
The idea has implications for chemotherapy in that 
cells in a highly primed state (with all the apoptotic 
machinery in place) might be more susceptible than 
unprimed companions to the triggering of apoptosis 
by cytotoxic stimuli. The increased sensitivity to 
cytotoxic agents of cells in `proliferative' compart- 
ments of tissues when compared with non- prolifer- 
ative compartments has been cited as an example of 
priming, although whether this difference is due 
simply to accumulation of effector molecules is 
unproven. In fact current models suggest that cell 
cycle activation is actually lethal itself, unless specific 
rescue factors prevail (see next section). 
The regulation of apoptosis 
Broadly speaking, physiological apoptosis can be 
externally triggered or a cell- autonomous event (Fig- 
ure 3). Cell- autonomous apoptosis is a hard -wired 
phenomenon, often termed `programmed cell death'. 
It is exemplified in morphogenesis by the coordinated 
death of web space cells that sculpts digits from the 
coarsely- shaped limb bud,' and by the chronologically 
and spatially invariant death of 131 cells (12% of total, 
excluding germ cells) that occurs during develop- 
ment of the nematode Caenorhabditis elegans.25 The 
nature of the internal clock or switch that activates 
death is not known, although study of mutant C 
elegans with abnormal cell death phenotypes has led to 




Matrix attachment, e.g. integrin receptors. 
Figure 3. Cartoon illustrating the diverse sources of signals that regulate susceptibility to 
apoptosis. 
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discussed below. The rationale for this sort of inevita- 
ble cell death is easy to appreciate in limb morphoge- 
nesis but is less clear for C elegans, where mutant 
animals that lack programmed cell deaths survive and 
appear grossly normal. Observed minor behavioural 
changes and slower maturation have been hypothe- 
sized to put the cell death -deficient animals at a 
selective disadvantage compared with wild- type.25 
External signals 
Specific ligand- receptor binding can transduce both 
death and survival signals. It is of relevance that a 
`survival factor' need not be a mitogen and also that 
mitogens are not necessarily survival factors; indeed 
there appears to be benefit in separating the two 
functions. The TNF receptor superfamily includes 
several members that participate in positive and 
negative regulation of cell death, for example TNFRI, 
®40, NGFR, CD30 and the fas antigen.2628 Receptor 
activation is not necessarily determinate of outcome 
and signal context is critical. For example, TNFa- 
induced apoptosis is blocked by expression of the zinc 
finger peptide A2029, and fas stimulation kills chron- 
ically but not recently activated T cells, (a distinction 
postulated as a mechanism for limiting the extent of 
normal immune responses)." The importance of 
context is well illustrated by the dual signal model of 
B cell responses to crosslinking of surface immunoglo- 
bulin by antigen.27 Crosslinking induces apoptosis, 
but not if a second signal is provided by costimulation 
of surface CD40. The ligand for CD40 is present on 
activated (but not resting) T helper cells, so apoptosis 
is only blocked during an antigen- specific immune 
response. Therefore, according to the model, self - 
reactive B cells will normally be deleted on encounter- 
ing antigen, as a result of the absence of activated self - 
reactive T cells that could provide a rescuing signal. 
Thus the humoral signal of antigen binding is read in 
the context of a cellular signal (CD40 binding). Some 
agents have dual effects on the same cell population, 
for example TGFf31 is a cytokine that both inhibits 
DNA synthesis and stimulates apoptosis of hepatocytes 
and endometrial stromal cells.3lS2 It is not clear what 
determines the particular response at individual cell 
level. 
Competitive selection 
When apoptosis is the default fate of newly generated 
cells, competitive selection for survival factors is a 
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powerful strategy to ensure that only those cells 
survive that are best suited to perform a particular 
function. Evidence from central nervous and haemo- 
poietic systems suggests there are specific factors for 
different cell types and `windows of susceptibility' 
during which cells are dependent upon particular 
factors.33-35 This type of scenario is in contrast to the 
fixed, programmed cell death of C. elegans. For 
example, in neuromuscular development lower motor 
neurones are generated in excess and deleted by 
apoptosis if their axons fail to contact muscle end 
plates, the source of neurotrophic survival or rescue 
factors.34 Likewise, during nephrogenesis, metaneph- 
ric mesenchyme converts to epithelium under the 
influence of an inductive signal from the ureteric 
bud "6 This signal rescues from the apoptosis that is 
the fate of uninduced cells. A similar principle brings 
about the increase in affinity of specific antibody 
produced during a humoral immune response (affin- 
ity maturation). This is achieved by selection for long 
term survival of only a small subpopulation of 
centroblasts, based upon the relative affinity of their 
surface immunoglobulin for the antigen, presented 
on follicular dendritic cells.37 The remainder die by 
apoptosis in the light zone of the lymph node 
germinal centre, being seen as `tingible bodies' within 
adjacent macrophages. Accessory survival signals are 
provided by cell adhesion molecules on the follicular 
dendritic cells, ICAM -1 and VCAM -1, which bind 
centroblast LFA 1 and CD49d respectively.ss 
Dependence on survival factors is also a key method 
of cell population size regulation. In kinetic terms a 
continuously renewing tissue (e.g. gut epithelium, 
bone marrow) consists of stem cells, progeny transit 
cells (which may or may not divide a few times) and 
post-mitotic, differentiated cells. There is normally 
overproduction of transit cells of which only a 
proportion survive to maturity, through the action of 
specific rescue factors, e.g. IL-la, IL-6 for myeloid 
progenitor cells. The concentration of transit cell 
rescue factors is thus limiting and a determinant of 
final population size. Paracrine survival factors also 
maintain tissue localisation, e.g. within bone marrow. 
A requirement for survival factors by mature cells, 
which may differ qualitatively from that of immature 
cells, is illustrated by the atrophy of thyroid or adrenal 
glands after hypophysectomy, prostatic regression 
after castration and involution of post lactational 
breast parenchyma that are all characterised by 
increased apoptosis.l2 The social control hypothesis 
provocatively takes the concept of survival factors to 
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its limit by suggesting that all cells (except blas- 
tómeres) are continuously dependent on survival sig- 
nals from other cells to avert an intrinsic death 
program 55 
This section has so far described how soluble factors 
and cell -cell interactions can control cell death, but 
cell -matrix interactions also regulate apoptosis. Spe- 
cific contact of surface integrin receptors with extrac- 
ellular matrix molecules is an important survival 
signal for differentiated endothelial and epithelial 
cells.8940 Without integrin- matrix binding these cells 
undergo apoptosis, a phenomenon that has been 
termed anoikis (`homelessness').40 Such cells cannot 
therefore survive out of position if the appropriate 
matrix requirements are not fulfilled. Thus matrix 
composition localizes seed to soil in an unforgiving 
manner, a concept of critical importance to under- 
standing mechanisms of neoplastic progression. In 
contrast, fibroblasts do not show integrin depend - 
ence,40 in keeping with the need to rove across tissue 
boundaries during repair of injury. 
Signal transduction 
The signal generated by a stimulus must be trans- 
mitted to effector molecules that often lie in different 
subcellular compartments. Transduction pathways 
vary according to the trigger stimulus but two major 
areas of focus are cytosolic calcium and protein 
kinases. Apoptosis is usually preceeded by a rise in 
cytosolic calcium concentration and possible down- 
stream targets include calmodulin and calpain 41.42 
Calmodulin and calpain are themselves pleiotropic 
molecules whose precise roles in apoptosis need to be 
clarified. Protein kinase C (PKC) has been identified 
as both a positive and negative regulator of apopto- 
sis,42 while a protein kinase A pathway is active in 
thymocyte apoptosis.45 It is possible, though without 
proof, that the conflicting roles of the PKC family may 
reflect the selective involvement of PKC isotypes44 or 
interaction with other signalling pathways such as 
sphingomyelin- ceramide45 The ras pathway has long 
been known to transduce growth signals from plasma 
membrane to nucleus but is also a negative regulator 
of apoptosis when overexpressed in fibroblast cell 
lines.4647 Overexpression of activated raf kinase, a 
downstream element in the ras pathway, was also 
found to prevent apoptosis induced. by IL-3 with - 
drawal.48 New evidence for crosstalk between these 
different pathways is revealing a complex network of 
vertical and horizontal interactions that integrates 
different signals to determine the outcome of a 
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stimulus.49 The machinery for context -dependent 
responses is thus coming to light. A major unanswered 
question is how these pathways converge on the 
common effector processes of apoptosis. 
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common mechanism - those suppressing apoptosis, 
those defining the final common activation elements 
and those `upstream' of the suppressors, but 'down- 
stream' of the signal transduction described earlier, 
which we call here intermediate genes. 
Genes suppressing apoptosis 
Induction of the bd-2 gene is often critical in the 
Fo action of survival factors. Bel -2 is a mammalian 
trt homologue of the C. elegans ced-9 gene, whose 
function it can partially replace,5s and it can prevent 
tce apoptosis caused by a variety of physiological, patho- 
C logical and pharmacological stimuli.56 How bd-2 
ell works is uncertain, although presumably it acts close 
ed to the final irreversible steps of apoptosis on which 
ell afferent pathways converge. There is evidence that bet 
an 2 affects calcium partitioning and cellular redox 
)Ie status, although this is still controversial (see ref 57, 
ith RW Craig, this issue, pp35-43, also 58,59). However 
nl- Bel -2 is not a universal antidote to cell death. For 
or example, ectopic bd-2 expression by cortical thymo- 
of cytes can prevent the induction of apoptosis by 
lly irradiation, glucocorticoids and antibodies to CD3, 
tn, but does not affect negative selection.60 This may be 
trs partly due to the presence of bd-2 antagonists such as 
Las bclxs which is expressed at high levels in immature 
m (CD4 +CD8 +) thymocytes.61 Bclxs has not been shown 
of to interact directly with bd-2 but another antagonist, 
igs bax, seems to exist in dynamic equilibrium between 
ell bax -bax homodimers that are permissive for apoptosis, 
rei and bax -bcl -2 heterodimers which may be a biologically 
9. active form of bd-2 that suppresses apoptosis.62.6s It is 
o- not yet clear whether the bd-2 antagonists simply 
ic quench survival functions of bd-2 or whether they 
n- have intrinsic lethal properties that bd-2 must hold in 
e, check. In either case the relative amounts of such 
er molecules in a cell could predetermine its response to 
ell a lethal stimulus. In tissues where bcl -2 is not essential 
al for survival such as the CNS (which develops normally 
ut in mice lacking bd- 2),64 functional analogues exist, 
'et such as bc/xL which is expressed at high level in 
ily brain 61 The antiapoptotic actions of the ras pathway 
ut were discussed earlier and it will be of interest to 
ig determine whether the bd-2 family interacts with ras/ 
'ly raf transduction pathways. Abl is another antiapoptotic 
ill gene that in contrast to bd-2 is biochemically well 
defined. The abl product is a tyrosine protein kinase 
ed and a constitutively activated form, retroviral v-abl, can 
nt suppress the apoptosis that follows growth factor 
ey withdrawal in vitro.ó5 Protein kinase C and phospho- 
a lipid hydrolysis may be mediators of this effect.66 An 
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abl fusion product (bcr -abl) in Philadelphia chromo- 
some-positive human leukaemic cells is also con- 
stitutively activated and probably suppresses apoptosis 
in the malignant cells.67 In addition to v-abl viruses 
have evolved a number of strategies to suppress 
apoptosis and these are discussed separately below. 
Distal activating genes 
The ced3 and ced4 genes of C. elegans are strong 
candidates for distal activating genes if not ultimate 
effectors of apoptosis.25 One vertebrate structural 
homologue of ced3 is ICE (interleukin -1 [3 converting 
enzyme), a cysteine protease that when overexpressed 
in fibroblasts induces apoptosis and inhibitors of 
which prevent the neuronal apoptosis that follows 
NGF withdrawal.54 The universality of ICE's ability to 
induce death and its actual relevance to physiological 
apoptosis of normal cells are yet to be tested and it is 
likely that a family of ICE -related proteases will be 
identified. In some systems bd-2 is able to inhibit ICE - 
induced cell death, placing it downstream of ICE -like 
proteases in regulation of apoptosis.54 Analogous 
attempts to order the ced3 /ced4 and ced9 genes in a C. 
elegans putative death pathway are more speculative. 
Animals with ced9 gain of function do not show ced3/ 
ced4-dependent cell deaths, whilst animals lacking ced9 
function show excessive and abnormal ced3 /ced4- 
dependent cell deaths.52 If the three genes lie along 
one linear pathway then these observations place ced9 
proximal to ced3 /ced4.52 However, if ced9 activation is a 
separate pathway to a ced3 /ced4 death cascade then 
ced9 action could be either proximal or distal to ced3/ 
ced4 and still be consistent with the data above. Given 
the many similarities of ced9 to bcl -2 and of ced3 to ICE 
it would seem reasonable at present to expect ced9 to 
act downstream of ced3. The reaper peptide of 
Drosophila also seems to be a distal activator for 
apoptosis.51 Reaper expression precedes apoptosis by 
1 -2 hours and is detectable in apoptotic bodies. 
Deficiency of reaper blocks developmental and radia 
don- induced apoptosis, although not completely, 
showing that reaper is not obligate for apoptosis to 
occur. Reaper has no homology to known peptides 
and the effect of expression in vertebrate cells is not 
yet reported. 
Intermediate genes 
Many genes that regulate apoptosis were first identi- 
fied as oncogenes or oncosuppressor genes. The c -myc 
oncogene is classically associated with promotion of 
C.O.C. Bellamy et al 
cell division and one might expect that constitutive 
activation of myc would be sufficient to induce 
autonomous cell proliferation. However, this is not so; 
in culture, activation of myc induces apoptosis unless 
specific rescue factors are also present, for example 
IGF -1 for fibroblasts or IL-3 for myeloid cells.3'68 Thus 
myc activation simultaneously generates two possible 
outcomes in these cells: death (by default) or pro- 
liferation (if rescued) (Figure 4). Deregulated 
expression of the myb oncogene, at Ieast in myeloid 
cells, may have a similar effect.ó9 Such coupling of 
oncogene activation to survival factor dependence 
may serve two purposes. It opens a window of 
susceptibility to apoptosis (a `high turnover' state), 
allowing competitive selection of susceptible cells to 
regulate population size as described above. It also 
forms an inbuilt safety mechanism to delete cells in 
the event of incongruous oncogene activity. A corol- 
lary of the `high turnover' state model is that because 
proliferating cells in general are poised for apoptosis 
they will be susceptible to a variety of triggering 
agents, including cancer chemotherapeutic agents. In 
support of this idea epithelial cells in the proliferative 
zone of gastrointestinal crypts are more sensitive to 
irradiation and cytotoxic agents than adjacent non - 
proliferating crypt cells.70 Tissue compartments in a 
high turnover state are therefore in a precarious 
balance between population expansion (excess pro- 
liferation) and regression (excess apoptosis), deter- 
mined by the availability of mitogens, survival factors, 
cytotoxic stimuli and recruitment into or out of the 
high turnover state, e.g. differentiation. At a molec 
ular level it is unclear whether the coupling of cep 
cycle activation to apoptosis is specifically mediated 1:1 
myc or by a downstream component of an active cep 
cycle. ii 
The p53 oncosuppressor gene is the most frc, 
quently mutated gene in human malignancy (see rd 
71, C.E. Canman, M.B. Kastan, this issue, pp17 -25). U 
is critical for a DNA damage response to DNA strand 
breaks, produced either directly or during the exci 
sion- repair of other DNA lesions. In different cell 
types, such breaks result in G1 arrest or apoptosis.72.73 
What determines the differences in response is 
unclear, although of interest is the observation that 
overexpression in a cell line of transcription factor 
E2F-1 (a positive regulator of myc expression'', 
involved in cell cycle regulation), switched a p53-de. 
pendent G1 arrest to a high turnover state with excess 
apoptosis.75 E2F is shut off by hypophosphorylated 
pRb (the active retinoblastoma gene product), a 
negative regulator of cell cycle progression that is 
inactivated by cyclin- dependent kinases (cdk) in Gl, 
themselves a target in p53-induced G1 arrest (via 
WAF1).76 -78 An interesting pathway is thus sketched 
out, in which p53/WAF1 growth arrest is achieved 
through cdk inhibition to activate pRb, which then 
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Figure 4. Schematic diagram to illustrate the differential susceptibility to apoptosis of proliferation - 
competent cells: cell cycle activation invokes a committment to apoptosis (a 'high turnover state') 
that is modulated by the dynamic action of 'survival genes' and their antagonists to determine net 
tissue growth or contraction. Note that apoptosis can occur in all the states of activation depicted. 
This scheme is not concerned with apoptosis following cellular injury (e.g. p53- dependent death), 
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function would prevent shut -down of E2F -1, which 
could then induce a high turnover state, as described 
above. This model is supported by the example of 
mice deficient in the retinoblastoma gene product. 
They die in utero with CNS and haemopoietic abnor- 
malities, characterized by excessive proliferation and 
apoptosis.79 The direct mechanisms of p53- dependent 
apoptosis are also becoming clearer. p53 down - 
regulates bc1- 2 expression and also upregulates its 
antagonist bax.S9.81 This suppresses a major anti- 
apoptotic pathway and places p53 proximal to bel- 
2/bax in the regulation of apoptosis.82 
The purpose of the decision to enter G1 arrest after 
DNA damage is unclear but one attractive hypothesis 
suggests that it provides an opportunity to repair DNA 
lesions before DNA replication occurs.88 If the dam- 
age is in some way recognized as irreparable, the 
hypothesis suggests that p53- dependent apoptosis 
would be triggered, to prevent the replication of 
damaged DNA and a gradual accumulation of genetic 
defects that might result in carcinogenesis. In support 
of this hypothesis thymocytes and gastrointestinal 
crypt cells of p53- deficient mice lack the normal 
apoptotic response to DNA damaging agents, intrigu- 
ingly in a gene -dose dependent fashion.84,85 In 
addition p53 has been shown to be critical for the 
maintenance of genomic integrity in serially passaged 
cells, and mice without functional p53 genes die 
prematurely from malignancies.86.87 Thus p53 is 
involved in the policing, the ministration and the 
execution of cells with DNA damage. It is hardly 
surprising therefore that p53 mutations are common 
in malignancy, given the advantages for neoplastic 
progression that disabling of p53 confers. 
p53 is not critical for all apoptotic pathways (for 
example mutine thymocytes from p53- deficient ani- 
mals retain a normal apoptotic response to gluco- 
corticoid),84 but it is implicated in apoptosis effected 
in vitro by mechanisms apparently unrelated to DNA 
damage. Thus p53 is required for normal sensitivity in 
vitro of haemopoietic cells to survival factors and loss 
of even a single allele reduces (but does not remove) 
the requirement for survival factors.88 Introduction of 
wild -type p53 into a leukaemic cell line has also been 
reported to generate dependence on IL-6 for survival, 
and p53 was necessary for the apoptotic response to 
serum withdrawal in a cell line cotransfected with 
adenovirus E1A and ras oncogenes.89 -91 Therefore, 
although mice deficient in p53 develop normally" 
and p53 is clearly not essential for developmental cell 
death, altered survival factor thresholds may influence 
population selection during development and pro- 
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vide a more favourable environment for 
carcinogenesis. 
A number of other gene products are implicated in 
the control of apoptosis (e.g. clusterin, e -rei, fos, cyclin 
D192-95), but in most instances it still remains to sort 
primary regulators from secondary perturbations.96,97 
Recent evidence from a myeloid leukaemia cell line 
has implicated the Myd118 gene as a downstream 
mediator of TGF3- induced apoptosis and has sug- 
gested that bel -2 inhibits apoptosis of these cells via 
downregulation of Mydl18 expression.69 
Disease connotations: apoptosis in disease and 
the responses to disease 
It is evident that apoptosis provides a powerful 
regulatory mechanism for many aspects of normal 
tissue growth and function. This section extends the 
discussion to describe how apoptosis regulates the 
responses to disease and how defective regulation of 
apoptosis may be central to the pathogenesis of many 
important disorders. 
Inflammation 
The response to injury or infection has itself consider- 
able potential to damage tissue and it is therefore 
tightly regulated. Neutrophils, eosinophils and mono- 
cytes die by apoptosis within a relatively short period 
(e.g. 3-4 days for eosinophils in culture), however 
death can be significantly delayed by proinflammatory 
cytokines such as C5a (neutrophils), IL-13, TNF-a, 
IFN-y (monocytes) and IL-5 (eosinophils).98,99 In 
contrast TGFß and TNFa accelerate eosinophil and 
neutrophil apoptosis respectively.loo>LO' This suggests 
a potential mechanism in vivo for control of the 
survival and ultimately the removal of these poten- 
tially dangerous cells from sites of inflammation when 
the inflammatory stimulus subsides. Defects in these 
mechanisms or in the clearance of apoptotic cells may 
underlie some chronic inflammatory diseases (e.g. 
hypereosinophilic syndromes) due to inappropriate 
persistence of inflammatory cells with continued 
release of toxic cellular contents perpetuating tissue 
injury and inflammation. Of interest in this regard 
is the multifocal inflammatory disease and tissue 
necrosis that occurs in mice without functional 
TGF 31.102 
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Autoimmunity 
Apoptosis is critical for the development, function 
and regulation of the immune system (see ref 103, 
B.A. Osborne, this issue, pp27 -33). One instructive 
example is thymocyte maturation. A competent 
immune system must recognise a wide variety of 
foreign antigens but provision must be made to delete 
self -reactive effector cells that would otherwise cause 
autoimmune disease. In the thymus, 97% of thymo- 
cytes are deleted in their first few days of life.104 This 
occurs as a result of a complex weeding -out process in 
which immature thymocytes die by apoptosis unless 
able to recognise and bind antigen presented in 
association with self MHC molecules (positive selection 
for MHC restriction) and yet die also if the receptor 
occupancy is too great (negative selection).105 The 
principle is that high receptor occupancy is likely to 
reflect reactivity to self -antigen since most antigen 
presented in the thymus is self -derived. However, 
negative selection is certainly more complex than 
that, and further contributory mechanisms involving 
other surface signals are likely.105 -108 In concert with 
thymic selection, peripheral deletion of mature T cells 
is also important to prevent autoimmune tissue 
damage. One mechanism involves apoptosis induced 
by activation of surface fas molecules. Fas (CD95, Apo- 
1 receptor) is a member of the TNF receptor 
superfamily and like some other members can trans - 
duce a signal for either apoptosis or proliferation. 
Mice without functional fas or fas ligand accumulate 
abnormal CD4-CD8T cells and develop autoimmune 
disease resembling human systemic lupus erythemato- 
sus (SLE).94 These mice have lost the antigen -driven 
fas- dependent apoptosis of mature T cells that main- 
tains tolerance to self.11° Further compelling evidence 
for a direct pathogenetic role of fas- mediated cell 
death is provided by the recent observations in SLE 
patients of elevated serum levels of a soluble form of 
fas at concentrations that blocked induction of fas- 
mediated apoptosis in vitro, and that in mice caused 
altered lymphocyte development and proliferation 
responses to self antigen." 
Cytotoxic lymphocyte (CTL) killing 
Cell -mediated cytotoxicity is an integral component of 
specific host defences, for example against virally 
infected cells, and apoptosis is believed to be the 
mode of death in a proportion of CTL- induced target 
cell killing.26 Evidence suggests that activation of 
target cell fas by the CTL is an important mechanism 
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for this cell- mediated apoptosis, although engage. 
ment of target cell TNF receptors may also act to 
trigger apoptosis in some instances.112,113 The finding 
that activation of surface fas on hepatocytes triggers 
apoptosis114 suggests a potential pathogenetic mecha- 
nism for viral or perhaps autoimmune hepatitis that 
may have implications for new strategies of therapy. It 
is of relevance to note that CTL can kill by a 
mechanism that involves perforin insertion into target 
cell membranes and granule exocytosis.26 The relative 
importance and interactions of these different modes 
of killing is not established. 
AIDS 
The gradual depletion of CD4 +T cells during HIV 
infection that leads to clinical AIDS is thought to be 
due to excessive apoptosis.114 HIV-infected cells 
express a viral envelope transmembrane gp120 -gp41 
complex which binds the CD4 D1 domain of unin- 
fected T cells and triggers apoptosis directly."5 
Furthermore HIV particles shed gp120 which, 
although unable to trigger apoptosis itself, can bind É' CD4 and program uninfected T cells for apoptosis 
(instead of proliferation) in response to subsequent T 
cell receptor stimulation by antigen.116 The deletion 
of naive and memory T cell clones on encountering 
their specific antigen abolishes the individual's ability 























Escape by cells from normal activation of apoptosis 
allows survival of 'forbidden clones' that would 
otherwise have been deleted. This might allow the 
propagation of, for example, new genetic defects that 
would have been eliminated through p53- dependent 
apoptosis. In addition, reduced dependence on sur- 
vival factors may be important in the early stages of 
carcinogenesis to allow expansion of subpopulations 
of cells capable of subsequent progression to malig- 
nancy. An example is experimental liver tumour 
promotors such as nafenopin and phenobarbital that 
reversibly inhibit apoptosis with consequent hyper - 
plasia and development of preneoplastic foci." 
Constitutive bd-2 expression by follicular lymphomas 
is an example of a death suppression strategy in 
human neoplasia.118 The qualities that allow survival 
of malignant cells in foreign tissues have received little 
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metastasis. It is likely that escape from integrin 
dependence is one such necessary event. 
Oncogenic viruses 
Oncogenic viruses have developed strategies to pre- 
vent host cell apoptosis that have shed light on control 
pathways. The Epstein Barr virus BHRFI protein is a 
bd-2 homologue, whilst the LMP -1 protein upregu- 
lates bet - 2 expression and induces the A20 zinc finger 
protein that confers resistance to TNFa cytotox- 
icity.u19-121 The adenovirus E1B gene encodes a 
functional homologue of bel -2 and a protein that 
inactivates the p53 oncosuppressor.122,123 In fact 
several viruses inhibit p53 function in different ways, 
including SV40 (large T antigen), Epstein Barr virus 
(EBNA 5), human papillomavirus types 16 and 18 (E6 
protein) and hepatitis B virus (HBx protein) (see ref 
124 for references). This is a testament to the 
importance of that molecule in countering abnormal 
cell proliferation. Interestingly, many oncogenic 
viruses contain genes that activate cells from the 
growth arrested state (SV40 T antigen, adenovirus 
EIA, HPV E7) probably via inactivation of Rb protein, 
release of transcription factor E2F and activation of 
c -myc. At least some of these changes also imply 
increased susceptibility to apoptosis, as discussed 
earlier. The combination therefore of pro-apoptotic 
oncogenes with others having anti- apoptotic activity 
appears to be an essential part of the viral strategy to 
induce cell proliferation without also activating cell 
death. 
Cancer therapy implications 
The ability to modify sensitivity to apoptosis through 
the regulatory pathways has clear implications for the 
treatment of malignancy.125 Potential strategies fall 
into three categories - direct triggering of apoptosis 
by cytotoxic agents, enhancing susceptibility to apop- 
tosis to increase the efficacy of other therapies, and 
boosting the resistance of normal cells to apoptosis 
(with survival factors). Restoration of function of 
interrupted apoptotic pathways, e.g. p53- dependent 
apoptosis, with consequent self-deletion by tumour 
cells would be a most attractive strategy. Bc1-2 antago- 
nists might likewise be expected to cause regression of 
follicular lymphomas or at least to increase their 
radio- or chemosensitivity. Induction of a high turno- 
ver state (with survival factor dependence) or antago- 
nism of tumour survival factors (e.g. antiandrogens 
for prostate carcinoma, tamoxifen for oestrogen 
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receptor -expressing breast carcinomas) are other 
approaches to therapy. Boosting normal cell resis- 
tance to apoptosis with exogenous survival factors can 
be used after ablative therapy to improve restoration 
of the normal cell population,126 reducing treatment 
morbidity and allowing greater frequency of cytòtoxic 
treatments. 
Conclusion 
Apoptosis has an importance in physiology and 
pathology that has only recently become fully appre- 
ciated. Its purpose is to rapidly delete single cells from 
living tissue without interrupting tissue function or 
structural integrity. Diverse fields of developmental, 
cell and molecular biology are linking to contribute to 
a deeper understanding of apoptosis that has a direct 
relevance to a variety of human diseases and in some 
instances suggests new therapeutic strategies. Much of 
the basic biology of the regulation and effector events 
of apoptosis remains obscure but the field is now 
subject to such an intense level of investigation that it 
is not unrealistic to expect great advances within a 
very short time. 
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